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Resumo 
 
 
Cancro da Cabeça e Pescoço refere-se a um grupo de tumores que 
aparecem no trato aerodigestivo superior, sendo que o carcinoma das 
células escamosas da cabeça e pescoço (CCECP) corresponde a 
mais de 90% de todos os casos de cancro nesta região. Foi 
considerado o sexto tumor mais maligno em todo o mundo e, apesar 
de todos os avanços tecnológicos e clínicos, a taxa de sobrevivência 
a cinco anos não melhorou significativamente nas últimas décadas. 
Atualmente sabe-se que o CCECP é uma doença bastante 
heterogénea que se desenvolve devido à acumulação de alterações 
genéticas e epigenéticas. Alguns dos grandes problemas associados 
a este tipo de cancro são o diagnóstico em fase tardia da doença e os 
poucos resultados terapêuticos. Uma das escolhas terapêuticas para 
o CCECP é a radioterapia, no entanto, esta tem diversos 
inconvenientes, como a radioresistência adquirida por algumas 
células tumorais, que se associam a piores prognósticos. Um 
aumento do conhecimento na área da biologia da radiação é 
necessário para melhorar esta opção terapêutica, evitando futuros 
efeitos tóxicos e fornecendo uma melhor qualidade de vida nos anos 
subsequentes ao tratamento. Desta forma, a identificação de 
marcadores moleculares associados quer a uma resposta à 
radioterapia, quer a possíveis alterações celulares após tratamento 
com radiação, é essencial para melhorar o diagnóstico, taxa de 
sobrevivência e qualidade de vida destes doentes. Adicionalmente, 
existe uma grande falha no conhecimento em relação aos efeitos da 
radiação nas células, como tal, o principal objetivo deste estudo foi 
o de contribuir para um conhecimento mais alargado do efeito da 
radiação em doentes com CCECP. Para isso foram utilizadas duas 
linhas comerciais celulares, HSC-3 (derivada de um tumor 
metastático da língua) e BICR-10 (derivada de um tumor da mucosa 
bucal), que foram caracterizadas com recurso a aCGH, MS-MLPA 
e citogenética convencional. Estas linhas foram submetidas a 
diferentes doses de radiação e as alterações genéticas e de metilação 
pós tratamento foram determinadas. Estes resultados demonstraram 
uma grande variação de resposta à radiação para estas duas linhas 
celulares, permitindo a conclusão que a linha HSC-3 é mais 
radiossensível que a linha BICR-10. Tendo isto em mente, 
procedeu-se a análise da morte celular, ciclo celular e danos no DNA 
de forma a tentar compreender esta diferença.  
A caracterização genética de ambas as linhas celulares permitiu 
corroborar que a linha HSC-3 era derivada de um tumor metastático 
e sugeriu que a linha celular BICR-10 estaria associada a um estado 
de displasia. Para além disto, foi possível analisar alterações 
genéticas e epigenéticas ocorridas após irradiação e associar 
determinados perfis genéticos a uma melhor ou pior resposta à 
radiação. 
Em suma, os nossos resultados contribuiram para um conhecimento 
mais aprofundado dos efeitos da radiação no CCECP possibilitando, 
no futuro, melhores opções de tratamento e uma melhor qualidade 
de vida para estes doentes. 
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Abstract 
 
Head and Neck Cancers (HNC) are a group of tumours located in the 
upper aero-digestive tract. Head and Neck Squamous Cell Carcinoma 
(HNSCC) represent about 90% of all HNC cases. It has been 
considered the sixth most malignant tumour worldwide and, despite 
clinical and technological advances, the five-year survival rate has not 
improved much in the last years. Nowadays, HNSCC is well 
established as a heterogeneous disease and that its development is due 
to accumulation of genetic events. 
Apart from the majority of the patients being diagnosed in an 
advanced stage, HNSCC is also a disease with poor therapeutic 
outcome. One of the therapeutic approaches is radiotherapy. 
However, this approach has different drawbacks like the 
radioresistance acquired by some tumour cells, leading to a worse 
prognosis. A major knowledge in radiation biology is imperative to 
improve this type of treatment and avoid late toxicities, maintaining 
patient quality of life in the subsequent years after treatment. Then, 
identification of genetic markers associated to radiotherapy response 
in patients and possible alterations in cells after radiotherapy are 
essential steps towards an improved diagnosis, higher survival rate 
and a better life quality. Not much is known about the radiation effects 
on cells, so, the principal aim of this study was to contribute to a more 
extensive knowledge about radiation treatment in HNSCC. For this, 
two commercial cell lines, HSC-3 and BICR-10, were used and 
characterized resorting to karyotyping, aCGH and MS-MLPA. These 
cell lines were submitted to different doses of irradiation and the 
resulting genetic and methylation alterations were evaluated. Our 
results showed a great difference in radiation response between the 
two cell lines, allowing the conclusion that HSC-3 was much more 
radiosensitive than BICR-10. Bearing this in mind, analysis of cell 
death, cell cycle and DNA damages was performed to try to elucidate 
the motifs behind this difference.  
The characterization of both cell lines allowed the confirmation that 
HSC-3 was derived from a metastatic tumour and the hypothesis that 
BICR-10 was derived from a dysplasia. Furthermore, this pilot study 
enabled the suggestion of some genetic and epigenetic alterations that 
cells suffer after radiation treatment. Additionally, it also allowed the 
association of some genetic characteristics that could be related to the 
differences in radiation response observable in this two cell lines. 
Taken together all of our results contribute to a better understanding 
of radiation effects on HNSCC allowing one further step towards the 
prediction of patients’ outcome, better choice of treatment approaches 
and ultimately a better quality of life. 
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1 INTRODUCTION 
 
1.1 CANCER 
Willis, in 1960, defined neoplasm as “an abnormal mass of tissue, the growth of which 
exceeds and is uncoordinated with that of the normal tissues and persists in the same excessive 
manner after the cessation of the stimuli which evoked the change” (Willis, 1960). Considering this, 
it can be said that neoplastic cells are able to replicate indefinitely and are almost autonomous. The 
term that usually substitutes neoplasm is tumour, which can be benign or malign according to its 
potential clinical behaviour. A tumour is considered benign when is tough that it will remain 
localized, not spreading to other locals in the body and that it is susceptible to be local surgical 
removed. Malignant tumours are usually called cancers, that are able to invade and destroy other 
structures, metastasize and even lead to death (Kumar et al., 2007). 
Cancer is an enormous global health challenge, as it is one of the leading causes of death 
worldwide. According to GLOBOCAN, in 2012, 32.6 million people were living with cancer and 
8.2 million died due to this disease. It is estimated that, in 2035, almost 15 million people for year 
will die from cancer (GLOBOCAN, Accessed: 15-12-2014; WHO, Accessed: 15-12-2014). 
 
1.1.1 Hallmarks of Cancer 
 
In 2000, Hanahan and Weinberg introduced the term “Hallmarks of Cancer”. These hallmarks 
referred to processes that must be deregulated for the development of carcinogenesis and metastasis. 
There were six hallmarks: (i) Sustaining proliferative signalling; (ii) Evading growth suppressors; 
(iii) Activating invasion and metastasis; (iv) Enabling replicative immortality; (v) Inducing 
angiogenesis; (iv) Resisting cell death. Meanwhile, in the last years, two more hallmarks have been 
added: reprogramming of energy metabolism and evading immune destructions. Underlying these 
hallmarks are two important characteristics of cancer cells: genome instability, which is responsible 
for the genetic diversity that leads to the development of the hallmarks, and inflammation, which 
promotes many of the hallmarks functions (Figure 1) (Hanahan and Weinberg, 2011). 
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1.2 HEAD AND NECK CANCER 
Head and neck cancer (HNC) refers to the malignant tumours that arise from different anatomic 
sub sites of the head and neck region: Nasal Cavity/Paranasal, Oral Cavity, Salivary Gland, Trachea, 
Thyroid, Nasopharynx, Oropharynx, Hypopharynx, and Larynx (Figure 2). Squamous cell carcinoma 
represent more than 90% of all HNC and arise in the oral cavity, oropharynx, larynx or hypopharynx. 
This way, the term “Head and Neck Squamous Cell Carcinoma” (HNSCC) is frequently used to refer 
to these anatomical sites (Stadler et al., 2008). 
 
Squamous cell carcinoma, which arises from normal squamous epithelium through a stepwise 
process called dysplasia, is a neoplasm that penetrate through the basement membrane and extend to 
the connective tissue underline it (Radosevich, 2013). HNSCC results from the accumulation of 
Figure 2 - Diversity of head and neck cancer and histopathologic diagnosis that present at the various 
subsites in the head and neck. HNSCC regions are marked. Adapted from: Stadler et al. (2008) 
Figure 1 – The Six Hallmarks of cancer (Highlighted) alongside with the two new emerging hallmarks 
and the enabling characteristics. Adapted from: Hanahan and Weinberg et al. (2011) 
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many genetic and epigenetic alterations in various signalling pathways, which can lead to tumour 
development and invasive carcinoma (Tan et al., 2013). 
The fact that more than 90% of all types of HNC are squamous cell carcinomas could lead to a 
wrong conclusion: HNSCC is a homogenous disease. However, scientists have proven this theory 
wrong. HNSCC is a very heterogeneous disease, which makes the treatment planning and the 
identification of the etiologic genes much harder (Leemans et al., 2011). 
Despite technological and clinical advances, the five-year survival rate of these cancer patients 
does not have improved much in the last years, since this disease is still diagnosed at an advanced 
stage (Llewellyn et al., 2001; Smeets et al., 2006). 
 
1.2.1 HNSCC Histology 
All parts of the oral cavity are lined by a protective mucous membrane, called oral mucosa. 
The oral cavity is lined with stratified squamous epithelium, which, according to the region, can be 
keratinized or not. The nonkeratinezed epithelium appears in the soft palate, lips, cheeks and the 
floor of the mouth, whereas the keratinezed one is present on the gingiva and hard palate. The 
basement membrane, which regulates the differentiation and migration of the epithelial cells and 
function as a barrier to stromal invasion, is the interface between the keratinocytes and the lamina 
propria. The latter is responsible for the support of the oral epithelium (Pai and Westra, 2009; Young 
et al., 2013). 
World Health Organization (WHO) defined squamous cell carcinoma of the oral cavity as 
“an invasive epithelial neoplasm with varying degrees of squamous differentiation and a propensity 
to early and extensive lymph node metastases” (Barnes et al., 2005). The first steps for the 
development of oral malignancies are cellular disorganization of the epithelium, enhancement of 
mitotic activity, nuclear enlargement and pleomorphism. In posterior phases, the basement 
membrane is disrupted and the carcinoma can invade into the connective tissue. At last, it can reach 
skeletal muscle, craniofacial bones and facial skin, possible through perineural invasion and the 
lymphatic spaces (Barnes et al., 2005; Pai and Westra, 2009). 
 
1.2.2 Epidemiology and Risk Factors 
In 2012, HNSCC was considered the sixth most malignant tumour, with an estimative of 600 
000 new cases every year. Particularly, in Western European countries the incidence rate is estimated 
to be 15/100 000 (Wittekindt et al., 2012; Tornesello et al., 2014). 
Accordingly to the GLOBOCAN 2012, Portugal was in the highest group of incidence for lip 
and oral cavity cancer, alongside with Australia, India and other Asian countries (Figure 3) 
(GLOBOCAN, Accessed: 22-07-2014). Incidence rates of oral cavity and laryngeal cancers have 
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been decreasing worldwide over the past years, however, oropharyngeal cancer rates have been 
increasing about 2.9% per year since 2001, most likely due to changes in people’s lifestyle (Michaud 
et al., 2014). 
It was in 1957 that Wynder and Bross identified tobacco and alcohol as etiologic factors in oral 
and oropharyngeal cancer. Later, the use of tobacco and alcohol consumption were confirmed to be 
causes for the development of HNSCC and, nowadays, it is known their implication in 75% of all 
HNSCC cases (Argiris et al., 2008). Moreover, some investigators concluded that they have a 
synergistic effect in causing this type of tumours (Ragin et al., 2007; Argiris et al., 2008) . 
 Tobacco smoke induces carcinogenesis manly due to its carcinogens, like nitrosamine and 
polycyclic hydrocarbons, which have genotoxic effects. Those agents can induce structural changes 
in DNA, being the majority associated to oxidative damage. Although those changes can be repaired 
by the cellular mechanisms of base excision repair (BER) or nucleotide excision repair (NER), many 
studies have proved that changes in these pathways are common and they may have a part in the 
higher risks observed for tobacco smoking-related cancers (Stadler et al., 2008). Alcohol 
consumption has been considered a risk, especially for the hypopharynx cancer, and its carcinogenic 
effect is due to its ability to act as a solvent for the components of tobacco smoke. Besides, genetic 
polymorphisms in enzymes that metabolize tobacco and alcohol have also been linked to their 
elevated risk in inducing carcinogenesis (Argiris et al., 2008; Wittekindt et al., 2012). 
Despite the decrease of the tobacco smoking-related cancers, the number of HNSCC has not 
followed this decline. This phenomenon is attributed to an increase of oropharyngeal squamous cell 
carcinoma (OPSCC) in younger individuals due to infections with human papillomavirus (HPV) 
(Marur et al., 2010). However, HPV is not the only virus associated to HNSCC. The presence of 
Epstein-Barr virus (EBV) in nasopharyngeal carcinoma (NPC) have also been identified (Yoshizaki 
et al., 2007). 
Figure 3 – Schematic representation of the incidence of lip and oral cavity worldwide. Portugal isin the 
higher incidence group. Adapted from: GLOBOCAN 2012 
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Furthermore, there are some inherited disorders that predispose to HNSCC. One of the most 
documented is Fanconi Anemia, an autosomal recessive disorder. The cancer susceptibility aspect of 
this disease is associated with an incapacity to maintain the integrity of the genome, leading to an 
elevated stage of chromosomal instability (CIN). Hereditary non-polyposis colorectal cancer, Li-
Fraumeni syndrome and ataxia telangiectasia were also associated with a higher risk of developing 
HNSCC (Butturini et al., 1994; Argiris et al., 2008; Polanska et al., 2014). 
Other risk factors for this type of cancer include poor oral hygiene, environmental contaminants 
(gasoline and paint fumes, for example), diet and marijuana consumption. These factors do not have 
such huge impact as the previously ones described (Mao et al., 2004). 
 
1.2.3 Therapy for HNSCC  
Nowadays, HNSCCs are classified according to the T (size of tumour) N (involvement of 
loco-regional lymph nodes) M (evidence of distant metastasis) system, which is based on 
morphology and anatomic distribution of the tumour. However, it is obvious that this classification 
lacks important markers, such as the biological and molecular ones, leading to the same treatment 
approach for different tumours (Prince et al., 2010). It is important to mention that patients that suffer 
from HNSCC are at risk of developing subsequent primary tumours. Those with recurrent or 
metastatic disease have a worse prognosis, with a median survival of six to eight months (Goerner et 
al., 2010). 
Treatment for HNSCC requires a delicate balance between complete eradication of cancer 
and the preservation of the anatomical form and function of the organs of this sensible region. Organ 
preservation and quality of life are critical factors in the treatment planning, since the organs affected 
by this type of cancer are extremely important to the patient life (Ko and Citrin, 2009; Prince et al., 
2010). 
At the time of diagnosis, only 15-30% of the patients are in an early-stage disease (stages 
I/II), which is usually curable with surgery or radiotherapy. However, the majority of the HNSCC 
patients is diagnosed with locally advanced disease (stages III/IV). For these patients is required a 
multidisciplinary approach that incorporates chemotherapy, radiotherapy and surgery. This approach 
brings significant toxicity rates, however most of the patients dies from loco-regional progression 
(Langer, 2008; Goerner et al., 2010). Response to treatment therapy is independent of the TNM stage 
and has been proposed that patients with weak responses to primary therapy (radiotherapy or 
chemoradiotherapy) were more likely to present distant metastasis and, consequently, a lower 
survival (Akervall et al., 2014). 
 Reirradiation, with or without chemotherapy for recurrent and second primary head and 
neck cancers can bring local control, but usually also leads to dead related to the treatment. Moreover, 
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many patients often develop resistance to the treatments, chemotherapy or radiotherapy, and there is 
some variation in the response to the treatments, probably due to biological factors of each case in 
particular. Following this line of reasoning, one great aim nowadays is to try to predict beforehand 
which patients will benefit from certain types of therapy, in order to minimize the toxicity rates 
(Begg, 2012). 
The identification of specific molecules or pathways directly associated to tumourigenesis 
can provide opportunities to develop new strategies to treat and cure HNSCC with less toxic effects 
to the patient. Various techniques have been developed and studied for targeting cancer cells 
(Goerner et al., 2010; Prince et al., 2010). These new targets could improve the treatment outcome 
and patient’s quality of life (Skvortsov et al., 2014). 
 
1.2.4 Carcinogenesis  
Nowadays, it is known that HNSCC is a heterogeneous disease, subdivide in, at least, two 
different groups: tumours caused by HPV infection and tumours caused by other mechanisms 
(Tornesello et al., 2014). 
1.2.4.1 HPV Carcinogenesis 
HPV-induced carcinogenesis is thought to be present in about 20-25% of HNSCC cases and 
the patients tend to be younger, with no historical of tobacco or alcohol consumption. The majority 
of the cases occurs in the economically developed countries and are associated with a better prognosis 
(Polanska et al., 2014; Tornesello et al., 2014). 
Human Papillomaviruses belong to the family Papillomaviridae, 8 kb circular double-
stranded DNA viruses that infects basal cells of the epithelial mucosa. About 90% of HPV-related 
head and neck cancers harbour HPV 16 (Dufour et al., 2012). 
The HPV life cycle is related to the stage of differentiation of the epithelial cells that are 
infected. The infection starts in undifferentiated proliferating cells of the basal epithelial layer, 
leading to the expression of the early viral genes, particularly the E6 and E7 oncogenes. These target 
cellular tumour antigen p53 (p53) and Retinoblastoma protein (Rb) pathways, respectively. The E6 
protein binds to p53 and targets the protein to degradation, which leads to the inhibition of p53-
mediated apoptosis. The E7 protein binds to Rb and inactivates it. This action originates an 
enhancement of cyclin-dependent kinase inhibitor 2A (CDKN2A) and, consequently, abnormal cell 
proliferation (Figure 4). Furthermore, the E7 protein induces defective centrosome duplication, 
originating multipolar and abnormal mitoses, aneuploidy and genomic instability (Leemans et al., 
2011). 
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1.2.4.2 Non-HPV Carcinogenesis 
The majority of the knowledge about the carcinogenesis of HNSCC is due to oral cancers, 
mostly because precursor’s lesions are in the top of the most frequently diagnosed, being the 
commonest oral leucoplakia, a white lesion in the oral mucosa (Leemans et al., 2011). 
As in all cancers, there is a variety of mutations in the basis of the development of HNSCC. 
Those mutations can be inactivation of tumour suppressor genes (TSGs), activation of proto-
oncogenes, or both. However, tumour progression in HNSCC is not only a consequence of an 
accumulation of inactivating/activating mutations. Nowadays, it is known that many of these 
alterations crosstalk and interact with each other, integrating one major circuit in order to maintain 
the malignant phenotype of cancer. It is suggested that HNSCC results from a multistep development 
with characteristic alterations of cellular and molecular pathways occurring in the stratified 
squamous epithelium. With the help of molecular techniques, was proposed a progression model for 
the HNSCC carcinogenesis (Figure 5) (Argiris et al., 2008; Haddad and Shin, 2008). 
A few studies determined some cytogenetic alterations that may lead to dysplasia, carcinoma 
in situ and invasive tumours (Haddad and Shin, 2008; Pai and Westra, 2009; Rothenberg and Ellisen, 
2012).  Chromosomal alterations occur mostly at critical components of a few genetic pathways that 
regulate important cell functions, as cell growth, motility, squamous epithelial differentiation and 
stromal interactions (Rothenberg and Ellisen, 2012). Carcinomas that develop in large pre-neoplastic 
fields usually extend into the surgical margins of tumour’s excision, leading to recurrences and 
second primary tumours. Besides local invasions, HNSCC is also characterized for cervical nodes 
dissemination, leading to the conclusion that it is a disease associated with metastatic and invasion 
progression (Koontongkaew, 2013). 
Figure 4 – HPV genome contains two viral oncoproteins: E6 and E7. Whereas E6 binds to p53, leading to the 
elemination of this protein, E7 is able to bind and inactivate Rb protein. These alterations lead to inhibition of 
apoptosis and entry in cell cycle, allowing the vírus to replicate. The replication of the vírus will eventually 
lead to abnormal cell proliferation, aneuploidy and genomic instability. Adapted from: Leemans et al. (2011) 
and ViralZone 
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The metastatic and invasion progression of tumour cells appears to be closely related to the 
interactions between the cells and the microenvironment that surrounds them, which include cell 
adhesion, cytoskeletal rearrangements, cell migration and degradation of the basement membrane, 
intravasion, survival in the blood vessel, extravasion, growth of the tumour cells at the distant site 
and promotion of angiogenesis (Koontongkaew, 2013). 
 
1.2.5 Changes in Signalling Pathways 
Rather than point mutations, genetic alterations in HNSCC are frequently associated to 
different pathways involved in key regulatory events such as: proliferation, squamous epithelial 
differentiation, cell survival, invasion and metastasis (Rothenberg and Ellisen, 2012). 
1.2.5.1 Cellular proliferation - p53 and Rb pathways 
There are several proteins implicated in cellular proliferation. One of the most studied is p53, 
which is a short-lived protein, activated through different stress pathways. At low levels of stress, 
p53 can lead to a blockage of the cellular proliferation, whereas at enhanced levels of stress, p53 
induces apoptosis. Tumour protein p53 (TP53), a TSG, is frequently mutated in HNSCC patients and 
it is associated to an early event in carcinogenesis for this type of cancer. The inactivation of p53, 
not only stimulates cellular proliferation, but also gives rise to abnormal responses to DNA damage. 
Independent of the mechanisms, data studies appoint to the downregulation of the p53 pathway in 
more than 80% of all HNSCC cases (Partridge et al., 2007; Rothenberg and Ellisen, 2012). 
The Rb protein is involved in the initiation of cellular proliferation and is one of the most 
important proteins of the G1 checkpoint. The important role of Rb pathway is also evidenced through 
Figure 5 - Models of Genetic Instability and Progression in Head and Neck Cancer. The histologic evolution of HNSCC 
starts with normal characteristics and goes through hyperplasia, dysplasia, carcinoma in situ, invasive carcinoma and, 
finally, metastasis. According to this epithelium dysregulation, there is a progressive enhancement of genomic instability 
or aneuploidy and some molecular alterations are associated to different stages of the multistep progress. LOH: Loss of 
Heterozygosity. Adapted from: Haddad & Shin (2008) 
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the axis CCND1-CDK4/CDK6-RB, where oncogene CCND1 is amplified in more than 80% of 
HNSCC. This protein promotes cell cycle progression through activation of G1 phase cyclin-
dependent kinases (CDKs) 4 and 6. Together with the alterations in the p53, these changes lead to 
cellular immortalization (Rothenberg and Ellisen, 2012). 
1.2.5.2 Terminal differentiation – NOTCH pathway 
The NOTCH pathway has been associated to several cellular functions, such as regulation of 
self-renewal capacity, tumour angiogenesis, cell cycle exit and cell survival. Furthermore, NOTCH 
pathway is involved in squamous epithelium terminal differentiation promotion that can occur either 
through direct effects, such as the activation of suprabasal keratins, or through indirect effects, which 
involves the Wnt, Interferon and Hedgehog pathways. The NOTCH gene is inhibited in the basal 
epithelial cells by the transcription factor p63 and activation of p63 expression was observed in the 
dysplasic stage of HNSCC. Additionally, alterations in the Tumour protein 63 (TP63) that induced 
activation of p63, were observed in almost all of HNSCCs invasive cases (Rothenberg and Ellisen, 
2012; Sun et al., 2014). 
1.2.5.3 Cell survival – PI3KCA and EGFR pathways  
Several studies demonstrated that PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) 
pathway is commonly activated in HNSCC patients. PI3Ks are a family of enzymes, which function 
has been linked to the regulation of numerous cellular processes, like apoptosis, proliferation, cell 
cycle progression, cytoskeletal stability, motility, and energy metabolism. Many of these functions 
are related with the ability of PI3Ks to activate protein kinase B (AKT). Alterations in two genes that 
code for regulators of this pathway, phosphatase and tensin homolog (PTEN) and 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PI3KCA), are common. In 
the first one, loss of heterozygosity (LOH) is described in about 40% of all HNSCC cases. In the 
case of PI3KCA, gene mutations are activating and are thought to occur in 6-11% of the cases 
(Bussink et al., 2008; Stadler et al., 2008; Rothenberg and Ellisen, 2012). 
Epidermal Growth factor receptor (EGFR) is a member of the ErbB family, which is 
described as overexpressed in more than 90% of HNSCC cases. When the ligand binds to EGFR, it 
produces a conformation change that allows a homodimerization or a heterodimezition with another 
EGFR or another Human epidermal growth factor receptor (HER) family member, respectively. This 
action induces auto-activation. After phosphorylation, these molecules are able to bind to numerous 
molecules associated with many different signal transduction pathways. The EGFR overexpression 
is considered to be an early event in HNSCC progression and it is associated to a worse prognosis 
(Stadler et al., 2008; Leemans et al., 2011; Rothenberg and Ellisen, 2012). 
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The alterations mentioned are all associated with activities that prevents cell death indirectly. 
However, there are also alterations that are able to prevent cell death directly, like mutations in 
components of the apoptotic cascade. An example is mutations in caspase 8 (CASP8), which codes 
for the enzyme that is responsible for the initiation of the cascade (Rothenberg and Ellisen, 2012). 
1.2.5.4 Adhesion and Invasion – TGF-β/SMAD pathway 
Changes that lead to the inactivation of Transforming growth factor (TGF)-β pathway are 
common in all types of cancer, including HNSCC. This inactivation is mostly common through the 
loss of TGF-β receptor (TGFRB2) and the SMAD genes. These genes are mapped at chromosome 
18q, which is a region that is frequently lost in HNSCC patients. The inactivation of this pathway 
components via mutations is associated with tumour initiation and the activation of the pathway with 
metastasis promotion (Leemans et al., 2011; Rothenberg and Ellisen, 2012). Cohen et al. (2009) 
demonstrated that the loss of the TGF-β pathway was associated with the activation of nuclear factor 
kappa B (NFkB), a transcription factor that is important to the survival of the cells. 
 
1.2.6 Cytogenetic Alterations and Genes Common Altered in HNSCC 
Cytogenetic alterations have been considered useful for diagnosis and prognosis, not only 
for cancers, both also for other several malignancies. Additionally, they can point to specific genes 
that may be involved in the disease’s pathogenesis, helping in the understanding of the disease. 
However, classical cytogenetic analysis can be difficult because of many factors, including low 
mitotic index or small specimen size. In the specific case of the HNSCC, there is a small percentage 
(30%) of tumours that grow in culture and yield metaphases that are able to be analysed (Gollin, 
2001). 
Cytogenetic analysis of HNSCC samples have revealed consistent chromosomal 
breakpoints, structural chromosome rearrangements and homogeneously staining regions (hsr), 
which involve the centromeric region or juxtacentromeric bands and may result in whole-arm and 
Robertsonian translocations, and formation of isochromosomes. Isochromosomes have been 
identified for almost every chromosome. However, analysing karyotypes of HNSCC samples has 
proven to be a very difficult situation, not only by the points mentioned above, but also because they  
frequently range between diploid to pentaploid, with a large number of numerical and structural 
chromosome abnormalities (Gollin, 2001; Bockmuhl and Petersen, 2002; Martin et al., 2008). 
Recurring to different cytogenetic techniques it was possible to associate specific alterations 
to a particular stage in HNSCC development (Figure 5) (Haddad and Shin, 2008). 
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1.2.6.1 Region 3q 
The presence of an isochromosome 3q is common in HNSCC and gain of the distal part, 
seems to be one of the most frequent genetic gains. A few studies also considered it one of the most 
frequent alterations in HNSCC patients (Gollin, 2014; Ribeiro et al., 2014b). Gains in this region 
may suggest the presence of a cancer-related gene, such as ATR (ATR serine/threonine kinase), 
encoded at bands 3q22-q24. ATR is responsible for the checkpoint activation after stresses that 
damage the DNA. Previous studies showed that the overexpression of this gene could lead to tumour 
initiation and/or progression by promoting CIN. Other genes, like membrane metallo-endopeptidase 
(MME) (3q25.2), B-cell Lymphoma 6 (BLC6) (3q27), Hs.570518 (3q28), interleukin 12A (IL12A) 
(3q25.33) and TP63 (3q27-q29), were noticed to have extra copy numbers and are thought to be 
related to oral carcinogenesis (Gollin, 2001; Martin et al., 2008; Gollin, 2014; Ribeiro et al., 2014b). 
Another important proto-oncogene mapped in this chromosome arm is the PI3KCA (3q26.3). As 
described above, this pathway is commonly altered and it is part of the carcinogenesis process in 
HNSCC. In a study develop by Kozaki et al. (2006), mutations in the PI3KCA were associated to an 
advanced stage in HNSCC pathogenesis. 
1.2.6.2 Region 3p 
3p losses have been observed in dysplastic oral lesions, suggesting that they are associated 
to an early event in HNSCC carcinogenesis. One gene candidate in this region is the fragile histidine 
triad (FHIT) gene, which is a TSG that it is frequently lost in samples of HNSCC. It is mapped to 
3p14.2 and it is suggested that its loss of function plays a key role in the development and progression 
of this type of cancer. Loss of FHIT protein causes DNA damage and genetic instability. Other gene 
mapped in this region is the retinoic acid receptor beta (RARβ), that could help distinguish normal 
tissue from potential malignant lesions, since previous studies showed that 60% of the latter did not 
express this gene (Lotan et al., 1995; Gollin, 2001; Ribeiro et al., 2014b). 
1.2.6.3 Region 7p 
One of the major genes mapped in this region is the EGFR gene, which maps to band 7p12.3-
p12.1. The EGFR pathway is highly involved in HNSCC carcinogenesis, so it was foreseeable that 
the region where it is mapped showed alterations. There are several possible mechanisms that could 
explain EGFR overexpression, such as increased gene copy number, increased mRNA synthesis, 
decreased downregulation and expression of EGFRvIII. Studies have demonstrated that the increased 
expression of its protein and its ligand, TGF-α, could be a statistically significant predictor for disease 
recurrence and decreased overall survive (Gollin, 2001; Martin et al., 2008; Gollin, 2014). 
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1.2.6.4 Region 8q 
Like for other chromosomes, there are also reports of isochromosome formation for this 
region in HNSCC samples (Jin et al., 2001). However, there are also gains and losses on chromosome 
8 reported. Bands 8q24.12-q24.13 are very important in these tumours, since they encode the v-myc 
avian myelocytomatosis viral oncogene homolog (MYC) gene, an alteration observed in 70% of all 
cases in Ribeiro et al. study. Its amplification and overexpression has been observed in 10-40% of 
human oral tumours. MYC gene is also associated with poor survival rates. Other overexpressed 
genes encoded in the 8q chromosomal region are PTK2 (protein kinase 2) and WNT1 inducible 
signalling pathway protein 1 (WISP1). PTK2 is mapped in 8q24-qter, plays an important part in 
adhesion and growth-regulatory signal transduction and its overexpression has been associated with 
invasiveness. Gains of MYC and WISP1 genes are thought to be associated with tumours localized 
in the floor of the mouth (Gollin, 2014; Ribeiro et al., 2014a; Ribeiro et al., 2014b). When 
Bhattacharya et al. (2009) were studying the amplification of MYC gene in HNSCC samples, they 
proposed that MYC could be a predictor of the progression of dysplasia to hyperplasia in HNSCC  
Furthermore, gains involving bands 8q21.1-8q24.22, are thought to be an early event in oral dysplasia 
(Gollin, 2014). 
1.2.6.5 Region 8p 
The short arm of chromosome 8 is frequently lost in many tumours, including HNSCC. 
Losses are most frequent in three regions: 8p23.3, 8p22-p23 and 8p21. The genes that are usually 
deleted are CUB and Sushi multiple domains 1 (CSMD1), GATA binding protein 4 (GATA4) and 
microtubule associated tumour suppressor 1 (MTUS1). CSMD1, mapped at 8p23, is present in other 
epithelial cancers and it is associated with a poor prognosis, with reduced overall survival and a short 
interval without disease. Although GATA4 has been thought to be a tumour suppressor gene (TSG), 
its function in human cancer is not yet fully understood. MTUS1 gene has a potential role as tumour 
suppressor in HNSCC carcinogenesis and reduction of its expression could be associated with an 
advance stage in oral tongue squamous cell carcinoma (Gollin, 2001; Ribeiro et al., 2014a; Ribeiro 
et al., 2014b). 
1.2.6.6 Region 9p 
Associated with an early event in HNSCC development, loss of chromosome 9p is very 
common, in particularly breakpoints at 9p21, 9p13 and 9p11. Formation of isochromosomes 9q are 
also frequent (Gollin, 2014). LOH at 9p21-p22, is a common event, with a frequency of 72%. Band 
9p21 contains several TSGs, including CDKN2B, CDKN2A, CDKN2C and CDKN2D. All these 
genes encode for CDK inhibitors, which block cell cycle progression after the checkpoint of G1 
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phase. Inactivation of these genes may lead to loss of cell cycle checkpoints, which result in 
deregulation of cellular proliferation (Martin et al., 2008; Ribeiro et al., 2014b). 
1.2.6.7 11q13 Band 
This amplification has been very studied not only because it harbours a few oncogenes, but 
also because this amplification is very heterogeneous (Szyfter et al., 2014). 11q13 amplification 
usually occurs as a result of a breakage-fusion-bridges cycles initiated by a break at one chromosomal 
fragile site, FRA11F. This chromosomal change has been seen in about 50% of all HNSCC tumours. 
The 11q13 band contains 13-14 genes, most of all are overexpressed in HNSCC. This band contains 
the CCND1, considered one of the most important target genes in 11q13, which is thought to play a 
direct role in oral cancer. Overexpression of this protein can make the passage through the G1-S 
phase faster, leading to accumulation of genetic alterations, therefore, may leading to cancer. In 
HNSCC, CCND1 protein expression is correlated with less recurrence time, higher stage disease, 
lymph node involvement and reduced overall survival (Gollin, 2001; Martin et al., 2008; Gollin, 
2014). So, the overexpression of this gene has been associated with an aggressive tumour behaviour 
(Argiris et al., 2008). This amplification is considered as an early change in HNSCC and it is involved 
in the transition from moderate to severe dysplasia (Gollin, 2014). 
1.2.6.8 Region 11q 
Beside amplification of 11q13 band, there is also a common loss on chromosome 11. This 
loss is distal to the amplified 11q13 band. This deletion is thought to occur as a first step for the 
characteristic amplification, between the dysplasia stage and the carcinoma in situ stage. Together, 
amplification and loss, happens in about 50% of the cases of HNSCC. In this region are mapped 
several DNA damage responsive (DDR) genes, including caspase 1 (CASP1) (11q23), MRE11 
meiotic recombination 11 homolog A (MRE11A) (11q21), ATM serine/threonine kinase (ATM) 
(11q23.3), H2A histone family member X (H2AFX) (11q23.3) and checkpoint kinase 1 (CHEK1) 
(11q24.2) (Gollin, 2001; 2014; Ribeiro et al., 2014b).  
Moreover, amplification of 11q13 and loss of distal 11q have been associated with tumours 
of the tongue, retromolar trigone and buccal mucosa and provide a decreased survival. It has been 
pointed out that these combination could be used as biomarker for prognosis (Gollin, 2014). 
1.2.6.9 Region 13q 
Chromosomal deletion on region 13q is also common in HNSCC patients, especially at two 
bands: 13q12.11 (44%) and 13q14.2 (41%). One important gene mapped at 13q is the retinoblastoma 
gene, RB1 (13q14.2). Rb protein function was described above. Other gene that has also been 
considered is the inhibitor of growth family member 1 (ING1) gene mapped at 13q34. This is also a 
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TSG as it is proposed that the mutations occurred would lead to the suppression of its normal function 
(cooperates with p53, preventing cell growth) (Gollin, 2014; Szyfter et al., 2014). 
1.2.6.10 Region 17p 
Mapped at 17p13.1 is TP53 gene. Disruption of the p53 pathway is one of the most frequent 
alterations in HNSCC, which happens through mutations, LOH or interaction with viral proteins. 
Mutations in this gene are often present in 50-80% of HNSCC tumours and are associated to an early 
stage of carcinogenesis. They can even be detected in premalignant dysplasic lesions and in the 
surgical margins considered to be histopathological negative for tumours. TP53, a TSG, is often 
called “the guardian of the genome” due to its involvement in cell cycle arrest, DNA repair and 
apoptosis. Furthermore, alterations of p53 seem to be particular relevant for HNSCC development 
since two major risk factors, tobacco carcinogens and HPV, target this protein (Blons and Laurent-
Puig, 2003; Loyo et al., 2013). 
There is some controversial about the prognostic significance of TP53 mutations among the 
science community, however, TP53 mutations are frequently associated with reduced survival, at 
least after surgical treatment (Argiris et al., 2008). However, mutations in the gene are not the only 
way that p53 expression could be altered. It can also be a consequence of the tumour development 
process, radiation, among others (Scully et al., 2000). 
Other genes have also been found to be lost in HNSCC samples that are mapped at 
chromosome 17, like breast cancer 1 (BRCA1) (17q21) and v-crk avian sarcoma virus CT10 
oncogene homolog (CRK) (17p13.3) (Ribeiro et al., 2014b). 
1.2.6.11 Region 18q 
Loss of the q-arm of chromosome 18 has been well documented as a cytogenetic alteration 
common in HNSCC, however, the relevant TSG of this region has not yet been determined. 
Nevertheless, it is known to be associated with an advanced stage of the tumour development and 
poor prognosis (Scully et al., 2000; Gollin, 2014). 
DCC netrin 1 receptor (DCC) and serpin peptidase inhibitor, clade B (ovalbumin) member 
13 (SERPINB13) are examples of genes in this location that are frequently deleted. LOH of DCC 
gene has been observed and associated to a decreased survival, however, it is only altered in 12-24% 
of the cases. SERPINB13 is normally expressed in normal oral mucosa, oral keratinocytes and skin 
but it is poorly expressed in HNSCC, which suggest that its reduced expression may be involved in 
HNSCC development (Gollin, 2001; Martin et al., 2008; Ribeiro et al., 2014b). 
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1.2.7 Epigenetic Alterations 
Epigenetic changes, which occur more frequently than gene mutations, are modifications in 
gene function that are mitotically and/or meiotically heritable without alterations of the DNA 
sequence. They can persist for the entire cell life or even for multiple generations.  
Several differentiation processes are regulated through epigenetic mechanisms. Then, 
disruption of epigenetic mechanisms can lead to gene expression alterations, which can induce 
carcinogenesis and other diseases (Table 1). Since they can be reversible, epigenetic changes are 
more attractive therapy targets than genetic alterations (Mascolo et al., 2012; Arantes et al., 2014). 
Table 1 - The most frequent epigenetic alterations. Adapted from: Mascolo et al. (2012) 
Epigenetic Change Putative Mechanism Biological Consequence 
 
DNA hypomethylation 
Activation of cellular oncogenes 
 
Activation of transposable elements 
Increased proliferation, 
growth advantage 
Genomic instability, 
transcriptional noise 
DNA 
hypermethylation 
De novo hypermethylation of CpG 
islands within gene promoters 
leading to silencing of TSG and 
cancer-associated genes 
Genomic and chromosomal 
instability, increased 
proliferation, growth 
advantage 
Loss of imprinting 
Reactivation of silent alleles, biallelic 
expression of imprinted genes 
Expansion of precursor cell 
population 
Relaxation of X-
chromosome 
inactivation 
Mechanisms is unknown but it 
appears to be age-related 
Altered gene dosage, growth 
advantage 
 
Histone acetylation 
Gain-of-function 
 
Loss-of-function 
Activation of tumour 
promoting genes 
Defects in DNA repair and 
checkpoints 
Histone deacetylation Silencing of TSG 
Genomic instability, 
increased proliferation 
Histone methylation 
Loss of heritable patterns of gene 
expression (“cellular memory”) 
Genomic instability, growth 
advantage 
MicroRNAs (miRNAs) 
amplification in cancer 
Function as oncogenes Neoplastic transformation 
miRNAs deletion in 
cancer 
Function as tumour suppressors Neoplastic transformation 
 
1.2.7.1 DNA Methylation 
DNA methylation, the most common and studied epigenetic modification, is a known 
mechanism for silencing gene expression and maintenance of genomic stability. The DNA 
methylation machinery in mammals is composed of DNA methyltransferases (DNMTs) and 
methylCpG binding proteins (MBDs). The function of the first ones is to establish and maintain DNA 
methylation patterns, where the second ones are capable of detecting the methylations marks. This 
epigenetic alteration occurs more frequently at repetitive genomic regions. DNA methylation is the 
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covalent addition of a methyl group to the 5-carbon position of cytosine to bases that are located 5’ 
to a guanosine base in a CpG dinucleotide. CpG dinucleotides are often found in clusters, were they 
are called CpG islands (Robertson, 2005; Mascolo et al., 2012). 
Methylation can affect gene expression by two principal mechanisms: (1) it can interfere 
directly with the ligation of factors that are sensible to methylated CpG islands; (2) cytosines 
methylated can be recognised by the methyl binding domain (MBD) protein family which is 
responsible for the recruitment of enzymes that remodel the chromatin, like histone deacetylases. 
The result will be condensation of chromatin and, consequently, the silencing of the neighbouring 
gene (Delpu et al., 2013). 
Several studies through the years showed that DNA methylation has a crucial role in the 
development of the cancer genome (Figure 6), since this particular epigenetic mutation is considered 
an early event in carcinogenesis. There are, at least, three different ways by which CpG methylation 
could lead to cancer: hypomethylation of the cancer genome, hypermethylation of the promotors of 
TSG and direct mutagenesis. CpG islands are usually localized at the promoter of TSG and this event 
can contribute to carcinogenesis, since CpG islands are often hypermethylated in tumours 
(Hatziapostolou and Iliopoulos, 2011). 
Hypermethylation results in alterations in chromatin structure, which leads to the silencing 
of the TSG transcription, since it blocks the accessibility of the transcription factor to the promoter. 
The genes most frequently hypermethylated reside in chromosome regions that usually shows signs 
of LOH (Mascolo et al., 2012). 
Besides hypermethylation, hypomethylation can also occur in tumour cells, mainly due to 
the loss of methylation from repetitive regions of the genome, which could lead to the genomic 
instability often seen in cancer. Furthermore, hypomethylation of the genome can also induce re-
expression of silenced genes. It is important to refer that hypomethylation was the first epigenetic 
Figure 6 - DNA methylation and cancer. The diagram shows a representative region of genomic DNA in a normal 
cell. The region shown contains hypermethylated pericentromeric heterochromatin and an actively transcribed 
tumour suppressor gene associated with a hypomethylated CpG island (indicated in red). Adapted from: 
Robertson (2005)  
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alteration identified in tumours (Robertson, 2005; Hatziapostolou and Iliopoulos, 2011; Delpu et al., 
2013).  
In HNC, methylation is the epigenetic change most studied and promoter methylation has 
been found in a large number of genes. One of the most important risk factors for HNSCC, tobacco, 
has been linked to non-specific hypomethylation. Contrarily, alcohol consumption has been 
associated to an enhancement of hypermethylation at CpG islands. Methylation has been well studied 
in oral squamous cell carcinoma (OSCC) and genes that are methylated in OSCC are involved in 
various cellular processes, including cell cycle control, apoptosis, DNA repair and cell to cell 
adhesion (Viswanathan et al., 2003; Gasche and Goel, 2012; Mascolo et al., 2012) . 
A lot of studies have, nowadays, focused in analyse the promoter methylation of TSGs panels 
that play a role in vital cellular mechanisms. As a result, there is knowledge of numerous genes that 
are methylated in head and neck cancer (Table 2) (Demokan and Dalay, 2011). 
Recently, Worsham et al. (2014) have tried to delineate an epigenetic progression model for 
HNSCC based on different reports of genes hypermetylated (Figure 7). Hypermethylation of 
CDKN2B, CDKN2A, APC and BRCA2 were proposed to occur as epigenetic events leading to the 
progression to a stage of carcinoma. 
  
Figure 7 – Possible epigenetic model of HNSCC regarding DNA hypermethylation. They suggested that DNA 
hypermethylation of CDKN2B, CDKN2A, APC, BRCA2, DAPK1, HIC1, TP73, and ESR1 were early events in 
tumorigenesis, whereas CDH13, CHFR, CADM1 and RARβ were primary tumour-specific events. Finally, KLK10 and 
FHIT were associated to metastasis devolpment. Adapted from: Worsham et al. (2014). Histological images were taken 
from Digital Pathology – Brown Medical School 
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Table 2 – Some candidate genes frequently methylated in HNC. Adapted from: Demokan and Dalay (2011) 
Gene Gene name Gene function 
Methylation 
range (%) 
APC Adenomatous polyposis coli Tumour suppression 21-34 
ZMYND10 MYND-type containing 10 Tumour suppression 34-74 
CCNA1 Cyclin A1 Cell cycle 45-53 
CDH1 E-cadherin Cell adhesion 23-85 
CHFR 
Checkpoint with forkhead and 
ring finger domains, E3 ubiquitin 
protein ligase 
Early G2/M checkpoint 19-61 
DAPK1 Death-associated protein kinase 1 Apoptosis 7-77 
DCC DCC netrin 1 receptor Tumour suppression 50-75 
DLC1 
DLC1 Rho GTPase activating 
protein 
Tumour suppression 43-89 
DLEC1 
Deleted in lung and esophageal 
cancer 
Tumour suppression 60-86 
EDNRB Endothelin receptor type B Signalling mechanism 60-97 
SCGB3A1 
Secretoglobin, family 3A, 
member 1 
Tumour suppression 7.3-77% 
MLH1 mutL homolog 1 DNA repair 32.5-50 
MSH2 mutS homolog 2 DNA repair 30-50 
KIF1A Kinesin family member 1A 
Axonal transport of 
synaptic vesicles and cell 
division 
35-98 
MGMT 
O(6)-methylguanine-DNA 
methyltransferase 
DNA repair 6-56 
APBA1 
Amyloid beta precursor protein-
binding 
Synaptic vesicle exocytosis 23-48 
CDKN2AARF 
Alternative open reading frame 
(ARF) of INK4a locus 
Tumour suppression 14-34 
CDKN2B 
Cyclin-dependent kinase inhibitor 
2B 
Tumour suppression 22-65 
CDKN2A 
Cyclin-dependent kinase inhibitor 
2A 
Tumour suppression 5-68 
UCHL1 
Ubiquitin carboxylterminal 
esterase L1 (ubiquitin 
thiolesterase) 
Processing of ubiquitin 
precursors and of 
ubiquitinated proteins 
60-82 
RARβ Retinoic acid receptor beta Tumour suppression 15-80 
RASSF1 
Ras association (RalGDS/AF-6) 
domain family member 1A 
Tumour suppression 2.4-84 
RASSF2 
Ras association (RalGDS/AF-6) 
domain family member 2 
Tumour suppression 22-51 
SFRP1 Secreted frizzled-related protein 1 
Inhibition of Wnt 
signalling 
24-58.6 
RARRES1 
Retinoic acid receptor responder 
(tazarotene induced) 1 
Response to retinoic acid 
receptor 
51-91 
TIMP3 
Tissue inhibitor of 
metalloproteinases 3 
Inhibition of angiogenesis 
and tumour growth 
40.5-71.8 
WIF1 Wnt inhibitory factor 1 
Inhibition of Wnt 
signalling 
85-89.7 
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1.3 RADIOTHERAPY IN CANCER 
In 1961, Munro and Gilbert published a paper in which they mentioned the goal of using 
radiotherapy to treat cancer: “the object of treating a tumour by radiotherapy is to damage every 
single potentially malignant cell to such an extent that it cannot continue to proliferate” (Munro and 
Gilbert, 1961). 
Although surgery is the primary form of treatment for the majority of the tumours, it is 
estimated that half of all cancer patients are submitted to radiotherapy at some point during their 
treatment. Surgery gives good treatment results in tumours early detected and non-metastatic, 
however radiotherapy is a good alternative for the long-term control of several tumours, such as head 
and neck cancers (Joiner and van der Kogel, 2009). 
The principle of radiation treatment of cancer is that cells with high proliferative rates are 
more sensitive to radiation, meaning that cancer cells are more sensitive to radiation than normal 
cells (Kelsey et al., 2013). Radiation therapy uses low and high linear energy transfer (LET – number 
of ionizations which radiation causes per unit of distance as it trespasses the living cells or tissue) 
radiations in order to kill the most possible malignant cells, while minimizing the effects on normal 
tissues and trying to prevent toxicity on them. Over the years, improvements have been made in 
radiotherapy treatment, increasing the number of cancer survivors. However, tissue toxicities due to 
late effects induced by radiation in normal cells are a major problem, especially in children (Figure 
8) (Baskar et al., 2014; Barker et al., 2015). 
Figure 8 - Biological effects and normal tissue toxicity after radiotherapy. The early biological effects of 
irradiation lead to acute tissue effects that usually are transient. However, these can also lead to late biological 
effects than can be notice in tissues or by the appearance of secondary malignancies. Moreover, both early and 
late effects affect therapeutic efficacy and patients’ quality of life. Adapted from: Barker et al. (2015) 
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1.3.1 Effects of Radiation on Tissue 
There are four effects of radiation on tissues: direct effects, indirect effects, bystander effects 
and adaptive response. 
The major effect of ionizing radiation is the direct cell killing, which occurs mostly by 
producing DNA damage. When the interaction of the energetic charged particles occurs directly with 
the target in cells, the process is referred as direct action, producing direct effects. When the 
interaction occurs with water molecules in the cell, the radiation produces free radicals. Free radicals 
interact strongly with biomolecules, producing damaging chemical reactions, which leads to damage 
in cells. This process produces indirect effects, which correspond to 60% of the damage cause by 
irradiation (Kelsey et al., 2013; Baskar et al., 2014). 
Recently, radiobiologists found that radiation not only affect adjacent cells of the tumour but 
it is also able to affect cells far away, due to the transmission by gap-junctions, cytokine-mediated 
cellular toxicity or by the involvement of cellular and microenvironmental signalling cascades. This 
phenomenon has been called bystander effect. The radiation-induced bystander effect refers to the 
ability of radiation to induce alterations, commonly reported in directly irradiated cells, in non-
irradiated cells, like induction of cell death, sister chromatid exchanges, formation of micronuclei, 
mutations and delay in cell cycle. Chromosomal aberrations can arise de novo in cell progeny several 
generations after irradiation (Baskar et al., 2014). 
 Finally, ionizing radiation also triggers cancer cells adaptive responses. In response to 
irradiation, several resistant signal transduction pathways become activated. This resistance can be 
an intrinsic characteristic of the cell or can be acquired due to fractionated radiation treatment. This 
will give those cells a selective advantage, since they end up with a higher proliferative ratio or with 
capability to evade cell death. These adaptive responses are major clinical problems nowadays and 
there are several molecular events that allow tumours to become radioresistant, such as ligand-
independent activation of signal transduction pathways. The greater example are those regulated by 
membrane-bound receptor tyrosine kinases (RTK), such EGFR (Baskar et al., 2014). 
 
1.3.2 Irradiation-induced damage 
Ionized molecules affect the cells randomly, causing damage to the molecules. However, 
there are several copies from the most of the molecules, and the majority undergo a continuous and 
rapid turnover. So, the damage to these molecules turns up to be very small. Contrary, the DNA only 
has two copies, turning it to the most affected molecule on a cell by irradiation. 1 Gy (Gray) of 
irradiation can cause, in each cell, approximately 105 ionizations, more than 1000 damages to DNA 
bases, about 1000 single-strand DNA breaks (SSBs) and 20-40 double-strand DNA breaks (DSBs). 
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However, due to efficient DNA repair, 1 Gy will only kill about 30% of cells (Joiner and van der 
Kogel, 2009). 
Regarding SSBs, they are easy to repair, since the intact strand serves as template. DSBs are 
more difficult and more likely to result in deficient repair, once the molecule may come apart. Most 
DSBs are lethal to the cells because they will trigger DNA checkpoints in cell cycle. Taking this into 
consideration, DSBs are the greater source of cell killing due to radiation (Kelsey et al., 2013). 
Moreover, radiation can originate chromosomal aberrations, of which there are two types: 
Chromosome aberrations and chromatid aberrations. The first ones happen early in interphase, before 
DNA duplication and the last ones happen later in interphase, after S phase of cell cycle. Many 
different types of aberrations can occur and, generally, three of them are considered to be lethal for 
the cell, two of which are chromosome aberrations and one is a chromatid aberration. Dicentrics, a 
type of chromosome aberration, happens when two different chromosomes suffer breaks and re-join, 
being subsequently replicated during S phase. The dicentric chromosome will have two centromeres, 
causing problems during anaphase. The other type of lethal chromosome aberration is the ring 
formation, that happens when one chromosome has breaks in both arms and is able to reconnect 
itself. It is replicated, however the problems happen during mitotic spindle in anaphase. The anaphase 
bridge is the lethal chromatid aberration and it happens after the damage sister chromatids fail to 
separate properly, going to one of the poles of the cell. Regarding non-lethal aberrations, examples 
are translocations and small interstitial deletions (Kelsey et al., 2013). 
 
1.3.3 Irradiation-induced cell death 
Cells respond to irradiation by the activation of the DNA damage response and cell cycle 
arrest, leading to senescence or apoptosis of the cells irradiated. Nowadays, it is still not know 
precisely which pathways are responsible for these mechanisms (Partridge et al., 2007; Eriksson and 
Stigbrand, 2010). It is, however, important to highlight that, in the context of radiobiology, cell death 
is referred to any process that results in loss of clonogenic capacity (Joiner and van der Kogel, 2009). 
The effects of radiation on cells depends on the LET, total dose, fractionation rate and 
radioresistance/radiosensitivity of the target cells (Eriksson and Stigbrand, 2010). Cell death to 
irradiation is due to autophagy, senescence, apoptosis, necrosis and mitotic catastrophe (Joiner and 
van der Kogel, 2009). 
Radiation-induced apoptosis was considered one of the main cell death mechanism after 
radiation therapy and the central characteristics of this controlled mechanism of cell death are often 
seen: pyknosis, cell shrinkage and internucleosomal breakage of chromatin. As described 
extensively, apoptosis is due to the activation of caspases, a family of proteases. These proteins are 
activated when the cell receive external and internal stimuli’s, one example is radiation. Radiation 
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can induce apoptosis either via the extrinsic and intrinsic pathways. The endpoint of both these 
pathways is the activation of the effectors caspase-3, caspase-6 and caspase-7, which play important 
roles in apoptosis. Apoptosis is the major cell death mechanism, however, the majority of cancer 
cells lose their pro-apoptotic mechanisms during tumorigenesis. So, there have to be other types of 
cell death mechanisms involved in the death of cancer cells after radiation (Partridge et al., 2007; 
Eriksson and Stigbrand, 2010). 
Nowadays, mitotic catastrophe is considered to be the major radiation-induced cell death 
mechanism for solid tumours. Mitotic catastrophe is used to refer to a cell death that occurs as a result 
of an aberrant mitosis and can be induced by several agents that are able to damage the DNA, 
radiation included. Two important mechanisms have been proposed for the initiation of this type of 
cell death. The first one is related with problems in the cell cycle checkpoints and DNA damage. 
Since the majority of cancers have alterations in the cell cycle checkpoints, the mitotic catastrophe 
is the cancer cells response to DNA damage. Secondly, it is proposed that hyperamplification of 
centrosomes could lead to mitotic catastrophe. Centrosomes are important during mitosis in order to 
organize the microtubule centres and in the formation of bipolar mitotic spindles. The 
hyperamplification of centrosomes could result in abnormal chromosome segregation and originate 
cells with nuclei alterations. This will lead to mitotic catastrophe (Eriksson and Stigbrand, 2010). 
Other type of cell death induced by radiation is senescence, referred as a condition of 
permanent cell cycle arrest, and can occur after extensive cellular stress induced by a number of 
DNA damaging agents. DDR are induced after radiation, they sense the damages of the DNA and 
transmit information in order to activate a transient cell cycle arrest wherefore the DNA will be 
repaired. DNA damage not repaired will induce cell death, by apoptosis or mitotic catastrophe, or 
activate a persistent and chronic DDR signalling, leading to senescence. This will prevent DNA 
damage to be passed for the next cell generations (Eriksson and Stigbrand, 2010). 
Autophagy describes a process in which cells are able to digest parts of their own to generate 
small macromolecules and energy. This process has been observed after treatment, however it is 
currently unknown if it represents an attempt by the cell for survival or if it is an induced type of cell 
death. As for necrosis, it is generally thought to be an uncontrollable type of cell death, however 
proves have appear that this could also be regulated by the cell. Necrosis is also commonly observed 
in tumour after treatment with radiation (Joiner and van der Kogel, 2009). 
 
1.3.4 Radiotherapy in HNSCC 
Radiotherapy is one option for HNSCC’s treatment. Radiotherapy alone results in high 
tumour control and cure rates for early stage glottis, base of tongue, and tonsillar cancer (Argiris et 
al., 2008). 
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The amount of radiation given in the treatment of HNSCC usually is 2 Gy in daily fractions, 
5 days a week, reaching up to total of 70 Gy through 7 weeks. When radiotherapy is interrupted for 
a long time it can have a harmful effect because of repopulation of cancer cells (Argiris et al., 2008). 
Two major fractionation variants have been tested to make possible to delivery multiples 
fractions per day: hiperfractionation and accelerated fractionation. The first one was designed to 
improve effectiveness by delivering two or three fractions every day, but with reduce dose per 
fraction. The second one was designed to increase radiation dose intensity in a short period of time. 
Phase III trials showed that these approaches improve loco-regional control with enhance infield 
toxic effects, but with greater effects on survival, when compared with conventional radiotherapy 
(Argiris et al., 2008). The toxicities originated from radiotherapy include mucositis, xerostomia, 
dermatitis and dysphagia, which leads to reduced quality of life and morbidity (Bhide and Nutting, 
2010). 
 
1.3.5 Radioresistance in HNSCC 
The terms “radiosensitive” and “radioresistant” are common to describe tumours that regress 
rapidly or slowly, respectively, after radiation treatment. Resistance to radiotherapy is very common, 
and it is related with a worse prognosis. Radioresistance can have three different results: (1) no 
treatment response at all, (2) only a partial response to treatment or (3) it can cause that recurrences 
appear too early. Radioresistance is a major clinical problem, since affects the probabilities of tumour 
control and the patient quality of life (IAEA, 2010; Perri et al., 2014). The response rate to 
radiotherapy from a tumour is highly dependent on the proliferative capability of cells, because the 
majority die due to cell cycle checkpoints activation, leading to promotion of cell death. So, a tumour 
that has a high proliferative ratio will regress quickly, because its cell will die faster (IAEA, 2010). 
There are a few mechanisms proposed as potential causes for radioresistance, however, the 
three major biological factors associated with this adverse effect are (1) intrinsic radiosensitivity, (2) 
hypoxia and (3) capacity of cancer cells to repopulate after the treatment (Baskar et al., 2014). 
Furthermore, it is important to highlight that the infection of HPV can influence tumour 
behaviour, such as the tumour vascularity. Since these patients respond better to the treatment than 
HPV-negative patients, it is hypothesized that the virus can modify one of the three factors highly 
related to radioresistance (Begg, 2012). 
1.3.5.1 Intrinsic Radiosensitivity/Radioresistance 
Several scientists worldwide have been hypothesized about a lot of genes and chromosomal 
regions that could be involved in intrinsic radiosensitivity/radioresistance to radiotherapy. However, 
as many predictor studies, these results lack independently validation and possible mechanisms that 
explain how they are involved (Begg, 2012). 
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One of the examples of how molecular alterations can be involved in radiation response is 
the ligand-independent activation of signal transduction pathways, as RTKs, such as EGFR, which 
plays an important role in the regulation of several downstream signalling pathways. Examples are 
the PI3K and its downstream effectors AKT and mTOR, signal transducer and activator of 
transcription (STAT) pathway and Ras-mitogen-activated protein kinase (MAPK) pathway. These 
pathways are involved in almost all hallmarks of cancer: cell cycle and cell survival, invasion, 
metabolism, angiogenesis and genomic instability. The PI3K-AKT-mTOR signalling pathway has 
been studied as one of the most important pathways involved in the resistance to cancer treatment 
(Bussink et al., 2008; Baskar et al., 2014). 
Regarding chromosomal regions, it has been previous described an association between 
distal 11q loss and radioresistance (Parikh et al., 2007). This loss is in the neighbouring of ATM gene, 
and the protein ATM is essential for survival of cells after irradiation. It was proposed that a 
chromatin protein, H2AX, plays a role in the induction and repair of DSBs. This protein, H2AX is 
phosphorylated, minutes after irradiation-induced DSB, by ATM. However distal loss of 11q is 
associated with decreased expression of ATM and H2AXF. The proteins ATM and H2AX are 
important members of ATM-CHECK2 DNA damage repair pathway and, since their levels are 
reduced, the cell upregulate ATR-CHECK1 pathway, resulting in a prolonged S and G2/M 
checkpoint arrest. The cells with this loss seem to “repair” the damage DNA in this prolonged arrest, 
enabling them to progress through the cell cycle without suffer mitotic catastrophe. This enables 
survival and result in decreased sensitivity to irradiation (Begg, 2012; Sankunny et al., 2014). 
Moreover, a lot of studies have been developed in order to discovery a panel of biomarkers 
responsible for the radioresistance seen in HNSCC tumours (Higo et al., 2005; Toulany et al., 2005; 
Ishigami et al., 2007; Eckers et al., 2014; Skvortsov et al., 2014; Van Limbergen et al., 2014). 
1.3.5.2 Repopulation of cancer cells 
The first evidence of repopulation of cancer cells came from a study that showed that local 
tumour control was decreasing when the overall duration of radiotherapy was increasing. The main 
reason behind this event was the enhancement of tumour cell proliferation due to the loss of cells 
during treatment (Bussink et al., 2008). 
HNSCC cells have a high capacity of rapid repopulation after irradiation treatment and that 
is one of the reasons that leaded to the study of other type of therapies, like accelerated fractionation. 
Cell proliferation could be affected by many factors such as differentiation stage, cell-cycle 
regulation and even microenvironmental factors, like hypoxia (Bussink et al., 2008; Begg, 2012). 
In the majority of cancers, high proliferation rate has been considered a bad prognostic factor, 
however, in HNSCC patients, the proliferation signatures were not predictive. It was proposed that 
the response capacity to HNSCC therapy could be a more important factor to predict the tumour 
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population rate than proliferation. This response capacity is hypothesized to correlate with the 
differentiation stage (Begg, 2012). 
1.3.5.3 Hypoxia 
The term hypoxia refers to a reduction in the normal level of oxygen tensions, being hypoxia 
a condition where tissues are not sufficient oxygenated, usually due to a deficient oxygen 
concentration in the blood. It is considered to be an important factor that leads to the metabolism 
reprogramming seen in cancer cells. When severe or protracted, it could result in cell death. Tumours 
become hypoxic because they develop new blood vessels that are aberrant and have a decreased 
blood flow. Hypoxic is toxic to both normal and cancer cells, since it is able to alter the DNA 
replication and genomic instability; however, the last ones undergo a series of genetic alterations that 
enable them to proliferate and survive in these extreme conditions. This effect is associated with an 
aggressive tumour behaviour and, thus, to a more malignant phenotype (Weinberg, 2013). 
Solid tumours which undergoes rapid growth, exceed vascularization and the result is a lack 
of nutrients and oxygen supply. Within these conditions, the hypoxia-inducible transcription factor 
1 (HIF-1) pathway becomes activated. In the lack of oxygen, HIF-1 binds to hypoxia-response 
elements (HREs). This ligation induces the expression of a series of target genes, involved in 
angiogenesis, glycolysis, growth-factor signalling, immortalization, genetic instability, tissue 
invasion and metastasis, apoptosis and pH regulation (Harris, 2002; Pereira et al., 2013; Weinberg, 
2013; Suh et al., 2014). 
Radiation creates DSBs in the DNA and these breaks can trigger cell cycle arrest and cell 
death. Oxygen can potentiate the production of reactive oxygen species (ROS)/free radicals, which 
are essential for the occurrence of the DSBs. With the growth of the tumours, the microenvironment 
lacks blood supply, leading to hypoxic areas. Since this hypoxic areas lack oxygen, the breaks in the 
dsDNA will not occur so easily and the desired effects of radiation would not happen (Hsu et al., 
2014). Furthermore, it is been reported that the DNA damage produced by free radicals can be 
repaired in hypoxic environments and, in opposite, at normoxic conditions, the oxygen is able to 
react with the DNA radicals and produce stable organic peroxides. Also, hypoxia is able to alter the 
expression and function of proteins that are involved in the DSB repair, such as the number of 
phosphorylated histone H2AX foci and it is also able to decreases the levels of the Rec A 
recombinase (RAD51) protein. By decreasing the levels of this protein, hypoxia inhibit homologous 
recombination DNA repair (Peitzsch et al., 2014). 
 Hypoxia is frequent in HNSCC. It is important to highlight that hypoxia has been considered 
a negative prognosis factor for radiotherapy, chemotherapy and also surgery. It is well established 
that solid tumours may contain oxygen-deficient hypoxic areas and that cells in those areas can make 
tumours radioresistant. (Bussink et al., 2008; Begg, 2012). In HNSCC, hypoxic areas are often 
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present and it is thought that they could be associated with the resistance to ionizing radiation that is 
often seen in patients (Koontongkaew, 2013; Perri et al., 2014). 
1.4 LAB TECHNIQUES  
1.4.1 Cell Culture and Karyotyping 
Primary cultures is the term used to refer to cultures that were prepared directly from a tissue 
or an organ. They can be subcultured for a certain amount of time, being called secondary cultures. 
The use of trypsin only become common in the 50s after Dulbecco described its utilization in 
monolayer cultures for viral plaque assays (Freshney, 2005; Alberts et al., 2007). Grey, in 1952, was 
the responsible for a huge breakthrough in the field: he was able to establish the first continuous 
human cell line, the known HeLa cells (Freshney, 2005). 
Cell culture have developed much and this is due especially to two branches of medical 
research: the demand for knowledge of neoplasia and the production of antiviral vaccines. Nowadays, 
tissue culture has a spectrum of applications (Freshney, 2005). 
Commercial cell lines are an attractive option to be used as models for cancer research, since 
they are promptly and economically available. Furthermore, several of them are well described in 
literature regarding biochemical, pharmacological and genetic characteristics. However, one of the 
most important reasons is the fact that various cancer cell lines are well suited to allow the 
characterization of the pathophysiological properties of individual tumours. For example, the detailed 
study of cancer cell lines allows the forethought of several biomarkers and responses to target 
inhibiton (Dudley et al., 2011).  
It was in the XIX century that the chromosomes were, for the first time, identified. However, 
the right chromosome complement was only established in 1956. After this, the association between 
Down’s syndrome and the presence of an extra chromosome was a big step for the utilization of 
karyotyping in research. In 1969, the development of chromosome banding allowed the detection of 
more subtle structural chromosomal abnormalities. Furthermore, the enhancement of the knowledge 
regard to malignant diseases and the development of the cell culture methods led to the first discovery 
of chromosomal abnormalities in malignant tumours. This discovery was a specific characteristic of 
chronic myelogenous leukemia, the Ph1 chromosome (Faas et al., 2011). 
Almost all of the chromosome banding methods are made by staining of the chromosomes 
in mitosis. This is achieved by treating cells with tubulin inhibitors, such as colchicine or colcemid. 
These tubulin inhibitors, inhibit microtubule polymerization by binding to the tubulin, arresting the 
cells in metaphase. After, the use of dyes, like Giemsa, allows distinction of AT-rich chromosomal 
regions from GC-rich chromosomal regions in a unique banding pattern for each chromosome. The 
utilization of dyes makes possible the association between chromosome abnormalities and diseases. 
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The most common chromosome banding methods are the G (Giemsa) banding, the R (Reverse) 
banding, the C (centromere) banding and the Q (Quinacrine) banding (Bickmore, 2001). 
Conventional karyotyping is a highly reliable method to diagnose any aneuploidy and 
genomic structural rearrangement with about 5-10 million base pairs (bp) of length. Also, it allows 
visualization of all chromosomes. However, it also have some limitations associated. It is time 
consuming, since cell culture is an obligatory step. To the current days, its resolution is quite limited, 
which can lead to interpretation difficulties. It is necessary to have personnel with specific formation 
in order to analyse correctly the karyotype, leading to an increase in the costs. Finally, it also is 
hardworking and expensive (Boormans et al., 2008; Faas et al., 2011). 
 
1.4.2 Methylation-Specific Multiplex Ligation-dependent Probe Amplification (MS-
MLPA) 
The Multiplex Ligation-dependent Probe Amplification (MLPA) was developed in 2002 and 
is an extension of the Polymerase Chain Reaction (PCR). In opposite of the common PCR, MLPA 
is a technique were the DNA is not the one that is amplified, but instead the probes are. They are 
amplified using only one PCR prime pair, which allows a simultaneous and semiquantitative 
amplification of up to 50 MLPA probes in just one reaction (Schouten et al., 2002). 
MLPA comprises four steps:  Denaturation and hybridization; Ligation; PCR amplification; 
Capillary electrophoresis and fragment analysis. Each MLPA probe is constituted with two 
oligonucleotides, one synthetic and other derived from the single chain bacteriophage M13. These 
oligonucleotides hybridize to adjacent locations from the target sequence. After successful 
hybridization to their target sequences, the ligase is added. At this point, the probe can be amplified 
by PCR. Every probe has identical final sequences, which allows the amplification by a universal 
primer pair labelled with a fluorophore. Each probe is able to produce an amplification product of 
unique length that will ranges from 130-480 bp. This is possible because one of the oligonucleotides 
has a stuffer sequence of unique length for each probe, allowing fragment separation and 
quantification accordingly to their length and fluorescence intensity by capillary electrophoresis 
(Figure 9) (Schouten et al., 2002; MRC-Holland, Accessed: 22-05-2014). 
MLPA is a method capable of detect gene copy number status, DNA methylation and point 
mutations simultaneously. In order to detect promotor hypermethylation, the variant of MLPA, MS-
MLPA is used. In this variant, the methylation-sensitive restriction enzyme HhaI is the crucial 
component. However, there is an obvious limitation, this detection only happen in hot spots of 
methylation that contains the recognition site (GCGC) for HhaI. MS-MLPA is quite similar to 
MLPA, however, the samples are divided in two after the ligation step. One half is submitted to the 
endonuclease HhaI and the other remains undigested. If the sample is not methylated in the 
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recognition sequence of HhaI, it will cut the probe-sample DNA hybrid and the fragment would not 
be amplified. If the DNA is methylated, the enzyme would not be able to cut and the fragment will 
be amplified. In the analysis step, the uncut and the cut samples will be compared, allowing the 
determination of status’ methylation (Homig-Holzel and Savola, 2012; MRC-Holland, Accessed: 02-
01-2015). 
1.4.3 Array Comparative Genomic Hybridization (aCGH) 
In the last years, chromosomal microarray analysis (CMA), like comparative genomic 
hybridization, aCGH and single nucleotide polymorphism array, have become widely used in both 
research and diagnostic. CMA combines a high resolution analysis of variations in the copy number 
of all the genome with a short time of procedure. Also, it has a high income and allow the observation 
of alterations with 1kb of resolution (Armengol et al., 2012; Evangelidou et al., 2013). 
The principle associated with aCGH is based in the detection of chromosomal deletions and 
duplications, by comparison of equal genomic DNA quantities between a patient and a healthy 
control. In aCGH, equal genomic DNA quantities from a control and a sample are labeled. One of 
them is labeled with Cyanine 3 (Cy3) whereas the other is labeled with Cyanine 5 (Cy5). They are 
Figure 9 – The four steps of MS-MLPA reaction. Since the reaction is divided in two, two electropherograms are 
the final result, being the comparison result with sample references. At left we have a control sample, where the 
reference probes were amplified and the target probes are not (there is no signal), since the DNA is normally 
unmethylated. At right we have a tumour sample: the arrows are pointing for the probes that were not digested, 
since target was methylated. Adapted from: Hömig-Hölzel and Savola (2012) 
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co-hybridized in an array with the DNA fragments immobilized. The analytic principle involve 
competition between de DNA fragments differently labelled. The slides are, then, transformed in 
images by a microarray scanner. The intensity of the spots is measured and the images are quantified 
by a software. The resulting ratio of fluorescence intensity is proportional to the ratio of the copy 
number of DNA sequences in the sample and in the controls. If the intensity of both fluorescence 
dies is equal for a probe, the corresponding region of the genome is considered to have the same 
amount of DNA between the sample and the control. If an alteration in the ratio Cy3:Cy5 is detected, 
the interpretation is that the sample as a gain or a loss of DNA in that region, when compared to the 
control (Figure 10) (Shinawi and Cheung, 2008). 
 
Figure 10 - Principles of the aCGH technology. Sample of DNA is labeled with the red dye (Cy5) and the control DNA 
with the green one (Cy3). Both samples are mixed and co-hybridize in an array with the genomic DNA targets. The ratio 
of intensity is analyzed. A Scanner of samples is responsible for the transformation of the results into images. At left we 
have an Array profile. Adapted from: Shinawi & Cheung (2008) 
 
1.4.4 Flow cytometry 
Flow cytometry (FC) is a multiparametric technique that allows detailed analysis of single 
cells in a fluid suspension regarding their intrinsic light-scattering properties, being evaluated for one 
or several extrinsic properties with resource of fluorescent probes. The fluorescent probe may bind 
directly to the target or a fluorescent dye may be coupled with an antibody probe, in order to detect 
some specific protein. After the labelling of cells, they are funnelled while passing through lasers of 
specific wavelengths. The flow rate of cells in the flow cytometer is rapid, allowing the analysis of 
thousands of cells in seconds. As the cells are travelling and passing through the different lasers, the 
fluorescent probes are excited, producing a specific light that passes through several filters and mirror 
sets, being finally collected and amplified by photomultiplier tubes. The last step in the conversion 
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of this light into digital signals that are visualized on a computer screen (Coleman and Tsongalis, 
2006; Barnard, 2012). 
One of the cellular events that is possible do analyse with FC is cell cycle. For this, propidium 
iodide (PI), is the most commonly used dye, that emits red fluorescence when excited with blue light 
(488 nm). PI is capable to bind to DNA by intercalating in the double strand. Furthermore, it also 
binds to RNA, being necessary to remove the RNA with a nuclease treatment (RNase) in order to 
achieve optimal DNA resolution. Since there is different amounts of DNA in the different cell cycle 
phases, it is possible to assess the amount of cells in each phase, once the quantity of fluorescence is 
proportional to the quantity of DNA. It is possible to categorize the cell in four different phases: the 
G0/G1 phase, the S phase, the G2/M phases (that have double DNA content) and the pre-G0 phase. 
This latter phase is associated to the fractional DNA content of apoptotic cells (Darzynkiewicz et al., 
2001). 
Other cellular event that is commonly analysed by FC is cell death. This is possible due to 
the existence of characteristic markers for apoptosis and necrosis, as for annexin-V (AV) and IP. 
This allows the distinction between live and death cells and is even possible to distinguish apoptosis 
from necrosis (Darzynkiewicz et al., 2001). 
There is an alteration on the distribution of the membrane phospholipids during apoptosis. 
In the first steps of apoptosis, phosphatidylserine (a negative charged phospholipid) is translocated 
from the inner surface to the outside surface. AV is an anticoagulant protein that binds 
phosphatidylserine with high affinity in the presence of calcium. Binding of AV to a fluorophore 
allows the determination of the localization of phosphatidylserine on cellular membrane, leading to 
the identification of cells in early apoptosis. During necrosis lysis occurs after cellular swelling, 
causing the cellular components to be exposed to the intercellular space, allowing IP to intercalate 
with DNA (Darzynkiewicz et al., 2001). 
 This combination allows the identification of four categories in cell death: live cells (AV and 
PI negative); early apoptotic cells (AV positive and PI negative) and late apoptotic as well as necrotic 
cells (PI positive) (Darzynkiewicz et al., 2001). 
 
1.4.5 Comet Assay 
The comet assay is a simple method that allows the measure of DNA strand breaks in 
eukaryotic cells (Collins, 2004). The basic principle associated to this mini-gel electrophoresis 
technique is the DNA migration in agarose in electrophoretic conditions (Speit and Rothfuss, 2012). 
The cells are embedded in a tiny agarose layer on a slide, are lysed with detergent plus a high salt 
concentration in order to form nucleoids with supercoiled DNA loops attached to the nuclear matrix. 
After they are subjected to electrophoresis, which can be performed in neutral, alkaline or super-
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alkaline conditions. The electrophoresis is responsible for the DNA migration of the loops which 
contain DNA breaks, leading to the formation of a comet that is observable with fluorescence 
microscopy (Collins, 2004). 
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2 AIMS 
 
In spite of major advances in technological and molecular fields in regard of head and neck 
cancer study, the 5-year survival rate for these patients remains very low. One of the biggest problems 
is the late diagnosis of the disease, wherein 70-85% of all HNSCC patients are presented with a late 
stage (stages III/IV) at diagnostic's time (Langer, 2008). These patients are normally treated with a 
complex therapeutic approach that includes chemotherapy, surgery and radiotherapy. However, this 
approach has a high toxicity rate and several patients develop resistance to therapy.  
Radiotherapy is widely applied for cancer treatment, however, late tissues toxicity are a 
major problem in normal cells after this approach. Furthermore, resistance to radiotherapy is very 
common and it is related with a worse prognosis. All sum up, the use of radiotherapy, in spite its 
major benefits in treating cancer, is also associated to several problems, some of them appearing 
many years after the treatment. With this in mind, the need to find biomarkers associated to 
radiotherapy response in patients it is an essential step towards an increased 5-year survival rate for 
HNSCC patients, minimizing the damages that patients often suffer. 
Thus, it is essential to understand the effects of radiation, particularly the differences between 
radiation responses, to try to prevent the major toxicity problems in patients that are more sensitive 
to radiation. Then, identify some genetic alterations that could help to distinguish radiosensitive from 
radioresistant tumours is of utmost importance to access this major problem. Furthermore, little is 
known about the alterations that happen in cells after they were submitted to different doses of 
radiation. For example, adaptive response to low doses are described to be other of the radiation 
problems, but the alterations behind this response are unknown.  
The goal of this study is to unveil some genetic and epigenetic alterations that could be 
responsible for different responses of the tumour to different radiation doses, in order to improve the 
knowledge of this clinical problem in radiobiology. Furthermore, it is our aim to contribute to the 
understanding of radioresistance in HNSCC, accessing some alterations that could be associated to 
better or to worse responses to this kind of treatment. For this, two commercial cell lines were used: 
HSC-3 and BICR-10 cell lines. 
Due to possible differences induced by hypoxia in response to radiation treatment, once the 
lack of oxygen is considered to be a relevant cause of radioresistance in tumours, we also studied 
these cell lines after they were submitted to hypoxic conditions for a further acknowledge of the 
different responses that irradiation can have on hypoxic cells, frequently observed in solid tumours.  
 In order to achieve this goals, the epigenetic and genetic characterization of the two HNSCC 
cell lines was performed using MS-MLPA, aCGH and karyotyping techniques. This analysis was 
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conducted before and after the two cell lines were treated with the same type of radiation usually 
applied to HNSCC patients. We intend, this way, to analyse the differences in the copy number and 
methylation patterns induced by radiation to the cells. 
At the same time, since commercial cell lines are one of the most used models in research 
and clinical investigation, we will contribute to a better genetic and epigenetic characterization of 
both cell lines, in order to understand and study the characteristics of cancer cells and their 
development. A better characterization of commercial cell lines improve the translation of the results 
obtained from experiences to what happens with the patient’s cells, leading to a better understanding 
of the disease, better therapeutic approaches and better survival rates.  
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3 MATERIAL AND METHODS 
3.1 CELL LINES AND CULTURE CONDITIONS 
The cell lines used in this study are the commercial cell lines BICR-10 and HSC-3. 
BICR-10 is an adherent keratinocyte cell line derived from a recurrent squamous cell 
carcinoma of the buccal mucosa of a caucasian female, with markers for keratin and involucrin. 
Known mutations of this line are in TP53, CDKN2A and CDKN2AARF (Sigma, Accessed: 02-02-
2015). This cell line was cultured in Dulbecco's Modified Eagle's Medium (DMEM) medium 
(Gibco®, Life Technologies, California, USA) containing 10% Fetal Bovine Serum (FBS) (Gibco®, 
Life Technologies, California, USA), 1% of hydrocortisone (Gibco®, Life Technologies, California, 
USA) and 1% of penicillin and streptomycin (Gibco®, Life Technologies, California, USA).  
HSC-3 is a human oral squamous cell carcinoma cell line and it was derived from a Japanese 
male with 64 years old. It was from a primary tumour from the tongue with lymph node metastasis 
and was moderately differentiated (JCRB, Accessed: 02-02-2015). This cell line was cultured in 
DMEM medium containing 10% of FBS and 1% of penicillin and streptomycin. 
Controls were obtained from healthy patients undergoing surgical removal of wisdom teeth. 
They were cultured in DMEM medium containing 1% of FBS, 1% of hydrocortisone and 1% of 
penicillin and streptomycin. 
Both cultures and controls were maintained in an incubator at 37ºC in a 5% CO2 atmosphere 
with 65% humidity. After reaching confluence, the samples were subcultured by incubation with a 
solution of trypsin (Gibco®, Life Technologies, California, USA) and seeded into fresh tissue culture 
flasks.  
In order to further analyse the effects of irradiation on hypoxic cells, both cell lines were 
incubated for 48 hours in a controlled environment chamber (Plas-Labs, Lansing, MI) at 37ºC in a 
93% N2, 2% O2, and 5% CO2 atmosphere.  
3.2 MORPHOLOGY CHARACTERIZATION 
The photographs of the cells were accessed with the help of an inverted microscope (Motic 
AE31, Ted Pella, California) and the camera Axio Cam ERc55 (Zeiss, Germany). The software 
utilized to process the photographs was ZEN 2011 (Zeiss, Germany). 
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3.3 RADIATION TREATMENT  
The irradiation was performed at Serviço de Radioterapia do Centro Hospitalar e 
Universitário de Coimbra by experts on Medical Physics, on a Varian Clinac 600C linear accelerator 
(Varian Medical Systems) with a photon beam 4 MV used in clinical practice for treatment. The cells 
were irradiated and packaged in a irradiation box specially designed for this purpose in the 
Departamento de Física da Faculdade de Ciências e Tecnologia da Universidade de Coimbra. The 
box was constructed of acrylic material with walls with 1 cm of thickness. The dimensions of the 
box and the positioning references that the box has guarantee positioning conditions and reproducible 
packaging as well as ensure uniformity of radiation dose. Initially it was conducted a dosimetric 
study led by computed tomography, thereby generating a three-dimensional planning with the 
planning system Eclipse™ (Varian Medical Systems), in order to guarantee homogeneity in the 
distribution of radiation dose. The dimensions of the irradiation box and of the irradiation field (40 
cm x 40 cm), as well as the distance from the beam source to the box center allowed the calculation 
of the irradiation time required to administer the required dose, which is measured in Monitor Units 
(MU). 
To carry out the cells irradiation, the irradiation box was placed on the treatment table 
containing the vials, and the remaining empty space was filled with distilled water at a temperature 
of 37ºC. The positioning of the box was driven through a reference system of orthogonal lasers. The 
dosing was carried out using two side fields, by rotation of the gantry at 90º and 270º, to ensure a 
homogeneous dose distribution in accordance with planning. For all doses the collimator and the 
table were placed at 0º, with all multileaf collimator blades collected. 
In HSC-3 cell line case, the cells were exposed to 0,5 Gy, 1 Gy, 2 Gy, 3 Gy, 5 Gy and 10 
Gy. In BICR-10 cell line case, the cells were exposed to 0,5 Gy, 2 Gy, 3 Gy, 5 Gy, 10 Gy and 15 Gy. 
In Table 3, there is an example of the MU required for two of the irradiation doses applied. 
Table 3 - Two of the doses applied to the samplesin the irradiation box. 
Dose 1 Gy 3 Gy 
Gantry at 90º 46 MU 139 MU 
Gantry at 180º 47 MU 140 MU 
 
3.4 CLONOGENIC ASSAY 
Clonogenic assay is an in vitro study used to determine the cellular survival of a population. 
It is based on the capacity of a single cell to grow and divide in order to originate colonies after the 
population has been submitted to some treatment/effect.  
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After irradiation, the cells, BICR-10 and HSC-3, were seeded into six-well plate and cultured 
for approximately 14 and 21 days, respectively, in order to allow colonies formation. The base 
protocol was the one published by Franken et al. (2006). After colonies formation, they were stained 
with a solution of crystal violet (Sigma M2128, USA; 0.5% diluted in methanol) and counted (Figure 
11).  
 
The plate efficiency (PE) was determined as the ratio between the number of colonies and 
the number of cells seeded and the survival factor (SF) as the ratio of plating efficiencies for 
irradiated and nonirradiated cells.  
𝑃𝐸 =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝐹𝑜𝑟𝑚𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
 × 100 
𝑆𝐹 =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝐹𝑜𝑟𝑚𝑒𝑑 𝑎𝑓𝑡𝑒𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑 × 𝑃𝐸
 × 100 
These experiments were performed three to four times for each condition and a survival 
curve for each cell line was delineated. Furthermore, the median lethal dose (LD50) of each cell line 
was calculated. The colonogenic assay was performed to both cell lines in both, normoxic and 
hypoxic conditions. However, the survival curve and LD50 was only calculated for normoxic 
conditions (Figure 22).  
3.5 COMET ASSAY 
To access the damage in cell DNA, an alkaline single-cell gel electrophoresis was performed. 
The procedure was applied to both cell lines before and after radiation treatment and in normoxic 
and hypoxic conditions. The procedure was carried out accordingly to Olive and Banath (2006) . 
Briefly, a cellular suspension of 5 × 104 cells was prepared in PBS for each condition. The positive 
control was prepared from the untreated cells, by the administration of 20 ηM of hydroxide peroxide 
(Sigma Aldrich, USA) for 15 minutes.  
Figure 11 – Aspect of the six wells after the performing of Clonogenic Assay. At left is a representation of HSC-3 results 
and at right is a representation of BICR-10 results. The first well represents, in both cases, the control cells. 
Control Control 
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Cellular suspensions were diluted 1:1 in 1% low melting point agarose and applied in 
Starfrost slides. These slides were previously precoating with 1% normal melting point agarose. After 
application of the cellular suspension on the slides, they were maintain at -4ºC for 30-45 minutes in 
order to allow agarose to gel. The slides were then submerged in alkaline lysis solution (2,5M NaCl, 
100mM EDTA, 10mM Tris, 10% DMSO and 1% Triton x-100) (Sigma Aldrich, USA) for about 20 
hours at 4ºC. Afterwards, slides were equilibrated in alkaline electrophoresis buffer (300mM NaOH 
and 1mM EDTA, pH>13) (Sigma Aldrich, USA) and submitted to a potential difference of 25V and 
current of 1A for 15 minutes. After this slides were incubated with neutralizing buffer (0,4M Tris, 
pH 7,4) and stained with 25ηg/mL of ethidium bromide for 20 minutes. The slides were then washed 
with destilated water and visualized in an epifluorescent microscope (Eclipse-400, Nikon) with 
excitation at 546nm with 100W mercury lamp with emission at 580/10. Image acquisition was 
performed with a Texas Red filter (G-2A, EX510-560 - Nikon) using Cytovision software (Applied 
Imaging System).The comet images obtained were then analysed using the software CometScoreTM 
v1.5, in order to calculate tail moment. 
These experiments were realized three times in an independent way, 38-39 hours after 
irradiation. The comet assay was applied to several conditions: the untreated cells, cells submitted to 
LD50 dose of radiation, cells in hypoxic conditions and cells in hypoxic conditions submitted to 
LD50 dose of radiation. 
3.6 FLOW CYTOMETRY   
Flow cytometry (FC) was used to evaluate the effects of X-radiation in cell viability, types 
of induced cell death and changes in cell cycle on both cell lines in normoxic and hypoxic conditions.  
The conditions to which it was apllied were to the untreated cells, cells submitted to LD50 dose of 
radiation, cells in hypoxic conditions and cells in hypoxic conditions submitted to LD50 dose of 
radiation. 
The analysis was performed using a six parameter, four-color FACSCaliburTM flow 
cytometer (Becton Dickinson, San Jose, CA). For each assay, ten thousand events were collected 
using CellQuest software (Becton Dickinson, San Jose, CA) and analysed through Paint-a-Gate 
software (Becton Dickinson, San Jose, CA) and ModfitTM software (Verity Software House). 
These experiments were realized two times in an independent way, 37h30’-38h after 
irradiation.  
 
3.6.1 Cell death evaluation 
By FC is possible to analyse cell death due to the use of two different markers, annexin-V 
(AV) and Propidium Iodide (PI). These two markers allowed the distinction between live and death 
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cells. Furthermore, they make possible to distinguish which cells are suffering apoptosis and/or 
necrosis. So, both cell lines in all the conditions described earlier were stained simultaneously with 
Annexin-V – Allophycocyanin (BD Biosciences) and with PI (BioLegends). This assay discriminates 
amongst intact cells (AV-/PI-), early apoptotic cells (AV+/PI-) and late apoptotic or necrotic cells 
(AV+/PI+). 
To analyse the influence of X-radiation on cell viability and on the types of induced cell 
death, 5 × 105  cell per probe were used. The cellular suspension was washed in PBS by 
centrifugation (1000xg for 5 minutes) and then the pellet was resuspended in 100µl of binding buffer. 
Cells were incubated during 15 minutes with 1 µL of AV and 5µL of PI (Kit Immunotech, Marseille, 
France). Then 300µL of binding buffer was added and finally the cells were analyzed on the 
cytometer. The emission wavelength was 650nm and the excitation wavelength was 660nm. The 
results are presented as percentage ± standard deviation (SD) according to the double staining results.  
 
3.6.2 Cell cycle analysis 
For the cell cycle analysis, the PI/RNase detection probe panel (Immunostep, Salamanca, 
Spain) was applied. 1 × 106 cells were used to study the influence of irradiation on cell cycle on 
both cell lines, in normoxic and hypoxic conditions. 
The cells were fixed with 200µL ice-cold ethanol (70%) while vortexing. They were then, 
incubated on ice during 30 minutes for fixation purposes. Afterwards they were washed with PBS 
and incubated for 15 minutes with 300µL of PI/RNase solution, at room temperature. Finally, cells 
were excited at a wavelength of 488nm, with an emission filter of 617nm. The data was analysed by 
the ModfitTM software. The results were presented as a percentage mean ± SD of cells in each cell 
cycle’s phase. 
3.7 KARYOTYPING 
Semi confluent cell cultures were incubated for 1 hour with colcemid (Gibco®, Life 
Technologies, California, USA). After incubation, the cells were harvested and the slides were 
banded according to routine protocols used in the Cytogenetic and Genomic Laboratory. 
Chromosomes of 10 metaphases were counted and analysed. Metaphases were digitally imaged and 
karyotyped resorting to a microscope (Eclipse-400, Nikon) and Cytovision software (Applied 
Imaging System). Karyotype description followed the International System for Human Cytogenetic 
Nomenclature 2013 recommendations. The analysis was performed on control cell lines, before 
irradiation, and cell lines submitted to irradiation. 
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3.8 DNA EXTRACTION, QUANTIFICATION AND ASSESSMENT OF PURITY 
DNA was extracted from the culture cell lines using High Pure PCR Template Preparation 
Kit (Roche GmbH, Manmheim, Germany), according to the manufacture’s recommendations 
(Roche, Accessed: 02-02-2015).  
The next step was DNA quantification (ng/µL). This was performed with the use of the 
spectrophotometer NanoDrop-1000 (Thermo Scientific, Wilmington, USA). This method is also able 
to determine the DNA purity, which was evaluated using the ratio between absorbance at 260 nm 
and 280nm (A260/A280) and between absorbance at 260nm and 230nm (A260/A230). The DNA is 
considered to be pure when value of the ratio A260/A280 is approximately 1,8 and the value of the 
ratio A260/A230 is between 1,8 and 2,2 (Thermo, Accessed: 02-02-2015). 
3.9 ARRAY-CGH  
aCGH was the technique used for Copy Number Variations (CNV) analysis, through Agilent 
Oligonucleotide Array-Based CGH for Genomic DNA Analysis (Agilent Technologies, Santa Clara, 
California, USA), according to the manufacture’s recommendations (Agilent, Accessed: 30-04-
2015). aCGH was carried out using an Agilent SurePrint G3 Human Genome Microarray 18K 
(Agilent Technologies, Santa Clara, California, USA), an oligonucleotide microarray containing 
approximately 180 000 probes scattered throughout the genome. 
Briefly, DNA from each sample was labelled with Cy5 by random primer labelling. The 
control used was labelled with Cy3. After the labelling, DNA was purified and the degree of labelling 
was obtain resorting to NanoDrop-1000 (Thermo Scientific, Wilmington, USA). The expected 
specific activity of Cy3 or Cy5 labelled samples with a 1μg input of gDNA is 25-40pmol/μg and 20-
35pmol/μg, respectively. Excess of primers and nucleotides were removed using Amicon 30-kDA 
individual filters (Millipore, Billerica, MA, USA). Afterwards, both DNAs (sample and control) were 
combined with Human Cot-1 DNA (Kreatech Diagnostics, Amsterdam, Netherlands), treated with 
Agilent blocking agent and 2x Hi-RPM buffer and hybridized in a 4x180K oligonucleotide slide, at 
65°C for 24h in a hybridization oven (Agilent Technologies, Santa Clara, California, USA) at a 
constant rotation of 20rpm. The slides were then scanned with Scanner C (Agilent Technologies, 
Santa Clara, California, USA) and the data was processed with the Feature Extraction Software 
v10.7. These data were analysed resorting to an aberration calling algorithm, ADM-2, and a threshold 
filter that requires at least three contiguous probes. The last step was the analysis of the results with 
Agilent Genomic Workbench v6.5. 
aCGH was applied to both cell lines untreated and to both cell lines submitted to 0,5 Gy and 
10 Gy of irradiation.  
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3.10 MS-MLPA 
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA), a 
modification of the conventional MLPA assay, allows for the simultaneous detection of changes in 
methylation status as well as in copy number variations. The MS-MLPA technique was performed 
as previously described by Nygren et al. (2005). The probe panel used was the MRC-Holland SALSA 
MS-MLPA probemix ME002-C1 Tumour Suppressor-2 (MRC-Holland, Accessed: 05-03-2015). It 
was applied to the samples previous and after the radiation treatment, in both normoxic and hypoxic 
conditions. All the reagents utilized were acquired by MRC-Holland (Amsterdam, The Netherlands), 
except for the restriction enzyme HhaI (Promega, Madison, USA).  
This probe panel contains 41 MS-MLPA probes, 27 of those recognize different HhaI 
restriction sites in their regions, and it allows the analysis of the methylation status of the promoter 
region of 25 different tumour suppressor genes. Such genes are frequently silenced by methylation 
in tumour cells. Besides, it includes 14 methylation reference probes that are not affected by the 
restriction enzyme HhaI. Furthermore, all 41 probes are able to determined copy number variations 
of the samples (Figure 12).  
Briefly, the DNA (100ηg) was denatured for 10 minutes at 98ºC and subsequently cooled to 
25ºC. After the addition of the probe mix, the samples were heated to 98ºC for 1 minute and 
maintained at 60ºC during 15-16 hours, allowing hybridization. The thermocycler used was the ABI 
2720 (Applied Biosystems, Foster City, USA).  
After hybridization, the samples were divided into two: half of the sample was only incubated 
with the ligase enzyme, whereas the other half was combined with the restriction enzyme while 
ligation occurred. This latter digestion resulted in ligation of only the methylated sequences. This 
reaction was performed at 54ºC during 15 minutes. After inactivation of ligase enzyme, the multiplex 
PCR reaction (35 cycles of 30 seconds at 95ºC, 30 seconds at 60ºC and 1 minute at 72ºC) was carried 
on. After the PCR reaction, 0,70μL of the sample were combined with 9,4μL of a solution with RoxTM 
(Applied Biosystems, Foster City, USA) and highly deionized formamide (Applied Biosystems, 
Foster City, USA) to allow fragment separation. The capillary electrophoresis was performed using 
the capillary sequencer ABI PRISMTM 3130 (Applied Biosystems, Foster City, USA). Three reference 
controls and one negative control were used for each experiment. The results were analysed with the 
help of the software GeneMapper v4.1 (Applied Biosystems, Foster City, USA), which allows the 
analysis of the electropherograms. Automated fragment and data analysis was performed with the 
program Coffalyser.Net (MRC-Holland, Amsterdam, The Netherlands). This program determined 
the ratio between tumour samples and controls. The interpretation of the copy number status is 
described in Table 4. According to literature and lab experience, aberrant methylation was considered 
when the calculated methylation ratio was 0,20 or greater.  
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Table 4- Interpretation of Copy Number Status obtained from Coffalyser.Net. 
Ratio Copy number status 
≥ 1,2 Numerical Gain/ Amplification 
0,8 - 1,2 Normal 
< 0,8 Numerical Loss 
 
MS-MLPA was applied to both cell lines in normoxic and hypoxic conditions before and 
after irradiations, accordingly to Table 5. 
 
3.11 STATISTICAL ANALYSIS  
The graphics for clonogenic assay and LD50 calculation were obtain with resource to the 
software GraphPad Prism 5. 
For analysis of the results obtained with comet assay we used the software SPSS Statistics 
for Mac v21.0. The non-parametric Kruskal-Wallis test was apllied for comparison of quantitative 
variables in more than two goups and the Bonferroni correction was applied. It was considered a 
significance level of 5%. 
Untreated 0,5 Gy 1 Gy 2 Gy 3 Gy 5 Gy 10 Gy Hypoxia Hypoxia + 1 Gy Hypoxia + 3 Gy
HSC-3     -     -
BICR-10   -      - 
Table 5 – Conditions to which the MS-MLPA was applied. 
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Figure 12 - Chromosomal distribution of the genes studied using SALSA MS-MLPA ME002-C1 tumour suppressor-2 probemix. Reference probes are represented by *. APC - Adenomatous 
polyposis coli; ATM - ATM serine/threonine kinase; BRCA1 - Breast cancer 1; BRCA2 - Breast cancer 2; CADM1 - Cell Adhesion Molecule 1; CASR - Calcium-sensing receptor; CD44 - 
CD44 molecule; CDH13 - Cadherin 13; CDK6  - Cyclin-dependent kinase 6; CDKN2A - Cyclin-dependent kinase inhibitor 2A; CFTR - Chloride channels, ATP-gated CFTR; CHFR - 
Checkpoint with forkhead and ring finger domains; CREM - cAMP responsive element modulator; ESR1 - Estrogen receptor 1; GATA5 - GATA binding protein 5; GSTP1 - Glutathione S-
transferase pi 1; IL2 - Interleukin 2; KLK3 - Kallikrein-related peptidase 3; KLLN - Killin, p53-regulated DNA replication inhibitor; MGMT - O(6)-methylguanine-DNA methyltransferase; 
MLH3 – mutL homolog 3; MSH6 - mutS homolog 6; PAH - Phenylalanine Hydroxylase; PAX5 - Paired box 5; PAX6 - Paired box 6; PMP22 - Peripheral Myelin Protein 22; PTCH1 - Patched 
1; PTEN - Phosphatase and tensin homolog; PYCARD - PYD and CARD domain containing; RARβ - Retinoic acid receptor beta; RB1 – Retinoblastoma; STK11 - Serine/threonine kinase 11; 
THBS1 - Thrombospondin 1; TP53 – Tumour protein 53; TP73 - Tumour protein p73; TSC2 - Tuberous Sclerosis 2; VHL - von Hippel-Lindau tumour suppressor; WT1 - Wilms tumour 1.
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4 RESULTS 
4.1 CHARACTERIZATION OF HSC-3 AND BICR-10 CELL LINES 
4.1.1 Cell Line’s Morphology   
In spite of the fact that both cell lines are from the oral cavity, they are derived from different 
anatomical sites. BICR-10 is derived from buccal mucosa, whereas HSC-3 cell line is derived from 
the tongue. Since they are both squamous cell carcinomas, from different histological places, it is 
normal that they differ in their histological appearance (Figure 13).  While BICR-10 cell line appears 
more elongated, HSC-3 cell line has a more rounded appearance. It is noteworthy that, even on the 
cellular size, they are both very dissimilar. The BICR-10 cell line has bigger cells than the HSC-3 
cell line. 
 
4.1.2 Karyotyping 
Karyotyping analysis of BICR-10 and HSC-3 cell lines showed a big difference between the 
number of chromosomes in the different cells analysed: BICR-10 cell line presented on average 41 
chromosomes whereas HSC-3 cell line showed 57 chromosomes, on average. 
The most common alterations observable in BICR-10 cell line were structural alterations. It 
was possible to notice der(1), der(2)t(1;2), t(3;5)(p10;q10), i(5)(p10) i(7)(p10), der(7)t(7;11), 
der(8;8), der(8)t(5;8), del(9)(pter), der(15)t(X;15)(q10;q10) and der(17)t(7;17) (Figure 14). 
In HSC-3 cell line, it was possible to observe not only structural abnormalities, but also 
numerical ones. Regarding the latter, in addition to the monosomy of 10 and 18 that appeared 
frequently, we also found the trisomy of 9 and 20 to be common events. The structural abnormalities 
appeared in a higher number and the most common were der(X)t(X;8)(q10;q10), i(1)(q10), 
del(1)(p10), t(2;15)(q10;q10), del(2)(q10), del(5)(q?), del(7)(q?), t(11;13), dup(11q), 
der(13;13)(q10;q10) and der(14)t(14;17)(q10;q10). The loss of chromosome Y was also very 
Figure 13 - At left it is represented an image of BICR-10 cell line and at right an image of HSC-3 cell line. Photographes 
were taken by an Axio Cam ERc55 Camera (Zeiss, Germany). 
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frequent in this cell line (Figure 15 and Figure 23). The aberration on chromosome 4, 4q-, was also 
identified, although it only appear in 30% of the metaphases analysed. 
Besides the differences between the number of chromosomes, it is possible to observe that 
HSC-3 has a greater number of abnormalities in comparison to BICR-10 cell line.  
 
 
Figure 15 – Karyogram from HSC-3 cell line with the most common aberrations identified. Blue: Structural 
Aberrations. Orange: Numeric Aberrations. 
Figure 14 - Karyogram from BICR-10 cell line with the most common aberrations identified. 
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4.1.3  MS-MLPA 
Both cell lines were genetically and epigenetically characterized by MS-MLPA using SALSA 
MLPA probemix ME002-C1 Tumour Suppressor-2. The software GeneMapper v4.1 allowed to 
obtain electropherograms with a peak pattern for each sample.  
MS-MLPA probe sets contain quality control fragments that are able to signalize problems 
that may alter the results obtained (Table 6). 
Table 6- Quality control fragments of MS-MLPA.(MRC-Holland, Accessed: 08-07-2015) 
Name Length (nt) Interpretation 
92 nt benchmark 
probe 
92 
Normal probe, which forms a benchmark that allows the 
comparison for other quality control fragments. 
Q-fragments 
64, 70, 76, 
82 
These fragments are high when the amount of DNA is too 
low or the ligation step has failed. When all Q-fragments 
have signals ≥ 33% of the 92 nt control fragment, the DNA 
quantity in the sample is insufficient. 
D-fragments 88, 96 
These fragments are low when a poor sample denaturation 
occurred. When the signal is ≤ 40% of the 92 nt control 
fragments, the denaturation of DNA had problems. 
X & y fragments 100, 105 These two fragments are the control for sample swapping. 
 
In each reaction, three control samples and one negative control were used. The negative 
control used was water and, since there is no DNA present in water, the Q-fragments signals were 
greater than 33%, in relation to the 92 nucleotide (nt) control fragment. 
Regarding the control samples, they presented an electrophoresis peak pattern without any 
genetic or epigenetic abnormalities (Figura16a and Figure16c). This is also evidenced by the ratio 
charts that have the analysed data arranged by genomic location, since all the probes are localized 
between the limit lines. Above the blue line represent gain of genetic material and under the red line 
means loss of genetic material (Figura16b). Regarding the methylation pattern, when the probes are 
localized above the blue line, the gene is methylated (Figura16d).  
On the other hand, the electropherograms and ratio charts for the samples analysed had 
alterations. Using BICR-10 cell line as an example (Figure 17) we have a few probes outside the 
limit lines and we have increased and decreased peaks on the electropherogram. Regarding the CNV, 
for example, we have gain of genetic material of the VHL1 (3p25.3), RARβ (3p24.2) and APC 
(5q22.2) genes, since the probes for this genes have higher peaks on the electropherogram and are 
above the blue line on the ratio chart. BICR-10 shows loss of CFTR (7q31.2), CDKN2A (9p21.3), 
BRCA2 (13q13.1), RB1 (13q14.2) and TP53 (17p12) genes, since the probes have decreased peaks 
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on the electropherogram and are underneath the red line on the ratio chart (Figure 17a and Figure 
17b).  
It is important to highlight that concerning the methylation analysis, only the gene probes 
which do not have restriction site for HhaI enzyme, or the ones that are methylated, can be amplified 
in the PCR reaction. This will lead to less peaks and probes on the electropherogram in comparison 
with the data from CNV. In both ratio chart and electropherogram of BICR-10 cell line is possible 
to distinguish which genes were methylated in the sample seeing as they are the ones with higher 
peaks or the ones above the blue line, as, for example, RARβ (3p24.2) and WT1 (11p13) (Figure 17c 
and Figure 17d).  
Figure 17 - Electropherograms and ratio chart with the data from copy number variations(a), (b) and methylation profile 
(c), (d) of BICR-10 cell line. Obtained with the software GeneMapper v4. 
Figure 16 - Electropherograms and ratio chart with the data from copy number variations(a), (b) and methylation 
profile (c), (d) of a control sample. Obtained with the software GeneMapper v4 
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4.1.3.1 Methylation Profile 
For the analysis of the methylation profile of both cell lines, a cut-off was defined to 
determine which genes were methylated. So, when the methylation percentage of gene was equal or 
greater than 20%, the gene was considered to be methylated. This cut off was defined according to 
literature and previous lab experience in methylation profile analysis of cancer cells.  
Applying this cut-off, only nine genes for each cell line were considered to be methylated in 
this study (Table 7a). Regarding the methylation profile, HSC-3 and BICR-10 cell line have more 
resemblance than in CNV (Table 7b), since, in nine methylated genes for each cell line, six are the 
same: RARβ (3p24.2), PAX5 (9p13.2), PAX6 (11p13), WT1 (11p13), CADM1 (11q23.3) and GATA5 
(20q13.33). 
Besides the common genes, HSC-3 cell line also had TP73 (1p36.32), ESR1 (6q25.1) and 
MGMT (10q26.3) genes methylated and BICR-10 cell line had methylation of MGMT (10q26.3), 
CHFR (12q24.33) and CDH13 (16q23.3) genes. It is important to highlight that, even though both 
cell lines presented the gene MGMT methylated, they correspond to different probes that targeted the 
gene. 
4.1.3.2 Copy Number Variations 
Analysing the results regarding CNV from both cell lines (Table 7b), it is possible to observe 
that HSC-3 and BICR-10 are very different from each other. One of the greater differences is in the 
number of alterations, HSC-3 cell line has 55,26% (21/38) of the genes with some alteration, whereas 
BICR-10 only shows ten genes with CNV, which corresponds to 26,32% of all probes.  
Comparing the number of genetic gains with genetic losses, BICR-10 cell line has a higher 
percentage of losses than gains, respectively 60% (6/10) and 40% (4/10). In contrast, HSC-3 cell line 
has more gains, 63,67% (14/21), than losses, 33,33% (7/21). 
The majority of the alterations between both cell lines do not coincide. The only alteration 
common to both cell lines is located on CFTR gene (7q31.2), where both cell lines presented loss of 
the gene. Five of the ten alterations presented in BICR-10 cell line are losses of CDKN2A (9q21.3), 
BRCA2 (13q13.1), the two probes for RB1 (13q14.2) and TP53 (17p12), all of which had genetic 
gain in HSC-3 cell line, making these four genes the most interesting. 
There are several genes which did not showed any alterations on both cell lines: ESR1 
(6q25.1), CDK6 (7q21.2), PTCH1 (9q22.32), KLLN (10q23.31), MGMT (10q26.3), PAH (12q23.2), 
CHFR (12q24.33), TSC2 (16p13.3), PYCARD (16p11.2), PMP22 (17p13.1), BRCA1 (17q21.31), 
STK11 (19p13.3) and KLK3 (19q13.33). 
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It is notorious the presence of CNV in the reference probes (8/14), being the majority altered 
in the HSC-3 cell line. For BICR-10 cell line, only the reference probes on APC (5q22.2) and CFTR 
genes presented alterations. 
 
 
Chr Gene HSC-3 BICR-10
1p36.32 TP73
2p16.3 MSH6
3p25.3 VHL
3p24.2 RARB
3q21.1 CASR*
4q27 IL2*
5q22.2 APC*
6q25.1 ESR1
7q21.2 CDK6*
7q31.2 CFTR*
9p21.3 CDKN2A
9p13.2 PAX5
9q22.32 PTCH1*
10p11.21 CREM*
10q23.31 KLLN
10q23.31 PTEN*
10q26.3 MGMT**
10q26.3 MGMT***
11p13 PAX6
11p13 WT1
11p13 CD44
11q13.2 GSTP1
11q22.3 ATM
11q22.3 ATM*
11q23.3 CADM1
12q23.2 PAH*
12q24.33 CHFR
13q13.1 BRCA2
13q14.2 RB1
13q14.2 RB1
14q24.3 MLH3*
15q14 THBS1
16p13.3 TSC2*
16p11.2 PYCARD
16q23.3 CDH13
17p12 TP53
17p13.1 PMP22*
17q21.31 BRCA1
19p13.3 STK11
19q13.33 KLK3*
20q13.33 GATA5
Chr Gene HSC-3 BICR-10
1p36.32 TP73
2p16.3 MSH6
3p25.3 VHL
3p24.2 RARB
3q21.1 CASR*
4q27 IL2*
5q22.2 APC*
6q25.1 ESR1
7q21.2 CDK6*
7q31.2 CFTR*
9p21.3 CDKN2A
9p13.2 PAX5
9q22.32 PTCH1*
10p11.21 CREM*
10q23.31 KLLN
10q23.31 PTEN*
10q26.3 MGMT**
10q26.3 MGMT***
11p13 PAX6
11p13 WT1
11p13 CD44
11q13.2 GSTP1
11q22.3 ATM
11q22.3 ATM*
11q23.3 CADM1
12q23.2 PAH*
12q24.33 CHFR
13q13.1 BRCA2
13q14.2 RB1 
13q14.2 RB1
14q24.3 MLH3*
15q14 THBS1
16p13.3 TSC2*
16p11.2 PYCARD
16q23.3 CDH13
17p12 TP53
17p13.1 PMP22*
17q21.31 BRCA1
19p13.3 STK11
19q13.33 KLK3*
20q13.33 GATA5
(a) (b) 
Table 7 - Summary of (a) methylation profile (b) and CNV detected by MS-MLPA. (■) – Gain of Genetic 
Material; (■) – Loss of Genetic Material. (■) – Methylated gene. Chr: Chromosome. * - Reference Probe; 
** - 319 nt before exon 1; *** - 71 nt before exon 1;  
 
Results                         From genes to radioresistance in  
Head and Neck Squamous Cell Carcinoma 
 
  Joana Rodrigues                                                                                                  Page | 51  
4.1.4 Array-CGH 
Both cell lines were analysed through aCGH and, as expected, both presented various 
structural rearrangements. With the data obtained two ideograms showing chromosomal gains and 
losses were built for each cell line. 
In BICR-10 cell line, only the chromosome 19, 21 and 22 did not present any copy number 
variation. Chromosome X e Y were not analysed since the control used was male and this cell line 
was originated from a female patient. The chromosomes that showed bigger rearrangements were 
chromosome 5, 7, 8, 13 and 18 and CNV of only one arm are presented at 4p and 7p. (Figure 18).  
In HSC-3 cell line, all chromosomes presented alterations. Furthermore, it is important to 
highlight that the chromosomes 1 , 9, 12, 13, 14, 17 and 20 were completely altered, all of them 
showing gains of the entire chromosome. The chromosomes less altered are chromosome 2, 16, 19 
and 22 and gains of only one arm are observable at 3q, 4p, 5p 7p and 8q (Figure 19). These gains can 
also be observed when analysing the karyotype for this cell line, with chromosomes in trisomy 
(example: 9 and 20) and with chromosomes envolving structural translocations, such as i(1)(p10) 
(Figure 15) and i(7)(p10) , which was observed in other metaphases. 
HSC-3 cell line presented more structural rearrangements than BICR-10 cell line. In BICR-
10 cell line there is a higher frequency of losses than gains, whereas HSC-3 cell line showed a higher 
frequency of genetic gains (Figure 19). However, these results were expectable, since BICR-10 only 
has 41 chromosomes, whereas HSC-3 has 58 chromosomes.  
 
Figure 18- Ideogram showing copy number variations in BICR-10 cell line detected by aCGH  (■) – Gain of Genetic 
Material; (■)   – Loss of Genetic Material. Ideogram base obtained from David Adler. Available at: 
http://www.pathology.washington.edu/research/cytopages/ 
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Overall, there are clear differences between the two cell lines regarding alterations and CNV, 
namely at chromosome 1p, 1q, 3q, 4p, 9p, 9q, 10p, 10q, 11p, 12p, 12q, 14q, 17p, 17q, 20p and 20q. 
Moreover, in BICR-10 cell line, the majority of the abnormalities are small, having the smallest 12,3 
Kb at 11p15.5 and the biggest 109,2 Mb at 5q13.2-q35.3. In opposite, the majority of the 
abnormalities presented in HSC-3 cell line are bigger, however they have sizes ranging from 119,7 
Mb at 1p36.33-p12 to 145 bp at 1p32.32. Interestingly, there is none amplification or deletion of an 
entire chromosome in BICR-10, whereas HSC-3 has amplifications of seven entire chromosomes.  
In common between the two cell lines are only the gains in chromosome 5p, 7p and 8q and 
loss in 18q. 
4.2 ASSESSMENT OF RADIATION’S EFFECTS 
4.2.1 Cell line’s Morphology 
The morphologic alterations caused by radiation treatment were captured from both cell lines 
for all the dose spectrum.  
For BICR-10 cell line, all the photographs were taken seven days after the radiation 
treatment. It is possible to observe that, the higher the dose, more different is the appearance of cell 
morphology when compared with the untreated cell line (Figure 20). The cells lose their typical 
aspect and appear as tiny lines, being the tiniest when submitted to a dose of 15 Gy. However at a 
Figure 19 - Ideogram showing copy number variations in HSC-3 cell line detected by aCGH  (■) – Gain of 
Genetic Material; (■)  – Loss of Genetic Material. Ideogram base obtained from David Adler. Available at: 
http://www.pathology.washington.edu/research/cytopages 
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dose of 5 Gy this differences are also easily observed. Moreover, they are getting branched and some 
of them have resemblances to astrocytes.  
Regarding HSC-3 cell line (Figure 21), the majority of the photos were taken after twenty 
days of radiation treatment, except for the cells submitted to 3 Gy, which were taken are after seven 
days, and the cells submitted to 10 Gy, had photos taken after seven and 20 days after radiation 
treatment. One of the first things that calls the attention is the different confluences between the 
different cell cultures submitted to radiation. Excluding the cells submitted to 3 Gy, which photos 
were taken seven days after radiation treatment, it is possible to denote a big decrease in cell 
confluence as the radiation dose increases. At the lowest doses the morphologic differences are barely 
noticeable, however in the higher doses (5, 8 and 10 Gy) it is observable that the cells have an increase 
Figure 20 - Photograph’s taken by an Axio Cam ERc55 Camera (Zeiss, Germany) of BICR-10 cell line in untreated 
conditions and submitted to different doses of radiation (0,5; 2; 5; 8, 10 and 50 Gy), all of them after seven days of irradiation 
treatment. 
Untreated 
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in volume and gain several vacuolar regions. Its morphologic appearance is almost lost, and at 8 and 
10 Gy there it is almost impossible to observe cells with a typical histologic appearance. With respect 
to differences in time between the photos, after seven days the cells still have a healthy appearance, 
however, after thirteen more days the differences are huge and the typical aspect is lost, the formation 
of vacuoles and also the enhancement of cell volume is observed. 
 
4.2.2 Cell Survival – Clonogenic Assay 
For assessing cell survival after irradiation, a clonogenic assay was performed in order to 
obtain a cell survival curve for both cell lines (Figure 22), allowing the determination of LD50 and 
the assessment of radiation effect in each one of the cell lines. 
For BICR-10 cell line the linear mode was applied, whereas for HSC-3 cell line it was the 
Linear-Quadratic (LQ) model. 
Figure 21 - Photograph’s taken by an Axio Cam ERc55 Camera (Zeiss, Germany) of HSC-3 cell line submitted to line in 
untreated conditions and different doses of radiation (0,5, 2, 3, 5, 8 and 10 Gy) after twenty days of irradiation treatment, 
except for 3 Gy and the first 10 Gy photograph. 
Untreated 
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In the graphic is possible to observe that, for both cases, the increasing exposure to radiation 
led to a reduction in cell survival, except for a dose of 0,5 Gy in HSC-3 cell line. Still, the decreased 
is much more pronounced in HSC-3 cell line than in BICR-10 cell line. This is reflected in the median 
lethal dose (LD50), which is the dose needed to reduce cell survival by 50%, since for HSC-3 is 
0,821 and for BICR-10 is 3,542. For other experiments purposes, the dose applied to HSC-3 to 
represent the LD50 was 1 Gy, and for BICR-10 cell line was 3 Gy. 
In hypoxic conditions we were not able to have adequate results, however the motives are 
unclear. This needs to be further pursued.  
 
4.2.3 Karyotyping 
Karyotyping analysis was performed in HSC-3 cell line after cells were submitted to 0,5 Gy, 
1 Gy and 2 Gy, and in BICR-10 cell line after cells were submitted to 0,5 Gy, 2 Gy and 5 Gy. Similar 
to the analysis performed for the untreated cells, only ten metaphases per condition were analysed, 
except for BICR-10 cell line after submission to 5 Gy, where only 9 metaphases could be analysed. 
Regarding differences in the number of chromosomes between untreated and treated cells in 
both cell lines, no significative differences were observed.  
However, in HSC-3 cell line it is possible to notice that the majority of alterations are 
maintained after irradiation treatment (Table 8). The frequency of monosomy 18 seems to decrease 
and pass to a disomy at the lowest doses of irradiation, (Figure 23) and, after submission to 0,5 Gy 
the frequency of del(7)(q?) decreases to half. Additionally, some aberrations first appear after the 
cells were submitted to irradiation, as for example 11p-, der(11;17) and 12p+ (Figure 24). Besides, 
the cells exposed to the lower radiation dose is the one which presents less new chromosomic 
alterations in comparison to the untreated cells (Table 8).  
The differences in BICR-10 cell line between untreated cells and irradiated cells are easy to 
notice (Table 9). One of the differences is the loss of i(5)(p10). Even though this alteration is not the 
Figure 22 – Cell survival curve for BICR-10 and HSC-3 after irradiation treatment. 
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most common, only being present in four metaphases in untreated cells, in 28 other metaphases 
analysed after different doses of irradiation, this aberration is lost. Other alteration that seems to be 
decreasing the frequency after irradiation is der(8;8) that was highly frequent in the untreated cells. 
Furthermore, after irradiation treatment, some new aberrations also appear: del(2)(q10), which is 
particularly common after 0,5 Gy of radiation (Figure 25), 5q- (Figure 26), t(13;17), t(14;17) and the 
presence of i(7)(p10)del(7)(pter). After a dose of 5 Gy is noticeable that the most common alterations 
in the untreated cells suffer a decrease in frequency and that there is an enhancement of new 
aberrations (Figure 27) (Table 9). 
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Table 8 - Summary table of cytogenetic abnormalities in HSC-3 cell line after irradiation treatment with 0,5, 1 and 2 Gy in comparison with untreated cells. 
 
 
i(1)(q10) del(1)(p10) t(2;15)(q10;q10) del(2)(q10) del(5)(q?) del(7)(q?) t(11;13) dup(11q) der(14)t(14;17)(q10;10) der(X)t(X;8)(q10;q10) der(13;13)(q10;q10) Monosomy 18 Monosomy 10 Trisomy 9 Trisomy 20
10/10 9/10 9/10 9/10 9/10 10/10 8/10 10/10 10/10 9/10 10/10 7/10 9/10 9/10 8/10 4q- (3/10)
9/10 10/10 10/10 9/10 7/10 5/10 8/10 9/10 9/10 9/10 8/10 3/10 8/10 9/10 10/10 4q- (1/10)
der(11;17)  (2/10)
11p- (1/10)
5p- (1/10)
der(11;17)  (1/10)
11p- (2/10)
12p+ (2/10)
9q- (1/10)
9/10 10/10
Structural Numeric
Additional
Untreated
Condition
0,5 Gy
1 Gy 8/10 9/1010/10 7/10 9/10 10/10 10/10 8/10 10/10 8/10 2/10 10/10 9/10
10/102 Gy 9/10 9/10 10/10 8/10
HSC-3
9/10 8/10 10/10 10/10 8/10 10/10 9/10 8/10 9/10 8/10
der(1) der(2)t(1;2) t(3;5)(p10;q10) i(5)(p10) i(7)(p10) der(8)t(5;8) der(8;8) del(9)(pter) der(7)t(7;11) der(15)t(X;15)(q10;q10) der(17)t(7;17)
10/10 10/10 10/10 4/10 10/10 8/10 9/10 10/10 10/10 10/10 10/10 2p (1/10)
2p (8/10)
5q- (3/10)
5q- (3/10)
2p (1/10)
17p- (1/10)
21p+ (1/10)
i(7)(p10)del(7)(pter) (1/10)
5q- (6/9)
i(7)(p10)del(7)(pter) (2/9)
21p+ (2/9)
4q- (1/9)
8/10 10/10
AdditionalCondition
Untreated
0,5 Gy 10/10 9/10 10/10
8/10 1/10
0/10 9/10 8/10 6/10
2 Gy 10/10 9/10 10/10 0/10
5 Gy 9/9 8/9 6/9 1/9
BICR-10
Structural
8/9 4/9 6/9 8/9 8/9 6/9
7/10 10/10 9/10 9/10
6/9
7/10 8/10
9/10
Table 9 - Summary table of cytogenetic abnormalities in BICR-10 cell line after irradiation treatment with 0,5, 1 and 2 Gy in comparison with untreated cells. 
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Figure 24 – Karyogram from HSC-3 cell line after a irradiation with a dose of 1 Gy. In light Orange 
are the alterations common to the untreated cells and in blue are alterations that happened after 
irradiation. 
 
 
 
 
Figure 23 – Karyogram from HSC-3 cell line after a irradiation with a dose of 0,5 Gy. In light 
Orange are the alterations common to the untreated cells and in blue alterations that happened 
after irradiation. 
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Figure 26 - Karyogram from BICR-10 cell line after a dose of 2 Gy. In light Orange are the alterations 
common to the untreated cells and in blue are alterations that happened after irradiation. 
 
 
 
 
Figure 25 - Karyogram from BICR-10 cell line after a irradiation with a dose of 0,5 Gy. In light 
Orange are the alterations common to the untreated cells and in blue are alterations that happened 
after irradiation. 
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Figure 27 - Karyogram from BICR-10 cell line after a dose of 5 Gy. In light Orange are the alterations 
common to the untreated cells and in blue are alterations that happened after irradiation. 
 
4.2.4 Copy Number Variations 
4.2.4.1 Array-CGH results 
After irradiation treatment with 0,5 Gy and 10 Gy, DNA was extracted from both cell lines 
and it was analysed by aCGH. The differences in CNV between the different irradiations were too 
small to be presented in an ideogram, so a table was made.  
In Table 10 are represented genes and regions that could be further studied in order to 
understand the possible effects of radiation in a more radioresistant cell line, in a more radiosensitive 
cell line or even the effects of radiation in general. Chromosome X and Y were not analysed for 
BICR-10 due to the fact that this cell line is derived from a female patient and the control used for 
aCGH is from a male patient. 
Between the normal cell line (0 Gy) and the cells submitted to radiation (0,5 Gy and 10 Gy) 
in HSC-3 case, 31 differences in CNV were accounted. Using the same approach of comparison 
between the untreated (0 Gy) and the radiated cells (0,5 Gy and 10 Gy) there were 30 differences in 
CNVs observed for BICR-10 cell line. These numbers are similar, especially if we considered that 
two chromosomes were not analysed in the latter. Furthermore, in HSC-3 case there is an 
enhancement of gains, being most of the alterations located on chromosome 1. BICR-10 cell line is 
more heterogeneous. 
Regarding genes that showed alterations in CNV between the untreated (0 Gy) and the 
radiated cells (0,5 Gy and 10 Gy), in both cell lines, an extensive literature search was performed in 
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order to establish possible genes that could elucidate this question. We seletected 20 genes (Table 
10). Only 3 genes showed differences on both cell lines: WD Repeat Containing, Antisense to TP73 
(WRAP73) (1p36.32), Solute Carrier Family 22, Member 18 (SLC22A18) (11p15.4) and Collagen, 
Type I, Alpha 1 (COL1A1) (17q21.33). 
 The majority of genes altered were on HSC-3 cell line, with 11 noticeable alterations: 
Arginine-glutamic Acid Dipeptide (RE) Repeats (RERE) (1p36.23), Filamin Binding LIM Protein 1 
(FBLIM1) (1p36.23), VHL (3p25), Collagen, Type I, Alpha 2 (COL1A2) (7q21.3), Interferon 
Regulatory Factor 5 (IRF5) (7q32.1), microRNA 183 (MIR183) (7q32.2), T-box 4 (TBX4) 
(17q23.2), Nascent Polypeptide-associated Complex Alpha Subunit 2 (NACA2) (17q23.2), BRCA1 
Interacting Protein C-terminal Helicase 1 (BRIP1) (17q23.2), Integrator Complex Subunit 2 (INTS2) 
(17q23.2) and Mediator Complex Subunit 13 (MED13) (17q23.2).  
As for BICR-10 cell line, 6 genes presented alterations: Kinesin Family Member 26B 
(KIF26B) (1q44), G Protein-coupled Receptor 39 (GPR39) (2q21-q22), N-acetylated Alpha-linked 
Acidic Dipeptidase-like 2 (NAALADL2) (3q26.33), Msh Homeobox 1 (MSX1) (4p16.2), Heparan 
Sulfate (glucosamine) 3-O-Sulfotransferase 3A1 (HS3ST3A1) (17p12), and TAF4b RNA polymerase 
II, TATA box binding protein (TBP)-associated factor (TAF4B) (18q11.2). 
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Table 10 – Table showing CNV in HSC-3 and BICR-10 cell lines after exposure to X-irradiation detected by aCGH.  (■) – 
Gain of Genetic Material; (■) – Loss of Genetic Material; (■) – Absence of CNV; (■) – Not analysed. 
0 Gy 0,5 Gy 10 Gy 0 Gy 0,5 Gy 10 Gy
p36.32 p36.32 p36.32 p36.32 WRAP73
p36.23 p36.23 p36.23 RERE, FBLIM1
p36.21 p36.21 p36.21
p36.13 p36.13 p36.13
p36.13 p36.13 p36.13
p13.3 p13.3 p13.3 p13.3
q42.3 q42.3 q42.3
q44 q44 q44 q44 q44 KIF26B
q12.21
q21.1 - q21.2
q21.2 GPR39
q31.1 q31.1
p p25.3 p25.3 p25.3 p25.3 VHL
q11.2 q11.2 q11.2 q11.2
q26.33 q26.33 q26.33 q26.33 q26.33 NAALADL2
p16.2 p16.2 p16.2
p16.2 p16.2 p16.2 p16.2 MSX1
p11 p11 p11
p11 p11 p11 p11
q q31.21 q31.21
5 p p12-p11 p12-p11 p12-p11 p12-p11
6 p p21.32 p21.32
q11.1-q11.21
q21.3 q21.3 COL1A2
q22.1
q22.3-q32.1 IRF5, MIR183
q32.3
q32.3-q34
p21.3 p21.3 p21.3 p21.3
p11.21
p11.1
p24.1 p24.1 p24.1
p24.1 p24.1 p24.1 p24.1
p15.5 p15.5 p15.5 p15.5 p15.5 p15.5
p15.4 p15.4 p15.4 p15.4 p15.4 p15.4 SLC22A18
p11.2-p11.12 p11.2-p11.12 p11.2-p11.12 p11.2-p11.12 p11.2-p11.12
p11.2
q11-q12.1
q14.3 q14.3
q22.3 q22.3 q22.3 q22.3
q25 q25
p13.31 p13.31 p13.31 p13.31 p13.31 p13.31
p13.31
q24.13 q24.13 q24.13 q24.13 q24.13
q24.33 q24.33 q24.33 q24.33
14 q q32.33 q32.33 q32.33 q32.33 q32.33
q21.3 q21.3 q21.3
q21.3
q26.2 q26.2
p p13.2
q q22.2 q22.2
p12 p12 p12
p12 p12 p12 p12 HS3ST3A1
q21.33 q21.33 q21.33 q21.33 q21.33 COL1A1
q21.31 q21.31 q21.31 q21.31
q23.2 q23.2 q23.2 TBX4, NACA2, BRIP1, INTS2, MED13
q11.1-q11.2 q11.1-q11.2 q11.1-q11.2
q11.2 q11.2 q11.2 q11.2 TAF4B
q12.3 q12.3 q12.3 q12.3 q12.3 q12.3
q12.3
p13.2 p13.2 p13.2
p13.2
p11.22
p11.22
p p11.2 p11.2
q11.1-q11.21
q11.23
Y
p
q
p
13
15 q
16
17
p
18 q
19 p
q
Genes
1
p
q
X
q
11
q
12
p
8 p
9
7
p
q
q22.3-q34
4
HSC-3 BICR-10
2 q
3
q22.3-q34 q22.3-q34q22.3-q34q22.3-q34
q
p
Chromosome Arm
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4.2.4.2 MS-MLPA results 
The cells submitted to 0,5, 1 (in HSC-3 case only), 2, 3 (in BICR-10 cell line only), 5 and 10 
Gy were analysed by MS-MLPA. The cells in hypoxic conditions and in hypoxic conditions plus 
LD50 Gy for each cell line were also analysed. The results are presented in Table 11 for both cell 
lines 
In HSC-3 there are several genes that maintain the alterations in all the conditions: CASR 
(3q21.1), CFTR (7q31.2), CDKN2A (9p21.3), CD44 (11p13), GSTP1 (11q13.2), ATM (11q22.3), 
BRCA2 (13q13.1), RB1 (13q14.2), MLH3 (14q24.3), CDH13 (16q23.3) and GATA5 (20q13.33). 
Moreover, TP73 (1p36.32), PAX5 (9p13.2), PAX6 (11p13) and TP53 (17p12) have slight alterations, 
being the ratio closer to the limit of the cut offs. Besides, alterations noteworthy are the loss of APC 
(5q22.2), VHL (3p25.3), WT1 (11p13) and TSC2 (16p13.3), gain of PMP22 (17p13.1) all at 1 Gy and 
hypoxia plus 1 Gy. The loss of MSH6 (2p16.3) and ESR1 at low doses of irradiation also seem 
interesting alterations. Finally, the gain of CHFR at cells submitted to 0,5 Gy and loss after they were 
submitted to 2 Gy of irradiation are also noteworthy.  
Furthermore, HSC-3 cell line submitted to 2 Gy is the one who presents more alterations in 
comparison with all the other conditions. The ones who showed less alterations in comparison to the 
control are cells in hypoxic conditions and when they were submitted to high doses of radiation (5 
and 10 Gy). 
In BICR-10, it is noticeable the alteration of several genes when cells are submitted to 
different doses of radiation. When cells are submitted to 3 Gy, either in normoxic or hypoxic 
conditions occurred gains of TP73, PTCH1 (9q22.32) and CREM (10p11.21). Comparing the results 
obtain from normoxic and hypoxic conditions, there are slight differences, as the decrease in copy 
number of MSH6, gain of PTCH1, CREM, MLH3 and BRCA1, and loss of MGMT. Furthermore, 
BRCA1 gain also happens in hypoxic conditions after a dose of 3 Gy. In untreated cells, the exposure 
to low dose radiations leads to an enhancement in copy numbers of PAX5, PTCH1 and CREM. In 
general, the genes that were altered in the untreated cell line are maintained after irradiation, with 
exception to the enhancement of copy number of CFTR at 10 Gy, the loss of GATA5 in hypoxic 
conditions and the decrease in copy number for the MSH6 gene in all conditions.  
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1p36.32 TP73
2p16.3 MSH6
3p25.3 VHL
3p24.2 RARB
3q21.1 CASR*
4q27 IL2*
5q22.2 APC*
6q25.1 ESR1
7q21.2 CDK6*
7q31.2 CFTR*
9p21.3 CDKN2A
9p13.2 PAX5
9q22.32 PTCH1*
10p11.21 CREM*
10q23.31 KLLN
10q23.31 PTEN*
10q26.3 MGMT**
10q26.3 MGMT***
11p13 PAX6
11p13 WT1
11p13 CD44
11q13.2 GSTP1
11q22.3 ATM
11q22.3 ATM*
11q23.3 CADM1
12q23.2 PAH*
12q24.33 CHFR
13q13.1 BRCA2
13q14.2 RB1
13q14.2 RB1
14q24.3 MLH3*
15q14 THBS1
16p13.3 TSC2*
16p11.2 PYCARD
16q23.3 CDH13
17p12 TP53
17p13.1 PMP22*
17q21.31 BRCA1
19p13.3 STK11
19q13.33 KLK3*
20q13.33 GATA5
HSC-3 BICR-10
Table 11 – Copy Number Variations detected by MS-MLPA in HSC-3 and BICR-10 cell lines after submission to radiation 
and in hypoxic conditions(■) – Gain of Genetic Material; (■) – Loss of Genetic Material; Chr: Chromosome. * - Reference 
Probe; ** - 319 nt before exon 1; *** - 71 nt before exon 1;  
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4.2.5 Alterations on the methylation pattern 
In order to assess differences in the methylation pattern induced by irradiation, MS-MLPA 
was applied to HSC-3 submitted to 0,5 Gy, 1 Gy, 2 Gy, 5 Gy, 10 Gy of irradiation, HSC-3 in hypoxic 
conditions and hypoxic conditions submitted to 1 Gy of irradiation. As for BICR-10, cells submitted 
to 0,5 Gy, 2 Gy, 3 Gy, 5 Gy, 10 Gy of irradiation, hypoxic conditions and hypoxic conditions 
submitted to 3 Gy of irradiation were analysed for alterations in the methylation profile (Table 12).  
In both, the methylation pattern that was observed in the untreated cell line is maintained 
after irradiation and in hypoxic conditions. In HSC-3, the 2 Gy dose is the one with the most 
alterations. It showed methylation of both MSH6 (2p16.3) and ATM. The other alteration is 
observable in the cells submitted to 0,5 Gy, where MSH6 is methylated. Hypoxic conditions did not 
induced any methylation alteration besides the methylation pathern of the untreated cells.  
As for BICR-10, only one alteration was detected regarding methylation profile. This 
alteration occurs after the cell line was submitted to a dose of 10 Gy, which leaded to the methylation 
of MSH6 gene. 
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1p36.32 TP73
2p16.3 MSH6
3p25.3 VHL
3p24.2 RARB
3q21.1 CASR*
4q27 IL2*
5q22.2 APC*
6q25.1 ESR1
7q21.2 CDK6*
7q31.2 CFTR*
9p21.3 CDKN2A
9p13.2 PAX5
9q22.32 PTCH1*
10p11.21 CREM*
10q23.31 KLLN
10q23.31 PTEN*
10q26.3 MGMT**
10q26.3 MGMT***
11p13 PAX6
11p13 WT1
11p13 CD44
11q13.2 GSTP1
11q22.3 ATM
11q22.3 ATM*
11q23.3 CADM1
12q23.2 PAH*
12q24.33 CHFR
13q13.1 BRCA2
13q14.2 RB1
13q14.2 RB1
14q24.3 MLH3*
15q14 THBS1
16p13.3 TSC2*
16p11.2 PYCARD
16q23.3 CDH13
17p12 TP53
17p13.1 PMP22*
17q21.31 BRCA1
19p13.3 STK11
19q13.33 KLK3*
20q13.33 GATA5
HSC-3 BICR-10
Table 12 – Methylation alterations induced by different doses of radiation and hypoxic conditions in HSC-3 and BICR-10 
cell line accessed by MS-MLPA. (■) – Methylated gene. Chr: Chromosome. * - Reference Probe; ** - 319 nt before exon 
1; *** - 71 nt before exon 1;  
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4.2.6 Comet Assay 
The comet assay, a method that allows the measure of DNA strand breaks, was performed in 
order to discovery possible explanations for the different response to radiation of both cell lines 
regarding the amount of damages induced by irradiation to the cell lines (Figure 28 and Figure 29). 
The amout of damages is proportional to the tail length, this is, the longer the tail, the greater the 
amount of damages. The objective was to analyse the amount of damages induced by irradiation 
when the cells were in normoxic and hypoxic conditions. 
Figure 28 – Comet Assay in the BICR-10 cell line. Results for the (a) untreated cells, (b) cells submitted to a dose of 3 Gy, 
(c) cells in hypoxic conditions, (d) cells in hypoxic conditions submitted to a dose of 3 Gy, as well as the positive control. 
Figure 29 - Comet Assay in the HSC-3 cell line. Results for the (a) untreated cells, (b) cells submitted to a dose of 1 Gy, 
(c) cells in hypoxic conditions, (d) cells in hypoxic conditions submitted to a dose of 1 Gy, as well as the positive control. 
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Analysing the comets obtained, the data was organized into percentiles. The results are 
presented in Table 13 and Table 14. The Kruskal-Wallis was used for comparision between the 
different conditions and Bonferroni correction was applied (Table 15). 
Table 13 – Data obtained from tail moment analysis for BICR-10 cell line in the diferente conditions. 
BICR-10 Untreated 3 Gy Hypoxia Hypoxia + 3 Gy 
Median 16,04 19,83 18,16 11,94 
Percentile 90 184,11 179,51 64,89 50,1 
 
Table 14 – Data obtained from tail moment analysis for HSC-3 cell line in the different conditions. 
HSC-3 Untreated 1 Gy Hypoxia Hypoxia + 1 Gy 
Median 46,79 50,56 31,26 29,37 
Percentile 90 123,76 128,85 143,74 132,59 
 
Table 15 - Results obtained from statistical analysis of the tail moment for the different conditions in both cell lines. Each 
row tests the null hypothesis that the different samples distributions are the same. Asymptotic significances (2-sided tests) 
are displayed. The significance level considered was 0,05. Statistical significance between the conditions is highlighted in 
yellow. 
Sample Comparison Adjusted Significance 
HSC-3 
Untreated - 1 Gy 1,000 
Untreated - Hypoxia 0,012 
Untreated - Hypoxia + 1 Gy 0,000 
Hypoxia - Hypoxia + 1 Gy 0,444 
1 Gy - Hypoxia + 1 Gy 0,000 
BICR-10 
Untreated - 3 Gy 1,000 
Untreated - Hypoxia 1,000 
Untreated - Hypoxia + 3 Gy 0,000 
Hypoxia - Hypoxia + 3 Gy 0,005 
3 Gy - Hypoxia + 3 Gy 0,000 
 
4.2.7 Flow Cytometry 
Flow Cytometry was applied in order to access cell death and cell cycle phases of both cell 
lines. It was applied at both untreated cell lines and after submission to the dose of radiation 
calculated for the LD50, hypoxic conditions and cell lines in hypoxic conditions submitted to the 
LD50 dose. 
Results                         From genes to radioresistance in  
Head and Neck Squamous Cell Carcinoma 
 
  Joana Rodrigues                                                                                                  Page | 70  
The data is the median of two independent experiments.The objective of this FC analysis 
was to compare differences in cell death in a radioresistant and a radiosensitive cellular line after 
they were submited to irradiation (Figure 30). In order to assess possible explanations for the different 
response to radiation, the percentage of cells in the different cell cycle phases on both cell lines was 
also compared (Figure 31). 
 
Figure 30 - Preliminary data from flow cytometry cell death analysis of BICR-10 cell 
line (on the top) and HSC-3 cell line (at the bottom). 
Figure 31 - Preliminary data from flow cytometry cell cycle analysis of BICR-10 cell line 
(on the top) and HSC-3 cell line (at the bottom). 
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4.3 PREDICTING RADIOTHERAPY RESPONSE 
Analysing the aCGH results and the literature, we schematize the possible regions that could 
be associated with a worse prognosis and to radiation treatment response in our cell lines.  
In BICR-10 cell line (Figure 32) is possible to associate the losses of 4p11-pter and 11q distal 
to radioresistance. At the short arm of chromosome 8 there is a small band that, when it is loss, is 
also associated to radioresistance: 8p23.3. The loss in 17p represents the deletion of the TP53 gene. 
Gains of 3q26.1 and 7p11.2-12 have also been associated to a more radioresistant phenotype. As for 
CNV associated to a more radiossensitivity, in HSC-3 cell line (Figure 33). We found losses in 18q 
and gains of several regions: 8p23.3, 10q11-q22, 14q13, 14q distal, 15q11.2-q21.3, 17q, 18q21.2 and 
22q. 
 Furthermore, several regions with CNV from both cell lines were associated with a worse 
prognosis: Losses of 5q11, 8p23.3, 8p21-p22, 8p21.2 and 11q distal; Gains of 1q, 3q21-q29, 11q13 
and 22q. 
  
Figure 32 - Ideogram of BICR-10 cell line obtain by aCGH. Gains and Losses are represented with blue and red, 
respectively. Orange circles: CNV previous associated to radioresistance. Purple circles: CNV previous associated to a 
worse prognosis.   
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Figure 33- Ideogram of HSC-3 cell line obtain by aCGH. Gains and Losses are represented with blue and red, respectively. 
Green circles: CNV previous associated to radiossensitivity Purple circles: CNV previous associated to a worse prognosis. 
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5 DISCUSSION 
5.1 CHARACTERIZATION OF HSC-3 AND BICR-10 CELL LINES 
As previous referred, in spite the fact that HSC-3 and BICR-10 cell lines were established 
from different anatomic regions, both are classified as HNSCC commercial cell lines. Moreover, 
they can both be classified as OSCC, since both, buccal mucosa and tongue, belong to this sub 
anatomic region. On the other hand, they have different cell types and so, different characteristics. 
Taking this into consideration, it is important to mention that different anatomic regions have distinct 
clinical presentations and different clinical outcomes, which results in different treatment 
approaches. Taking this line of reasoning and the complexity of this disease, it is expected that the 
two different anatomic regions (buccal mucosa and tongue), from which the cell lines were 
established, present different genetic and epigenetic characteristics (Mao et al., 2004). Finally, it is 
important to highlight that HSC-3 was established from a patient with lymph node metastasis 
whereas BICR-10 cell line was established from a patient without metastasis, however, its clinical 
stage is unknown.  
The characterization of commercial cell lines has obvious benefits, since they are one of the 
most used model in biomedical studies. As such, genetic and epigenetic characterization are 
necessities in order to have as much information as possible about the cell lines, especially if they 
are used for translational research (White et al., 2007). 
Some scientists argue that cell cultures bring biased results, since specific cell populations are 
selected and those are the ones that evolve in culture conditions. However, it is already been proved 
that cell lines are similar to the tumours from which they arise and long-term HNSCC cell cultures 
present aberrations from the tissue which they were derived (Martin et al., 2008). So, since cell lines 
are representative from the tumours from they were derived, they remain helpful models in clinical 
research, enabling the correlation between their results and with patients’ results.  
For the genetic and epigenetic characterization of both cell lines, cytogenetic and genomic 
techniques were applied: aCGH, karyotyping and MS-MLPA.  
 
5.1.1 Methylation Profile 
Since DNA methylation is the most common epigenetic modification in cancer (Mascolo et 
al., 2012), the methylation profile of both cell lines was assessed through MS-MLPA. MS-MLPA is 
a target technique, allowing only the analysis of some genes. The probe panel used was not specific 
for HNSCC, but instead for cancer in general.  
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For this study a cut-off of 20% was defined, meaning that a gene was considered to be 
methylated when the ratio of methylation was over 20%. This cut off was established based on 
laboratory experience, as well as in scientific papers (Yalniz et al., 2011; Chmelarova et al., 2012). 
Concerning the reference samples used, none of them presented any genes with a methylation 
frequency above 20%, meaning that all the genes were unmethylated. However, it is important to 
increase the number of controls to define a more precisely cut-off, since three controls is considered 
to be a small number.  
Both cell lines presented RARβ, PAX5, PAX6, WT1, CADM1, GATA5 genes methylated. 
Even with some differences, both of them also had the MGMT gene methylated.  
Regarding RARβ gene, it encodes the retinoic acid receptor that belongs to a superfamily of 
nuclear transcriptional regulators, and it is associated with cell growth and differentiation. RARβ 
loss in cancer frequently results from promotor hypermethylation, rather than genetic aberrations 
(Noorlag et al., 2014). Since methylation of the promoter is associated with gene silencing, it is 
probable that an analysis of mRNA expression showed lack of expression of RARβ on both cell lines. 
This lack of RARβ expression is associated to an enhanced mitotic activity and loss of differentiation 
(Marzese et al., 2012). In studies of cervical cancer, the decrease of the gene and protein expression 
were correlated with late response to therapy (Kim et al., 2011), whereas in breast cancer studies, it 
was correlated with poor prognostic (Marzese et al., 2012). In HNSCC, the lack of expression was 
verified in the majority of oral potential malignant lesions in comparison to normal tissue samples in 
a study performed by Lotan et al. (1995), indicating the involvement of RARβ methylation in the 
early stages of HNSCC carcinogenesis. Given that both our cell lines showed methylation of this 
gene, this hypothesis cannot be discarded, since HSC-3 cell line may have kept this alteration since 
the first steps of the carcinogenesis process and BICR-10 cell line could represent a early stage 
tumour. This hypothesis is also supported by the association of RARβ expression loss with the 
evolution from mortality to immortality in HNSCC (McGregor et al., 1997), making this epigenetic 
alteration an important characteristic in HNSCC development.  
Both PAX5 and PAX6 genes belong to a family with nine developmentally regulated genes 
that code for the PAX proteins, nuclear transcription factors that play roles in cellular differentiation, 
proliferation and migration. This family is thought to be a target for disruption during the oncogenesis 
process due to the fact that they are string transcriptional regulators. Besides, they are located at 
specific chromosomic regions that frequently suffer translocations in cancer, as the example of 
t(9;14)(p13;q32) in non-Hodgkin’s lymphoma, which harbours PAX5 gene (9p13) (Barr, 1997). 
Concerning PAX5, although its methylation has already been described in HNSCC, its role 
in cancer development is controversial. Whereas Liu et al. (2011) reported downregulation of this 
gene associated with its methylation status in Hepatocellular carcinoma and Deng et al. (2014) 
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highlighted its potential function of tumour suppressor in gastric cancer through direct regulation of 
the p53 signalling pathway, Norhany et al. (2006) and Kanteti et al. (2009) showed that in OSCC 
and small-cell lung cancer (SCLC), respectively, PAX5 gene was overexpressed, suggesting an 
oncogenic role. Even in HNSCC, the function of this gene is strongly controversial. Although 
Norhany et al. (2006) reported overexpression, a study performed by Guerrero-Preston et al. (2014) 
showed that PAX5 was methylated and downregulated in HNSCC. Additionally, Kanteti et al. (2009) 
also examined HNSCC cell lines and observed absence of expression. The possibility of tissue-
specificity interactions can be placed, however, since different studies with HNSCC cell lines showed 
opposite results, this hypothesis is unlikely. Other hypothesis is that this gene could play a double 
role in cancer, and could regulate different effectors during carcinogenesis, nonetheless this 
possibility lacks confirmation.  In the present study, our results showed promotor methylation on 
both cell lines, suggesting the silencing of the gene, supporting the tumour suppressor role for PAX5 
in HNSCC. In HSC-3 cell line, MS-MLPA also detected gain in copy number for this gene. Since 
the methylation ratio was not very high (24%), it is possible that this gene is able to have a normal 
expression or overexpression. Supporting this hypothesis, Norhany et al. (2006) realized gene 
expression studies on HSC-3 cell line, the metastatic cell line, and demonstrated overexpression of 
the gene. These results may be explained with the fact that methylation is a reversible process and 
the cell line may showed differences at the time of the analysis in both studies. On the other hand, 
recent investigations have correlated DNA methylation with both a decrease and an increase in gene 
expression and the further study of this gene could prove this theory (Wagner et al., 2014; Wan et 
al., 2015). Kanteti et al. (2009) putted the possibility of the overexpression of this gene being 
associated with a more metastatic and aggressive stage in small cell lung cancer cells due to the 
interaction between PAX5 and c-Met. Proving the two latter theories right, the expression of this 
gene could be an important biomarker in cancer progression. In BICR-10 cell line case, to our 
knowledge, no similar study was previous done, so gene expression analysis must be performed in 
order to highlight this possibility and take more accurate conclusions.  
Unlike PAX5, the PAX6 gene does not have this controversy associated and its tumour 
suppressor role is well accepted. It is though that its contribution to oncogenesis is due to the silencing 
of the gene, abolishing this way, tumour suppression (Robson et al., 2006). It was found to be 
methylated in breast and lung squamous cell carcinoma (Moelans et al., 2011; Rauch et al., 2012). It 
is not a gene well studied in HNSCC, but Gasche et al. (2011) found it to be methylated due to IL-6 
inflammation. Our results show that methylation of PAX6 gene could be a characteristic of HNSCC, 
since both cell lines were found to be methylated.   
The WT1 gene is other example of controversy. Just like PAX5, WT1 is considered to have a 
tumour suppressor and an oncogenic role in carcinogenesis. It was considered to be a tumour 
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suppressor involved in kidneys Wilms’ tumours, however, its overexpression in several tumours, 
such as carcinomas of the lung, colon, pancreas, breast and brain tumours, suggest an oncogenic role 
(Hartkamp and Roberts, 2008). Oji et al. (2003) showed an overexpression of this gene in HNSCC, 
leading to the conclusion that this gene may have an oncogenic role in this disease. However in 
Mikami et al. (2013) and in our study, the results showed promotor methylation of WT1 gene. 
Regarding gene expression, Mikami et al. (2013) showed that HSC-3 cell line did not had mRNA or 
protein expression. This result is interesting if we have in consideration that, accordingly to MS-
MLPA and aCGH, in HSC-3, besides the methylation of this gene, a gain was also detected. 
However, methylation ratio was closed to 100%. For BICR-10 cell line, as far as we know, no study 
was performed regarding WT1 gene expression. Our results suggest a tumour suppressor role for this 
gene in HNSCC pathogenesis. Recently, it has been proposed that downregulation of this gene was 
associated with a decrease in mRNA and protein levels of both Bcl-2 and Cyclin D1 and 
overexpression is thought to be associated with apoptosis, a quiescent state, and increase or a block 
in differentiation depending on the differentiation status of the affected cell. Rather than categorise 
the gene, Huff (2011) put the hypothesis that the developmental stage of the cell was an important 
aspect to determine the effect of WT1 gene expression alteration, suggesting a model where the 
alteration of this gene had a direct effect on the differentiation status of the cell, which would result 
in an alteration in cell viability and/or proliferative status (Hartkamp and Roberts, 2008; Huff, 2011). 
Other gene with promotor methylation on both cell lines was CADM1 gene. This gene was 
originally called Tumour Suppressor in Lung Cancer and it codes for a transmembrane protein from 
the immunoglobulin superfamily that plays a role in cell-cell interactions between epithelial cells 
(van den Berg et al., 2011). It was found methylated or downregulated in various cancers, including 
HNSCC (Steenbergen et al., 2004; Worsham et al., 2006; van den Berg et al., 2011). Methylation of 
this gene was associated with tobacco and worst prognosis in lung cancer in a study conducted by 
Kikuchi et al. (2006). Our results are in accordance with the literature, showing that this gene could 
be important in cancer development. 
Finally, we have GATA5 that was methylated in both HSC-3 and BICR-10 cell lines. The 
GATA family members are transcription factors that have essential roles in cellular growth and 
differentiation during embryogenesis and early development (Patient and McGhee, 2002). This gene 
is considered a tumour suppressor gene (TSG), since its silencing can prevent normal differentiation 
programs and contribute to tumour development (Fu et al., 2007). GATA5 is described to be 
methylated in a few cancers, like carcinomas of the lung, pancreas and renal (Guo et al., 2004; Fu et 
al., 2007; Peters et al., 2014). In the latter, it was associated with tumour progression and worse 
prognosis (Peters et al., 2014). Applying this to our results is possible that this association could also 
happen in HNSCC, since HSC-3 is a metastatic cell line and BICR-10 is a radioresistant cell line. 
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However studies for this gene in HNSCC are not common, Gasche et al. (2011) also found this gene 
to be methylated in HNSCC due to IL-6 inflammation, just like PAX6 gene. 
It is possible that these six genes, RARβ, PAX5, PAX6, WT1, CADM1, GATA5, could be 
important biomarkers for HNSCC, since two cell lines so different from each other, with molecular, 
histologic and anatomic differences, showed methylation on the gene’s promoters. However, studies 
regarding their expression and protein analysis are imperative in order to establish their roles in 
HNSCC tumorigenesis. Furthermore, an analysis on HNSCC patients could be helpful to understand 
their importance and if they could be reliable biomarkers.  
In the case of MGMT gene, the results obtained showed that both cell lines were methylated 
in this gene, however with some differences, since the probe panel had two different probes for the 
gene, one located 319 nt after the exon 1 and the other 72 nt before the exon 1. BICR-10 cell line had 
the first probe methylated, whereas HSC-3 had the second one methylated. Accordingly to the 
manufacturer’s instructions, this probemix is not the most adequate for the assessment of MGMT 
methylation. This happens because MGMT has two methylation hot spots near the transcription start 
site that are associated to the gene silencing and, between these two hot spots there is a region that 
has a much lower frequency of methylation (Qian and Brent, 1997). Both probes of this probemix 
are located in these two hot spots. For the assessment of MGMT methylation, MRC-Holland 
recommends the use of the ME011 probemix that has six probes for the gene. Taking this line of 
reasoning, it was decided in this work not take in consideration the results for the MGMT gene.  
Regarding the differences between the two cell lines, the genes TP73 and ESR1 were 
methylated in the metastatic cell line, HSC-3, and the genes CHFR and CDH13 were methylated in 
the non-metastatic cell line, BICR-10. 
TP73 gene is involved in cell cycle regulation and induction of apoptosis. The biggest 
problem of accessing the function of this gene in tumorigenesis is the fact that TP73 locus encodes 
two isoforms with opposite effects: TAp73, which is able to activate p53-responsive genes, inducing 
cell cycle arrest and apoptosis (tumour suppressor function); and ΔNp73, that is an inhibitor of  both 
TAp73 function and p53-induced apoptosis (oncogenic function) (Melino et al., 2002). This gene 
was found to be methylated in HNSCC (Worsham et al., 2006; Stephen et al., 2010; Worsham et al., 
2014) and in other types of cancer (Stephen et al., 2009; Marzese et al., 2012). Based in our results, 
it is hypothesized that the methylation of this gene could be associated to lymph node metastasis. 
Furthermore, in invasive ductal breast tumours, Marzese et al. (2012) concluded that TP73 
methylation was independently associated with high-grade tumours and co-methylation of TP73 and 
RARβ could be associated to a higher histologic grade, an increased proliferation ration and tumour 
size, and to lymph node metastasis. Since our metastatic cell line, HSC-3 showed methylation of 
both genes, whereas the non-metastatic cell line only showed methylation of one gene (RARβ), and 
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has a higher proliferation rate, it is possible that this conclusions could also be applied to HNSCC, 
however, further studies should be performed in order to confirm this result.  
Regarding ESR1 gene, it encodes an estrogen receptor, which is a ligand-activated 
transcription factor that is important for hormone binding, DNA binding and activation of 
transcription [NCBI-Gene: 2099]. Stephen et al. (2010) considered that this gene had a role as a TSG 
by suppressing metastasis development, which is in agreement with our results, since this gene is 
only methylated in the metastatic cell line and the most common result of gene methylation is gene 
silencing, thereby not contributing to metastasis suppression. Stephen et al. (2010) also considered 
ESR1 as a good predictor of advanced stage in laryngeal carcinoma and poorer survival outcomes. 
This gene was also found to be methylated in colorectal (Molinari et al., 2013), breast cancer (Gaudet 
et al., 2009) and in osteosarcoma (Sonaglio et al., 2013).  
According to the literature and our results, it is possible that the co-methylation of this two 
genes, TP73 and ESR1, could be a predictor of metastasis development, particularly with the 
envolvement of the lymph nodes. Regarding the association with RARβ methylation, it is more 
unlikely, since the non-metastatic cell line also presented this epigenetic alteration and other studies 
have shown this to be associated with early events in HNSCC (Lotan et al., 1995; Worsham et al., 
2014). 
BICR-10 cell line showed methylation of other two genes: CHFR and CDH13. 
CHFR is a checkpoint gene that delays metaphase entry in response to mitotic stress 
(Scolnick and Halazonetis, 2000). Baba et al. (2009) showed that the methylation of this gene was 
more frequent in buccal mucosa rather than in tongue. In our results, CHFR was methylated in BICR-
10 cell line. BICR-10 cell line is derived from a tumour in the buccal mucosa, whereas HSC-3 cell 
line is derived from the tongue. This goes in agreement with the results above mentioned. The results 
from Baba et al. (2009) also identified this epigenetic abnormality as a good distinguisher between 
primary tumours and normal adjacent mucosa, since the latter had a lower frequency of CHFR 
methylation. This gene was considered to have a high methylation frequency in HNSCC (Stephen et 
al., 2010; Demokan and Dalay, 2011; Noorlag et al., 2014; Worsham et al., 2014). Additionally, a 
study was performed with HSC-3 cell line, showing that CHFR was not methylated (Toyota et al., 
2003), which agrees to our results. 
The CDH13 gene encodes an intracellular adhesion molecule with a role on cellular 
proliferation regulation, invasion, and intracellular signalling during cancer progression. It works as 
an inhibitor for the Ras/PI3K/AKT pathway (Conacci-Sorrell et al., 2002; Adachi et al., 2010). It has 
a tumour suppressor role, maintaining cell adhesion integrity. Aberrant methylation for this gene was 
found in several cancers, like colorectal, lung and breast. It was considered to be an early event in 
HNSCC cell lines (Worsham et al., 2006; Stephen et al., 2010). Only one of the cell lines showed 
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methylation of this gene, the BICR-10 cell line and, since the methylation of this gene is thought to 
be an early event in HNSCC cell lines, it is possible that BICR-10 is derived from a tumour in an 
early stage, or kept this alteration during its development through the tumorigenesis process. 
Moreover, in the epigenetic model proposed by Worsham et al. (2014), the promotor 
methylation of four genes was considered to be specific for primary tumours. This four genes are 
CDH13, CHFR, CADM1 and RARβ. According to our results this is an unlikely possibility since the 
metastatic cell line, that is derived from a primary tumour did not presented the methylation of the 
four genes, whereas BICR-10 cell line, which was derived from a recurrent tumour, showed promoter 
methylation of this four genes.  
 
5.1.2 Karyotype  
The analysis of genetic abnormalities in both cell lines was accessed through conventional 
karyotyping, in order to provide a full picture of genetic alterations present in HSC-3 and BICR-10. 
Chromosome banding analysis allows the examination of individual tumour cells, which is 
particularly interesting in HNSCC since a high percentage shows intratumoral heterogeneity (Jin et 
al., 2005). This heterogeneity can be due to cytoskeletal alterations that originate chromosomal 
segregation problems, leading to differences between the progeny after mitosis. Cytogenetic 
aberrations have already been classified as good biomarkers for diagnostic, prognostic and treatment 
response (Gollin, 2014) and conventional cytogenetics is able to give a full image of the genome and 
detect structural aberrations, such as balanced translocations, that are not detected by other molecular 
cytogenetic techniques, as aCGH.  However, a problem with karyotyping analysis concerns the fact 
that it is only possible in limited cases, since it can be difficult to prepare metaphase spreads (Uchida 
et al., 2006). Regarding our cell lines, only ten metaphases were analysed mostly due to staining 
difficulties. However, this number is rather small and, at least, more 20 metaphases have to be 
analysed for more accurate results.  
Although, in our cell lines was noticeable some aberrations that are in accordance with 
literature results previously published (Jin et al., 2000; Uchida et al., 2006; Martin et al., 2008; 
Gollin, 2014). Concerning numeric aberrations, monosomy 18 and loss of Y chromosome were 
noticeable in HSC-3 cell line and are highly common in patients with HNSCC (Jin et al., 2005; Jin 
et al., 2006).  
Regarding structural aberrations, in both cell lines, there are various isochromosomes. In 
HSC-3 we have two isochromosomes: i(1)(q10) and der(13;13)(q10;q10), whereas in BICR-10 we 
have two other: i(5)(p10) and i(7)(p10). Regarding whole-arm translocations we have 
t(3;5)(p10;q10) and der(15)t(X;15)(q10;q10)  in BICR-10 cell line and der(14)t(14;17)(q10;q10) and  
der(X)t(X;8)(q10;q10) in HSC-3 cell line. Other aberrations are derivative chromosomes that are 
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formed due to translocations, as der(1), der(7)t(7;11), der(8;8), der(8)t(5;8) and der(17)t(7;17) in 
BICR-10 cell line and in HSC-3 cell line. Some breaks through centromere were observed as well, 
especially in HSC-3 case, for example, del(1)(p10) and del(2)(q10).  
These results suggest that centromeric breaks are common events in HNSCC, since the 
majority of the alterations observed were aberrations involving whole arm chromosomes. This 
hypothesis has already been suggested and, moreover, it is though that centromere cleavage is the 
mechanism behind these alterations (Jin et al., 2000; Uchida et al., 2006). 
 Of particular interest is BICR-10 cell regarding i(5)(p10) and der(8;8). This derivative of 
chromosome 8 is very similar to an isochromosome since it shows a duplication of the q arm of the 
chromosome, however it has also some genetic material that we were not able to identify. 
Nevertheless, the presence of these two isochromosomes in HNSCC is associated with genetic gain 
of 5p and 8q, which occurs in this cell line, and it is hypothesized that these two aberrations are 
important in OSCC, remaining to know if they are causes or effects in this type of cancer (Uchida et 
al., 2006).  
As for HSC-3 cell line, a previous study (Uchida et al., 2006) has already described some 
cytogenetic alterations, however, they were assessed by fluorescence in situ hybridization (FISH) - 
spectral karyotyping (SKY). Among the alterations that they described, four of them were also found 
in our study: der(X)t(X;8)(q10;q10), i(1)(q10), der(13;13)(q10;q10) and monosomy 18. However, 
some alterations detected in our study are not referred in this paper and even the average number of 
chromosomes is dissimilar due to the cell lines instability. To our knowledge, no previous study has 
been performed in order to characterize BICR-10 cell line, being this the first one. 
Furthermore, it is important to highlight the small number of aberrations identified in this 
study. HSC-3 and BICR-10, especially HSC-3, have much more aberrations than the ones mentioned 
above, however, by classical cytogenetic analysis they were not possible to identify. For this reason, 
a study with FISH, in particular SKY, is going to be helpful in order to make a more profound and 
accurate karyotype of both cell lines. 
 
5.1.3 Genetic Characterization 
In regard to the particular case of CNV, aCGH was used to obtain results from the whole 
genome, and MS-MLPA was applied for a more targeting analysis. Besides the previous mentioned 
problems with respect to the histological and anatomic characteristics of the two cell lines, the 
different stage in the disease progression was found to be a huge problem in the analysis of the cell 
lines. 
In our aCGH and MS-MLPA analysis is possible to verify that both cell lines are extremely 
different from each other. aCGH, being a technique that allows the analysis of all the genome, 
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demonstrated that HSC-3 has a higher number of gains, whereas BICR-10 presented a higher number 
of losses. Additionally, the metastatic cell line has a higher frequency of abnormalities. One possible 
explanation for the higher chromosomal instability (CIN) in HSC-3 is regarding its advanced stage 
of development. As it is known, cancer is characterized for genetic instability, once HSC-3 is in a 
higher stage of development, it is considered normal that it presents more aneuploidies and a higher 
CIN. However the differences could also be associated to the different sub anatomic regions from 
which each cell line was established. Other factors that may influence the results are the 
aggressiveness and response to treatment of each patient from who the cell line was established. The 
fact that the outcome of none of the patients is known makes even harder the analysis of the results 
obtained. 
One important thing to highlight is the fact that, even so different, both cell lines present 
abnormalities previous described as common events in HNSCC patients.  
5.1.3.1 Characteristics commonly present in HNSCC patients 
Chromosome 3 is commonly altered in HNSCC patients, both the long and the short arm 
(Gollin, 2014). In HSC-3 cell line there is a gain of the long arm of chromosome 3. This could induce 
the idea of a isochromosome 3q, which is very common (Gollin, 2014), however, our karyotyping 
results does not showed the presence of an isochromosome 3q. The gain of the distal part is also 
common and is associated to a worse outcome, especially the dup(3)(q21q29) (Freier et al., 2010). 
As the gain of this arm is common, there are suggestions regarding the presence of an important 
oncogene. The most considered gene is the ATR (3q22-q24), which is responsible for the activation 
of the checkpoint when DNA damages, due to stresses, are present on the cell (Gollin, 2014) This 
hypothesis is sustained in HSC-3 cell line, since the amplification of this gene is observed in aCGH. 
The PIK3CA is also an important oncogene in this region and it is involved in cell survival in HNSCC 
(Leemans et al., 2011). HSC-3 also presented amplification of this gene. It was also associated to an 
advanced stage, which is concordant to our results, once BICR-10 cell line did not presented any 
alteration of the gene.  
Regarding the short arm of chromosome 3, in HNSCC, it frequently showed losses, as in the 
case of BICR-10 cell line. Since they are associated to early events (Gollin, 2001; 2014) it is difficult 
to claim that BICR-10 cell line was established from a tumour in early stages, because it is possible 
that the tumour had suffered these losses and has kept them to the passage through later stages. Two 
TSG in this regions are the FHIT and RARβ (Lotan et al., 1995; Gollin, 2001). The first one is deleted 
on BICR-10 cell line and the deletion of FHIT combined with mutation on TP53 was associated to a 
worse prognosis in HNC cell lines (Raju et al., 2015). Even though we did not analyse the TP53 gene 
for mutations, BICR-10 cell line is described to have this gene mutated. In this case, this could 
indicate that BICR-10, even though the stage of development is unknown, could represent a model 
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for an aggressive HNSCC. However, the reason for the worse outcome it is not clear: could the 
tumour be resistant to therapy or evolve to metastasis? Regarding the RARβ gene, MS-MLPA 
analysis showed it to be amplified, however, as previous described, it was also methylated (98%), 
meaning that it was probably silenced. In MS-MLPA analysis, BICR-10 cell line presented a gain in 
VHL gene. This gene, encoded at 3p25.3, is a known tumour suppressor and it is involved in the 
regulation of various cellular processes, being its interaction with HIF-1α the most studied. When 
the VHL protein is absent, HIF-1α is not degraded, leading to the transcription activation of several 
target genes involved in processes like angiogenesis and glycolysis (Gossage et al., 2015). To our 
knowledge, there are no reports of gains associated to VHL so the hypothesis of this gene also had 
an oncogene role is discarded. The most probably explanation is that, even though VHL is amplified, 
it is non-functional due to other processes and its amplification is a contribution to genetic instability, 
characteristic of cancer cells. Nevertheless, further studies are required to assess the VHL function in 
this cell line.  
Other common aberration in HNSCC is 7p gain and both our cell lines showed this gain, as 
observed by aCGH and conventional cytogenetics. Furthermore, Bockmühl & Peterson (2002) have 
associated gain of 7p to earlier stages in HNSCC carcinogenesis. Since both of our cell lines 
presented this gain, it is possible that this alteration has occurred in the early stages and had been 
maintained. This could mean that 7p gain is highly important in order to keep the malignant 
phenotype once it happens in the beginning of the process and remains, even in the metastatic stage. 
One of the most important genes known to be associated with cancer is mapped at 7p12.3-p12.1, 
EGFR. The EGFR gene is highly involved in the development of HNSCC, as in other types of cancer, 
since it plays an important role in growth, survival, invasion, metastasis and angiogenesis. EGFR 
gain is correlated with poor prognosis and treatment resistance (Gollin, 2014). HSC-3 and BICR-10 
showed gain of this gene. The gain in the cell lines allows to drawn the possibility of both tumours 
have had worse prognosis: HSC-3 cell line is metastatic and this, by itself, has a worse prognosis. In 
BICR-10 cell line, it is possible other explanations: the tumour could had characteristics that made it 
prone to the development of metastasis or resistance to treatment could had happen.  
Both HSC-3 and BICR-10 cell line showed 8q gains. This gain is also a common alteration 
present in HNSCC tumours. One important oncogene in this region is MYC, which is associated to 
poorer survival rates (Ribeiro et al., 2014b). Results from both cell lines showed a gain of MYC gene, 
leading to the same hypothesis made previously for EGFR gene. PTK2 (8q24-qter) is other gene in 
this region, which gain has been associated to a higher invasiveness stage (Ribeiro et al., 2014a). 
This gain is only seen in HSC-3 cell line, which is concordant to the metastatic profile. BICR-10 did 
not showed this alteration, which is in accordance with the fact that it is not derived from a patient 
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with metastasis. Moreover, this also supports the hypothesis that this cell line was derived from a 
tumour in early stages of development. 
Losses on chromosome 9 are very common in HNSCC, especially at the short arm (Gollin, 
2014). This loss is associated to an early event in this type of cancer and LOH at 9p21-p22 appears 
in a high frequency. As mentioned, in this region are mapped genes that encode CDKs, which are 
very important in cell cycle regulation (Scully et al., 2000; Gollin, 2014). Even though BICR-10 cell 
line did not showed loss of the entire arm, this band is lost. Moreover, karyotpe analysis of this cell 
line detected del(9)(pter). As for HSC-3, it has a gain of all chromosome 9. Regarding the 9p, it is 
possible that, in earlier stages of development, one allele was lost, however, due to the high genomic 
instability and the progression in carcinogenesis, it is possible that, the allele that was not lost, had 
suffered exponential amplification in a way that the loss of the allele is not accounted for anymore. 
As showed by MS-MLPA results, BICR-10 has loss of one gene that it is commonly deleted in 
HNSCC: CDKN2A. This gene is a CDK inhibitor, which blocks cell cycle progression, leading to an 
unregulated cellular proliferation (Martin et al., 2008). Interestingly, HSC-3 shows genetic gain of 
this gene. A recent study, have associated the expression of this gene to a positive response to 
treatment (Tehrany et al., 2015).  
Amplification of 11q13 band is very common and was observed in HSC-3 cell line. This is 
a band with several genes, the most of all are overexpressed in HNSCC. Furthermore, this alteration 
is thought to be involved in the transition from moderate to severe dysplasia (Gollin, 2014). Since 
BICR-10 cell line did not showed this alteration, it is possible to hypothesize that the stage of this 
cell line was before the transition to severe dysplasia, meaning that it would represent a hyperplasia 
or a dysplasia. However, despite being common, this amplification does not happen in all HNSCC 
cases, so BICR-10 cell could also be an example of a case where this amplification did not occur. 
Nevertheless, BICR-10 showed 11q distal loss without 11q13 band amplification which has been 
associated to a stage between dysplasia and carcinoma in situ (Gollin, 2014). Accordingly to the 
literature, is possible that BICR-10 cell line represents a tumour in the dysplasia stage.    
Finally, loss of 18q is also a cytogenetic aberration that occurs frequently in HNSCC and 
both our cell lines showed this alteration (Scully et al., 2000). However the possible tumour 
suppressor gene (TSG) in this region was not determined yet, and, since the MS-MLPA panel used 
did not had any probe for any gene in chromosome 18 and aCGH gives an elevated number of altered 
genes, there are no conditions to draw any hypothesis without more results.  
5.1.3.2 Comparison between a metastatic and a non-metastatic cell line 
Both cell lines are much different from each other. Analysing the aCGH and the MS-MLPA 
results, the cell lines showed big differences.  
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The biggest similarities between the lines were described above. Even though, according to 
MS-MLPA, they have one more similar genetic alteration was the loss of CFTR, mapped at 7q31.2. 
The CFTR protein is a chloride channel, required for transepithelial salt and water transport. This 
gene is primarily expressed in epithelial cells, such as those of airways, gut, pancreas and 
reproductive tract. The major disease associated to alterations in CFTR is cystic fibrosis, however, 
its role has been studied in different types of cancer, including lung cancer (Zhang et al., 2013; Li et 
al., 2015; Mall and Galietta, 2015). It is suggested that the role of this gene in carcinogenesis depends 
upon the type of tumour. To our knowledge, no study was performed in order to analyse this gene in 
HNSCC carcinogenesis. Li et al. (2015) analyse CFTR in non-small-cell lung carcinoma (NSCLC) 
and concluded that it had a tumour suppressor role in this type of cancer, being its downregulation 
associated to an advanced stage, lymph node metastasis and poorer prognosis. Taking this into 
consideration and the fact that both cell lines showed a decrease in copy number for this gene, it is 
possible that CFTR also plays a part in HNSCC tumorigenesis, probably as a TSG. It is possible, 
however, that this gene is not associated to lymph node metastasis, since the non-metastatic cell line 
also had loss of the gene. Likewise, the association with an advanced stage is also unlikely, since 
BICR-10 cell line is hypothesized to be a dysplasia. Nevertheless, further studies are crucial in order 
to understand the role of CFTR in HNSCC development.  
Regarding differences between both cell lines, chromosome 1 is a good example. Whereas 
in HSC-3 chromosome 1 has a total gain, BICR-10 shows only losses. One interesting alteration 
observed in HSC-3 karyotyping was the presence of isochromosome 1q, already reported for this 
chromosome (Jin et al., 2001). Moreover, gains of several regions, such as 1q21-q24 and 1q32-q41 
have been associated with the presence of metastasis (Bockmuhl and Petersen, 2002). Our data is in 
accordance with these assumptions. Furthermore, 1q gain was associated to a metastatic phenotype 
in SCCs of the lung and it is one of the most frequent alterations in brain metastasis (Bockmuhl and 
Petersen, 2002). Together, the literature and our data suggest a strong relation between the presence 
of metastasis and 1q gains. Then, 1q gain could possibly be biomarker for metastasis development.  
Regarding chromosome 4p, in HSC-3 we are presented with all arm gain, whereas in BICR-
10 cell line we have 4p loss. This 4p loss is thought to be a relatively common alteration in HNSCC 
cell lines (Martin et al., 2008; Freier et al., 2010). Moreover, this loss was also associated to lymph 
node metastasis in oral cancer (Gollin, 2014). Although our results are contradictory, 4p gain in the 
metastatic line could be one case whereas a random amplification could have occurred, contributing 
for a higher genomic instability. This hypothesis is sustained by the fact that are no references to 4p 
gains in HNSCC. For BICR-10 cell line, it is probably that this alteration could indicate that this 
tumour would had a propensity to metastasis. It is important to highlight that this association with 
lymph node metastasis is not exclusively to oral cancer (Petersen et al., 2000; Yen et al., 2001).  
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Chromosome 10 appears to have big differences between both cell lines. BICR-10 shows a 
deletion in 10q23.1-q23.2, whereas HSC-3 has a loss in 10p15.3-p12.4 and a 10q11.21-q24.2 gain. 
It could be possible that aberrations on this chromosome allowed the distinction between metastatic 
and non-metastatic stages. However, since none of this alterations have been described in HNSCC, 
a more likely hypothesis is that the alterations seen in HSC-3 were due to randomly alterations 
usually seen in cancer cells. Furthermore, chromosome 10 is not usually mention as a common 
characteristic in the majority of cancers. In spite that, a few genes that are located on this chromosome 
are frequently studied, as the case of PTEN (10q23.31) (Scully et al., 2000; Mriouah et al., 2014). 
Still, only HSC-3 showed CNV of PTEN, detected by aCGH. Nevertheless, a more specific analysis 
of this chromosome on HNSCC could help understanding if it has a role in carcinogenesis. 
 Looking at the results obtained, alterations on chromosome 12 are more characteristic of the 
metastatic cell line, HSC-3. BICR-10 cell line barely shows any alteration and HSC-3 as a gain of 
all the chromosome. These aberrations on chromosome 12 are not common in HNSCC (Scully et al., 
2000). In germ cell tumours, however, it is described that 12p gains are common and are associated 
to the progression to a more invasive stage (Looijenga et al., 2011). In chronic lymphocytic leukemia 
trisomy 12 is common and it is considered to be a clonal driver mutation implicated in the formation 
of other genetic abnormalities. Even though it is common, no set of candidate genes was possible to 
define since, usually, all the chromosome appears altered. However, genes such as cyclin-dependent 
kinase inhibitor 1B (CDKN1B1), CDK4, huntingtin interacting protein 1 related (HIP1R), myogenic 
factor 6 (MYF6) and MDM2 proto-oncogene (MDM2) have been proposed (Puiggros et al., 2014). 
Recently it was also suggested that trisomy 12 could have a role in mammary neuroendocrine 
carcinoma (Xiang et al., 2014). Taking all this into consideration, it is important to analyse in more 
detail the role of chromosome 12 in HNSCC. In spite the fact that reports of alterations are not 
common, some important genes could be mapped at chromosome 12, and it could be as in the case 
of germ cell tumours and become a biomarker for invasiveness. The role of a clonal driver mutation 
is, however, unlikely, since these alterations occur early in carcinogenesis and BICR-10 cell line did 
not present much alterations on chromosome 12. 
 Analysing the data obtain by MS-MLPA the greater differences between the two cell lines 
are in chromosome 13, since BRCA2 (13q13.1) and RB1 (13q14.2) have genetic gain in HSC-3 cell 
line and in BICR-10 cell line loss. These results are in agreement with aCGH data and cytogenetics. 
It is possible that chromosome 13 could be pivotal in distinguish the metastatic from the non-
metastatic cell line. BRCA2 codes for the nuclear protein BRCA2, which binds to BRCA1 and to 
RAD51. The interaction with the latter, a recombination and repair molecule, reveals a role for 
BRCA2 in DNA repair, particularly in RAD51-dependent pathways for homologous recombination. 
Data have showed that cells deficient in BRCA2 accumulate aberrations, leading to the assumption 
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that this gene also plays an important role in genetic stability (Venkitaraman, 2001; Cornejo-Moreno 
et al., 2014). Although it is known the involvement of this gene in several types of cancer (Cornejo-
Moreno et al., 2014), there is a lack of evidence for the involvement of this gene in HNSCC 
pathogenesis (Nawroz-Danish et al., 1998). Regarding RB1, it is a critical tumour suppressor gene 
(TSG) with three different roles in cells. The most studied is the checkpoint function. Rb protein 
blocks the passage from G1 phase to S phase of the cell cycle when DNA is damage. The second is 
the inducing of apoptosis, since Rb is capable of activate apoptosis regulator BAX, a protein that 
binds to the apoptotic repressor Bcl-2, leading to the release of cytochrome c from the mitochondria. 
This release is a known apoptosis trigger. Finally, RB1 is thought to cause telomeric attrition and 
spontaneous CIN (Gollin, 2014). However, just like BRCA2, the frequency of alterations in RB1 in 
HNSCC is considered to be low (Yoo et al., 1994). Curiously, HSC-3 has a greater chromosomal 
instability (CIN) than BICR-10, which supports the function of RB1 in inducing CIN. Even so, 
deletions on 13q are very common in patients with HNSCC (Gollin, 2014). Sabbir et al. (2006) 
studied the chromosome 13 on an Indian population and found four regions with high frequencies of 
LOH: 13q13.1, where BRCA2 gene is mapped, 13q14.2 (RB1 gene), 13q21.2-22.1 (breast cancer 3 
(BRCA3) gene) and 13q31.1. They concluded that this four regions were highly associated with an 
advanced stage and poor patient outcome, having some cumulative effect in the progression of this 
type of tumour. Furthermore, this four regions are hypothesized to be needed for the development of 
later stages of HNSCC. BICR-10 cell line showed loss of BRCA2 and RB1 genes but not showed loss 
of BRCA3 or in the 13q31.1 region. One possible explanation is that loss of BRCA2 and RB1 are 
deletions that occur first in the development, being followed by the deletion of the other two regions, 
and, as the four regions are being deleted, the tumour is progressing (Sabbir et al., 2006). As for 
HSC-3 cell line, it shows a gain of all 13q, including gain of BRCA2 and RB1. This could be explained 
by the fact that this tumour already reached the last stage in the development, once it already 
metastasized, so these deletions could had occurred in the past but for some reason, possibly only 
one of the chromosomes was lost in previously stages, remaining one chromosome that was highly 
amplified, enhancing the genetic instability of the tumour.  
 Deletions on chromosome 17p are relatively common and mutations on the TP53 gene are 
associated to early events in tumorigenesis (Scully et al., 2000). It is interesting in the case of BICR-
10 cell line, since it is described has having mutations on this gene and aCGH and MS-MLPA studies 
showed copy loss, meaning that it is highly probably that this line do not have any p53, which is 
frequent to be associated to a worse prognosis (Scully et al., 2000). For the HSC-3 cell line, all 
chromosome is amplified, including TP53 gene. This could also be the case of an alteration that could 
predict metastasis, since gains of 17q are often seen in invasive and metastatic tumours (Bockmuhl 
and Petersen, 2002). 
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 Chromosome 20 is not one of the most mentioned chromosomes involved in HNSCC 
pathogenesis. However, 20q gains have been described (Bockmuhl et al., 1998; Smeets et al., 2006) 
and have been associated with metastasis in several cancers, such as colorectal, and with poor patient 
survival in breast cancer and even in HNC (Ashman et al., 2003; Bergamaschi et al., 2006; Bruin et 
al., 2011). Recently, a study in patients with hepatocellular carcinoma concluded that the specific 
gain of 20q13.12-13.33 was a prognostic marker of metastasis and death and suggested that the genes 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 (DDX27), UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 5 (B4GALT5), ring finger protein 114 (RNF114), ZFP64 zinc 
finger protein (ZFP64) and prefoldin subunit 4 (PFDN4) could be oncogenes involved in the 
unfavourable outcome of these patients (Wang et al., 2015). BICR-10 cell shows loss of 20p, whereas 
HSC-3 has a gain of the entire chromosome, which is evident in karyotype, with the presence of 
trisomy 20 or even tetrasomy in most of the metaphases. The 20q gain in HSC-3 cell line could 
indicate that this arm could also have a role in HNSCC carcinogenesis, like in other types of cancer 
and even be associated to metastasis development. Further studies are required to analyse the 
particular involvement of this arm, and even of the 5 genes proposed by Wang et al. (2015), in 
HNSCC carcinogenesis. 
Chromosome 3, 9 and 11 are other examples of differences between the metastatic and the 
non-metastatic cell line, however, they were described previously. 
5.1.3.3 BICR-10 and HSC-3 stages of development 
HSC-3 is a metastatic cell line and our study confirmed that it presented alterations that were 
associated with metastasis in different stages, such as gains of 1q21-q24, 1q32-q41, 1q21-q22, 1q42-
q43, 1q32, 3q25-q27, 5p, 7p, 7q11.2, 10q21 and 12q13 and loss of 5q11 (Bockmuhl and Petersen, 
2002; Wreesmann et al., 2004; Gollin, 2014). Additionally, it has the amplification of 11q13 band, 
very common in HNSCC tumours that is associated to a poor prognosis (Bockmuhl and Petersen, 
2002). 
Regarding BICR-10 cell line, its stage is unknown. Nonetheless, this study revealed that the 
majority of alterations in BICR-10 cell lines were associated to earlier events, such as 3p, 9p21-p22, 
13q losses, 7p gain, 11q distal loss without 11q13 amplification and TP53 mutations (Scully et al., 
2000; Gollin, 2001; Martin et al., 2008; Gollin, 2014). So, according to several progression models 
for HNSCC, this line shows more alterations of the mild dysplasia stage, however due to 13q and 
11q distal deletions, it is possible that it was progressing towards severe dysplasia (Argiris et al., 
2008; Haddad and Shin, 2008; Pai and Westra, 2009). Although, this line also presented alterations 
associated to metastasis and invasive carcinoma, this could be due to an enhancement of genetic 
instability or the tumour from which BICR-10 was obtain could had a propensity to develop 
metastasis.  
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5.2 ASSESSMENT OF RADIATION’S EFFECTS 
Radiotherapy is one of the most common treatments for cancer cells, and, although it has 
been used for many years, little is known about its effects on tissues. Anyhow, it is known that its 
effect differs depending on cell type, cell characteristics, cell surrounding, and even the dose applied 
translates in differences. Nevertheless, the mechanisms and genetic alterations that lead to different 
responses to radiation are not fully elucidated. Radiation-induced genomic instability (RIGI) is 
defined as the enhancement of de novo mutation events in the progeny of irradiated cells. Among the 
manifestations of RIGI are: delayed reproductive death, increased apoptosis, gene expression 
changes, micronuclei formation, chromosomal abnormalities and DNA methylation alterations 
(Ilnytskyy and Kovalchuk, 2011). 
In this study, we analyzed the effect of different doses in two different cell lines regarding 
copy number variations, alterations in the methylation profile and on the karyotype.  
Accordingly to the clonogenic assay performed, the two cell lines have big differences 
regarding their radiation response. The clonogenic assay measurements are based on the presence of 
the so called clonogenic cells. It is known that carcinomas have stem cells, which are cells with 
capacity to maintain their numbers while giving rise to cells that are able to differentiate and 
proliferate in order to replace the other functional cellular population. Some tumours regrow after 
treatment, namely after radiotherapy. This happens because some of the neoplastic stem cells were 
not killed during treatment, which means that the key in radiobiology is figuring out a way to kill all 
the stem cells of a tumour, preventing it from regrowing. Then, the efficacy of the radiation treatment 
is measured regarding the quantity of stem cells that are still in the tumour and have, therefore, the 
ability to form colonies – the clonogenic cells. A cell is considered to be clonogenic if it leads to the 
formation of a colony with, at least, 50 cells. The number 50 is used because it represents five to six 
generations of proliferation and the objective is to exclude two types of cells: (1) the ones that have 
entered on differentiation stage and have a limited growth potential and (2) the cells that suffered 
sublethal damages by therapeutic treatments. It is important to highlight that, after irradiation, the 
damaged cells do not die right after and some of them are able to originate descendants before they 
died. Taking this into consideration, the important factor of radiation response is not the cell killing, 
but rather the loss of reproductive integrity, which happens some hours after treatment due to genome 
damages, leading to metabolic and cell death processes (Joiner and van der Kogel, 2009). Thus, the 
cell survival curves that were obtained after clonogenic assays analysis measure reproductive cell 
death. 
Nowadays, there are three mathematical models that are used for the shape of the survival 
curve: the single-target/single-hit model, the multitarget model and the LQ model. All of them are 
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based on the idea that there is a target in the cell, which may be specific regions that are important 
for the maintenance of the reproductive integrity (Joiner and van der Kogel, 2009; Kelsey et al., 
2013). For BICR-10 cell line, the single-target/single-hit model was the one that was more adequate 
accordingly to the results obtained, whereas for HSC-3, the LQ model was the most adequate. The 
most common model used for survival cell curves of mammalian cells is the LQ model. However, 
this can vary between different cells. 
As expected, there is a decrease in cell survival with an enhancement of dose applied, except 
for HSC-3, which shows and enhancement of cell survival at 0,5 Gy. This is an example of an 
adaptive response, previously described. Furthermore, BICR-10 is a much more radioresistant cell 
line than HSC-3, which is noticeable not only by the cell survival curve but also for the LD50. HSC-
3 has a LD50 of 1 Gy and BICR-10 a LD50 of about 3 Gy. Even though they appear similar, in 
radiobiology they are very different, particularly if we take into consideration the fact that HNSCC 
is treated with 2 Gy daily doses of radiation. These changes in radiosensitivity are of big concern, 
since tumours with high levels of response to radiation can be treated with much higher doses than 
what it is needed, which leads to the submission of normal tissues to damages that could be avoided 
and are unnecessary for the accurate treatment of the tumour.  
 
5.2.1 Genomic Instability assessed by Karyotyping 
The major alterations associated with radiation-induced instability are chromosomal 
changes. Chromosomal gaps, breaks, duplications and partial trisomies are the ones that are most 
described. Bearing this in mind, the most supported hypothesis is that radiation exposure is capable 
of destabilizing the genome, leading to the formation of new genomic events in progeny of the 
irradiated cell, as, for example, chromosomal aberrations (Morgan, 2003). 
First it is important to highlight the fact that it was not possible to analyse all conditions by 
karyotype due to the fact that, for the highest doses the cells were not in division or the chromosome 
G banding showed a pattern that was not possible to analyse. In HSC-3 cell line this problem occurred 
with cells submitted to 5 Gy, 8 Gy and 10 Gy. In BICR-10 cell line, the cells submitted to 8 Gy, 10 
Gy and 15 Gy presented this problem.  
Concerning HSC-3 cell line, there are small diferences in the karyotype analysis for the 
different radiations. The cells submitted to a dose of 2 Gy are the ones that showed a frequency of 
the common aberrations more similar to the untreated cells. However, it is also the one which shows 
more new chromosomal aberrations as: 9q-, 11p-, 12p+ and der(11;17). Some of these alterations are 
also observable after the cells were irradiated with 1 Gy, particularly der(11;17). An aberration that 
appeared with some frequency in untreated cells was 4q- and, after irradiation it is only seen in one 
metaphase.  
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Regarding BICR-10 cell line the diffrences are more notorious. There is a decrease in some 
common alterations from BICR-10 cell line as the radiation dose is enhancing, as del(9)(pter) and 
der(7)t(7;11). One alteration that appears very frequently in cells submitted to 0,5 Gy of irradiation 
is der(2)(q10), that is observable in 8 of the 10 metaphases analysed. Two very interesting alterations 
between untreated and treated cells are the loss of der(8;8) and i(5)(p10) after irradiation treatment. 
der(8;8) is still observable, but with less frequency, as opposed to i(5)(p10), which only appears in 
one metaphase after irradiation treatment. This der(8;8), which resembles an isochromosome 8q and 
i(5)(p10) are two abberations that appear commonly in HNSCC patients (Uchida et al., 2006), so it 
is interesting to verify that alterations associated to this disease are being lost after radiation 
treatment. These losses could be results of the radiation treatment. 
Another alteration new in some metaphases after irradiation was 5q-, which frequency is 
enhancing with the enhancement of radiation dose. Furthermore, the highest dose of radiation, 5 Gy, 
is the one with less frequency of the most common alterations in untreated cells and the one where 
there is a higher frequency of new aberrations.  
The most common de novo alterations after radiation treatment are deletions. Since it is 
known that radiation produces double strand breaks (DSBs) in DNA (Joiner and van der Kogel, 
2009), it is possible that these losses are direct consequences of breaks on the chromosomes induced 
by irradiation. 
 To our knowledge, there is no study in HNSCC characterizing the karyotype after 
radiotherapy. These results suggest that the aberrations that occur in the progeny of irradiated cells 
are not random and their significance must be assessed with further studies. However, it is important, 
in the first place, to analyse more metaphases per condition, since some alterations that seem to be 
important in this analysis may only be due to the small number of metaphases analysed.  
 
5.2.2 Copy Number Variations 
There is a great number of CNV between the untreated cells and the cells submitted to 
radiation treatment on both cell lines. Since the amount of CNV between the cell lines after 
irradiation does not change a lot, it is possible that the difference in alterations induced by irradiation 
are not the cause for the radiosensitive differences observed between both cell lines. Nevertheless, 
some CNV in specific genes could help understand the mechanisms that lead to this radiation 
response difference. 
5.2.2.1 CNV assessed by aCGH 
Most of the genes that presented some CNV between the different doses at which cells were 
submitted were noticeable in HSC-3, the most radiosensitive cell line. RERE (1p36.23) 
subexpression triggers apoptosis. It is able to recruit BAX and consequently activate the caspase 
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cascade, leading to apoptosis (Waerner et al., 2001). Taking into consideration its function it is easy 
to understand the fact that lead to a gain of this gene after radiation treatment in the more 
radiosensitive cell line, regardless the fact that this gene was lost in the control cells. Also in this 
region it is mapped the FBLIM1 gene, commonly called migfilin. The encoded protein is a component 
of actin-cytoskeleton membrane junctions and it is postulated to regulate cellular processes such as 
shape modulation, motility and differentiation (Wu, 2005) Similar to RERE, this gene is lost in HSC-
3 cel line untreated and suffers a genetic gain after radiation treatment. This could mean that the 
tumour was losing its malignant phenotype, since the cells were losing the capacity to invade other 
tissues. 
The results for VHL (3p25.3), previously described, are interesting. BICR-10 cell has a gain 
of this gene, that it is maintained after the cells were submitted to radiation treatment. However, 
HSC-3 cell line had no CNV for this gene, except after irradiation with 0,5 Gy, which gives a 
proliferative advantage to this cell line. It is considered to be a TSG and there is no data regarding 
gain or overexpression of this gene in any type of cancer. This gene could have an important role in 
radioresistance, or could be associated to worse prognosis.  
COL1A2 (7q21.3) [NCBI-Gene: 1278] has been suggested to be a tumour suppressor gene 
in HNSCC pathogenesis and its hypermethylation associated to a higher tumour stage and metastasis 
(Misawa et al., 2011). This gene coded for the chain α2 of type I collagen, the most abundant collagen 
molecule. In the metastatic cell line, HSC-3, there is a genetic loss of this gene, that is maintained 
after cells were submitted to 0,5 Gy, which enhances cell survival. After 10 Gy, this gene suffers a 
gain and its copy number is considered to be normal. However, the non-metastatic cell line, BICR-
10, is normal in all conditions. The CNV in HSC-3 cell line could be representative of the loss of the 
the tumour malignant phenotype. However, since BICR-10 cell line was not in a metastatic stage, 
this gene had not suffered alterations yet.  
IRF5 (7q32.1) and MIR183 (7q32.2) are two genes that are lost in both cell lines, in all 
conditions except for HSC-3 cell line submitted to a dose of irradiation of 10 Gy. IRF5 [NCBI-Gene 
3663] codes for a protein that is a member of the interferon regulatory factor family. Proteins of this 
family have pleiotropic biological effects and are involved in several cellular processes, including 
differentiation and apoptosis. This gene plays as mediator for Interferon (IFN) and DNA damage-
induced signalling, which can lead to apoptosis and/or cell death (Hu et al., 2005). As for MIR183, 
to our knowledge, there are no studies regarding its involvement in HNSCC pathogenesis, and its 
role in carcinogenesis remains controversy. miR-183 is able to regulate the expression genes that 
have functions related to migration and invasion. In osteosarcoma and lung cancer, downregulation 
of miR-183 promotes migration and invasion of cancer cells (Wang et al., 2008; Zhu et al., 2012). 
Discussion                      From genes to radioresistance in  
Head and Neck Squamous Cell Carcinoma 
 
  Joana Rodrigues                                                                                                  Page | 92  
By inducing cell death or inhibiting the enhancement of the malignant phenotype, these genes could 
be examples of the efficacy of radiation treatment in the radiosensitive cell line. 
At 17q23.2, five genes showed genetic imbalances in the radiosensitive cell line: TBX4, 
NACA2, BRIP1, INTS2 and MED13. All five genes presented genetic gains in untreated cells, loss 
after submission to 0,5 Gy, and gain after submission to 10 Gy. These five genes could be important 
for the understanding of the mechanisms associated to one of the effects of radiation in tissues: the 
adaptive response, in our study represented in the HSC-3 cells submitted to 0,5 Gy of irradiation. As 
for their functions, TBX4 [NCBI-Gene: 9496] belongs to the T-box family gene, and codes for 
transcription factors involved in the regulation of developmental processes. The function of NACA2 
remains to be elucidated. However, it is though that it encodes a protein that prevents inappropriate 
targeting of non-secretory polypeptides to the endoplasmic reticulum [UniProt: Q9H009]. The 
protein encoded by BRIP1 [NCBI-Gene: 83990] interacts with BRCA1 for the normal repair of 
double-strand breaks. As for INTS2 [NCBI-Gene: 57508], it encodes a subunit of the Integrator 
complex, which mediates 3-prime end processing of small nuclear RNAs U1 and U2. Finally, 
MED13 [NCBI-Gene: 9969] codes for a protein that forms the mediator complex, which is 
responsible for the expression of almost all genes.  
As for BICR-10 cell line, the number of genes that suffered alterations that could lead to the 
radiation response is lower. The genes are KIF26B, GPR39, NAALADL2, MSX1 and HS3ST3A1.  
On the q arm of chromosome 1 there is one gene that after submission to radiation is lost. 
KIF26B (1q44) encodes a protein of the kinesin superfamily proteins, which are microtube-
dependent molecular motor proteins with several important cellular functions, such as vesicle 
transport, mitotic spindle formation, cytokinesis completion and chromosome segregation. Even 
though this family of proteins has already been associated with development and cancer progression, 
KIF26B is not well studied, with exception for a study in breast cancer, where its overexpression was 
associated to higher tumour size, grade and lymph node metastasis (Rath and Kozielski, 2012; Wang 
et al., 2013). First of all, this gene has not been studied for HNSCC yet. However, our results also 
suggest that it could be associated to lymph node metastasis due to gain of the gene in HSC-3 cell 
line. In the radioresistant cell line, its loss could be a representation of the decrease in the malignant 
phenotype and it is possible that this alteration could be related to the stage of tumour progression. 
This could mean that the tumours response to radiation could be different regarding their stage. 
Further studies are imperative for this gene. 
On chromosome 2, our results indicate other gene that could be involved in tumours response 
to radiation: GPR39 (2q21.2). It is a member of G protein-coupled receptors family, which is a family 
highly involved in cell signalling. Dittmer et al. (2008) suggested that overexpression of GPR39 
could inhibit cell death induced by different stresses, including oxidative stress (Dittmer et al., 2008). 
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Ionizing radiation can induce oxidative stress, and the fact that this gene loses copies in comparison 
to untreated BICR-10 (where it had genetic gain) could indicate that, in cells after irradiation there 
is less stimuli to the inhibition of oxidative stress-induced cell death induced by radiation, which 
eventually leads to a better elimination of cancer cells. HSC-3 cell line never presented gain of this 
gene. This could also be associated to the reason behind the differences in radiation response of both 
cell lines, since the radioresistant has alterations that inhibit cell death induced by damages that are 
caused by irradiation. Proving this theory right, GPR39 could be an important therapeutic target to a 
better result in cancer treatment.  
NAALADL2 (3q26.33) is another example of alteration after radiation that is only seen in the 
radioresistant cell line. There was no copy number alteration in the cells whitout radiation, and after 
being submitted to radiation treatment, both after 0,5 and 10 Gy, there is a gain of this gene. This 
gene is the least characterized gene that belongs to the N-acetyl-L-aspartyl-L-glutamate peptidase I 
family, which members act as M28 membrane metalloproteases and catalyse the hydrolysis of N-
acetylaspartylglutamate to glutamate and N-acetylaspartate. Whitaker et al. (2014) analysed the 
expression of this gene in several types of cancer, including in several regions of HNSCC and 
concluded that it was highly expressed and had an oncogenic role. They focused their study on 
prostate cancer, acknowledging that this overexpression was associated to a more aggressive disease, 
with more likelihood to metastasize. HSC-3 already showed gain of this gene, indicating that this 
assumption could also be true for HNSCC. However, BICR-10 cell line only had a gain after 
irradiation, possibly meaning that the radioresistant tumour was trying to counterbalance the loss of 
some of its cells, by trying to maintain the malignant phenotype. In addition, this protein family is 
interesting in a therapeutic point of view, since they act as matrix metalloproteases and are able to 
alter tumour microenvironment. Taking this into consideration, NAALDL2 needs further studies, not 
only in HNSCC but in cancer in general, and it is possible that this gene could eventually become a 
therapeutic target to maximize the therapeutic effects of radiation in radioresistant tumours.  
MSX1 [NCBI-Gene: 4487], encoded at 4p16.2, belongs to the muscle segment homeobox 
gene family. It codes for a protein that is a transcription repressor during embryogenesis. Moreover, 
this gene interacts with p53, inhibiting tumour growth by inducing apoptosis (Park et al., 2005). 
MSX1 did not show any copy number variations in BICR-10 cells and not even after irradiation with 
0,5 Gy. However, when submitted to 10 Gy, these cells showed a gain of this gene, indicating that it 
could represent a mechanism to cell death by apoptosis after radiation treatment. HSC-3 cell line 
showed gain of this gene which is maintained after irradiation treatment. This gene, due to its 
functions, may be related to the highest response to radiation of HSC-3 cell line when compared to 
BICR-10 cell line.  
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HS3ST3A1 (17p12) [NCBI-Gene:9955] encodes the enzyme 3-O-sulfotransferase, which 
catalyzes the biosynthesis of a specific subtype of heparan sulfate, 3-O-sulfated heparan sulfate. To 
our knowledge, the function of this gene remains unknown and because of its lack of study, there is 
no information regarding its involvement in carcinogenesis, with the exception of a paper 
characterizing a metastatic lung cancer cell line, where they postulated that the overexpression of 
this protein was associated to a higher propensity of a tumour to develop metastasis (Nakano et al., 
2012). However, for obvious reasons, this association lacks verification. This gene has a genetic gain 
in all conditions, except for BICR-10 in untreated conditions and after submission to 0,5 Gy, where 
no CNV was detected. It is possible that this gene is associated to higher sensitivity, since HSC-3 is 
a sensitive cell line, and after irradiation with 10 Gy the cells were dying, even in BICR-10 cell line.  
At last, TAF14B (18q11.2) [NCBI-Gene: 6875] participates in the TFIID protein complex 
and it is involved in the activation of several anti-apoptotic genes. Even though HSC-3 showed loss 
of the gene in all conditions, it is interesting to compare with BICR-10 cell line. In BICR-10 the only 
alteration is after submission to the lowest dose, where this gene has copy gains, which probably 
leads to an enhancement of apoptosis inhibition, in an attempt of the tumour to maintain its cells. In 
HSC-3 cell line, since this gene is lost, the balance between anti-apoptotic and pro-apoptotic genes 
is deregulated in favour of apoptosis. Thus, this gene could help provide a more radiosensitive 
response. To the best of our knowledge, there is no study involving this gene in irradiation-response. 
In both cell lines, only three genes have shown differences that could help understand the 
differences of the radiation’s effects: WRAP73, SLC22A18 and COL1A1. 
 In 1p32.32 we have the WRAP73 gene, it encodes for a protein that is a member of the WD 
repeat protein family. These family members have a wide spectrum of functions, being involved in 
cell cycle progression, signal transduction, apoptosis and gene regulation (Li and Roberts, 2001). 
HSC-3 cell line shows loss of this gene. However, when submitted to a dose of 0,5 Gy, which 
enhances cell survival, there is a gain of this gene. When submitted to a dose of 10 Gy, the loss 
remains. This could mean that this gene could have a role in the promotion of cell proliferation or 
inhibition of cell death. Moreover, in BICR-10 cell line, this gene only shows CNV in cells submitted 
to a dose of 0,5 Gy. It is possible, however, contradictory to the assumptions made for HSC-3, that 
this gene inhibits cell proliferation. In this cell line, it would balance the high proliferation rate of the 
tumour, leading to a more slowly proliferation, this would turn this cell line more radioresistant, since 
more proliferative cells are more sensible to radiation. However, when submitted to radiation, the 
cell, by deletion of this gene, reduces its expression, leading to an enhancement in cell proliferation, 
in order to counterbalance the death produced by radiation treatment. In cells submitted to 10 Gy, 
there is a higher frequency of cell death and it could be impossible for the tumour to activate this 
type of response, or it could have other mechanisms that would act faster. It is also possible that this 
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gene could have totally different responses due to the different stages of development of the cell 
lines. Since HSC-3 already showed metastasis, the effects of this gene regarding proliferation 
inhibition could not be relevant to its aggressive phenotype, contrary to BICR-10, which is still in a 
progression tumour phase.  
It has been postulated that SLC22A18 (11p15.4) [NCBI-Gene: 5002] functions as a TSG in 
tumorigenesis and, although it has not been well studied in HNSCC, our results support this function, 
since both our cell lines showed loss of this gene in untreated conditions. Furthermore, a study with 
glioma cell lines showed that the upregulation of SLC22A18 enhanced radiosenstivity, irradiation-
induced apoptosis and a delay in repair of DSBs, due to radiation treatment (Chu et al., 2014). These 
results are particularly interesting since, in HSC-3 cell line after irradiation, this gene passes from a 
loss to a gain in both conditions. This could indicate that alterations of SLC22A18 gene could be a 
mechanism of cell death after irradiation and consequently a good therapeutic target for enhancing 
radiation treatment response. In the most radioresistant cell line, a gain of this gene is also observed. 
However, it was the case only for cells submitted to 0,5 Gy. A possible explanation for the absence 
of copy gain of this gene could be that this is not the primary mechanism leading to irradiation-
induced cell death at 10 Gy, another mechanism of cell death could be more frequent.  
At 17q21.33 is mapped the gene that codes for pro-α chains of type I collagen, COL1A1 
[NCBI-Gene: 1277]. This gene was previously described as being overexpressed in tumour cells and 
associated to invasiveness of the tumour (Ryu et al., 2001). According to this paper, it is possible 
that this gene could also be associated to invasiveness, since HSC-3 cell line shows gain of the gene, 
whereas BICR-10 is normal. After irradiation, the gain is maintained in the cells submitted to 0,5 Gy 
in HSC-3. However, in 10 Gy and in BICR-10 cell line, there is loss of the gene. Then, alteration in 
this gene could be associated to a reverse of the malignant phenotype, caused by irradiation.  
5.2.2.2 CNV assessed by MS-MLPA  
MS-MLPA analysis showed differences in copy number in TSG after irradiation treatment. 
However, the alterations are very different when comparing one cell line to the other. 
In HSC-3, for example, regarding cells after submission to low O2 concentration, the 
majority of the differences are not relevant, since the ratios were close to the cut-offs. However, in 
BICR-10 cell line, the microenvironment change leads to some interesting alterations regarding 
CNV. Beyond that, some alterations detected by MS-MLPA were not detected by aCGH. This 
difference can be due to differences on probes and due to resolution differences between the two 
techniques, even though this topic is still controversial (Homig-Holzel and Savola, 2012; 
Evangelidou et al., 2013).  
The majority of the alterations are maintained in the different conditions. In HSC-3 CASR, 
CDKN2A, CD44, GSTP1, BRCA2, RB1, MLH3 and GATA5 gains and CFTR, ATM and CDH13 
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losses remain unaltered. In BICR-10 the gain of APC and the losses of CDKN2A, BRCA2, RB1 and 
TP53 also did not show any alteration in all the conditions. Moreover, in HSC-3 cell line, the 
alterations on TP73, PAX5, PAX6 and TP53 have slight differences in some conditions. However, 
the ratios were closed to the cut-offs, so it is highly possible that HSC-3 cell line also maintained this 
alterations in all conditions. The same is not applicable to BICR-10 cell line. Bearing this in mind, 
some alterations presented in the Table 11 need further studies to be considered relevant. 
Taking into account the most radiosensitive cell line, HSC-3 cell line, there are eight genes 
with alterations that are worthy to be mentioned: VHL, APC, WT1, TSC2, PMP22, MSH6, ESR1 and 
CHFR.  
VHL, APC, WT1, TSC2 and PMP22 presented alterations only in the cells submitted to the 
LD50 dose of irradiation, 1 Gy in both normoxic and hypoxic conditions. VHL has already been 
described in this study regarding its function and genetic gain. In HSC-3 cells submitted to 1 Gy in 
both environmental conditions this gene suffers loss and, interestingly, in aCGH results, this cell line 
suffers a genetic gain after a dose of 0,5 Gy (adaptive response). These alterations are both 
contradictory with the literature results for this gene (Gossage et al., 2015). If, on the one hand we 
have a more proliferative stage and a gain of VHL, in the LD50 dose we have a loss.  Then, this gene 
needs further studies in order to elucidate its role in HNSCC development, since by these results, it 
appears to have an oncogenic role, rather than the tumour suppressor.  APC is deleted after a dose of 
1 Gy of irradiation. The same happens with TSC2 and WT1 passes from gain to a normal number of 
copies. PMP22 is the only that suffers a gain after irradiation. APC [NCBI-Gene: 324] encodes a 
known tumour suppressor protein that functions as an antagonist of the Wnt signalling pathway and 
it is involved in cellular processes, including migration and cell adhesion, apoptosis and 
transcriptional activation. The activation of the canonical pathway of Wnt signalling leads to several 
neoplastic characteristics common in cancer such as evasion of apoptosis, insensitivity to growth 
inhibitors and tissue invasion and metastasis (Ilyas, 2005). It is possible that 1 Gy can also induce an 
adaptive response in HSC-3 cell lines, since the loss of APC decreases the inhibition of Wnt 
signalling. This is also observed in normoxic and hypoxic conditions. The clonogenic assay applied 
to this dose can highlight this issue. Regarding TSC2, it codes for the tumour suppressor protein 
tuberin [UniProt: P49815], which forms a complex with hamartin and negatively regulates 
Mammalian Target of Rapamycin complex 1 (mTORC1) signalling. This function allows this 
complex to exert translational control of protein synthesis and cell growth. Cells lacking this complex 
show increased proliferation. Moreover, it is also involved in cell adhesion (Nobukini and Thomas, 
2004). These alterations suggest a possible adaptive response when cells are submitted to 1 Gy in 
normoxic and hypoxic conditions, since these alterations favour the malignant phenotype of the 
tumour.  
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PMP22 role in carcinogenesis is controversy. In a study by Wilson et al. (2002), the 
enhancement of expression of this gene induced apoptosis. However, a more recent study indicated 
that the overexpression of this gene was associated, in breast cancer, to a more metastatic phenotype, 
indicating an oncogenic role for this gene (Tong et al., 2010). Due to the amplification of this gene 
when cells are submitted to 1 Gy of radiation, we want to believe that it will induce an enhancement 
of apoptosis. However, putting the hypothesis of this dose inducing an adaptive response, the 
oncogene role for this gene can also be taken into consideration. To our knowledge, no studies of 
PMP22 were performed in HNSCC, hampering any conclusions. WT1 has already been discussed 
and it is unlikely that the deletion of this gene in these two conditions would alter any cell 
characteristics, due to promoter methylation analysis, that revealed that it remains highly methylated 
(near 100%). 
ESR1 is lost after HSC-3 cell line was submitted to 0,5 and 1 Gy (in normoxic and hypoxic 
conditions). This gene was already mentioned as being a TSG that could suppress metastasis 
development (Stephen et al., 2010). Besides being methylated in all conditions, particularly, in these 
three conditions, it also is deleted. This supports the hypothesis that 1 Gy can also induce an adaptive 
response. 
Regarding MSH6, it shows loss after small doses of radiation in HSC-3 cell line and there is 
a loss of copy numbers in BICR-10 cell line, the radioresistant one, in all conditions, except the 
untreated cells. MSH6 [NCBI-Gene: 2956] encodes a member of the DNA mismatch repair MutS 
family. MSH6 [UniProt: P52701] is involved in the recognition of mismatched nucleotides. Thereby, 
it is involved in the initiation of DNA repair. Loss of this gene makes the cell advance to later stages 
of the cell cycle without repairing DNA damage. This advance can lead to an enhancement in the 
cell death by mitotic catastrophe once the DNA is not repaired after irradiation. In the radiosensitive 
cell line, HSC-3, this alteration is observable after low doses of treatment, which suggests that the 
low doses could induce an enhancement in the cell death by mitotic catastrophe after irradiation. At 
higher doses there is no alteration, probably because they induce other types of signalling that lead 
to cell death. However, it is also possible that the loss of this gene could lead to an enhancement of 
the malignant phenotype, once the damages induced by low doses of irradiation could not be 
sufficient to lead to cell death and, by advancing in cell cycle without repairing the damages, the 
tumour is enhancing its genomic instability. Regarding the hypoxic conditions, the fact that it does 
not show any alterations could be related to an enhancement in the radioresistance associated to those 
conditions. As for BICR-10 cell line, it had genetic gain of the gene. However, this gain is lost after 
the cells are submitted to the different doses and to hypoxic conditions. Being MSH6 a TSG, its loss 
contributes to carcinogenesis, meaning that in the radioresistant cell line, the irradiation probably 
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leads to a decrease in DNA repair capacity, making the tumour enhance its malignant phenotype 
rather than leading to cell death.  
CHFR gene suffers a gain after HSC-3 cells were submitted to 0,5 Gy of irradiation. As 
mentioned, this gene is responsible for a delay in entry to metaphase after mitotic stress (Scolnick 
and Halazonetis, 2000). The gain of this gene could help explain the adaptive response after 
irradiation treatment since, by inducing a delay in metaphase entry, it may allow the repair of the 
damages induced by irradiation. The fact that this gene is lost after treatment with 2 Gy can lead to 
the assumption that this checkpoint would not be active, enhancing the probability of the finally 
outcome of these cells would be mitotic catastrophe, due to the accumulation of irreparable damages 
to the DNA. Another hypothesis relates to the fact that CHFR gene is methylated in the radioresistant 
cell line, BICR-10, and the absence of this checkpoint makes the cells able to proliferate, avoiding 
apoptosis by the detection of damages. However, to our knowledge, a study of this gene in the context 
of radiation biology has not been performed. Our results suggest that this gene could be used as a 
future target for an enhancement of radiation treatment efficacy.  
 Moreover, these alterations bring the hypothesis that, at least for a radiosensitive cell line, 
the alterations on gene copy number could be dependent on the dose that they were submitted, rather 
than the environment differences since between normoxic and hypoxic conditions, there are no 
relevant alterations and even when the cells are submitted to the same dose in different environment 
conditions, the alterations present remain almost the same. Further analysis, however, is required, 
since it is only possible to compare the results obtained for conditions without submission to radiation 
and after 1 Gy of irradiation. In HSC-3 cell line, this could explain the major differences towards 
cells submitted to 2 Gy. 5 Gy and 10 Gy remain very similar to the untreated cells, probably because 
almost all cells died shortly after treatment. 
Analysing BICR-10 cell line, gain of TP73 is an example that happens both in normoxic and 
hypoxic conditions after treatment with a dose of 3 Gy of irradiation. Even though there are some 
alterations that are not consistent with the hypothesis that alterations are dependent on the dose, the 
majority are, so the hypothesis remains valid. However, it needs to be further studied and evaluated. 
Additionally, the data from the different doses regarding CNV shows variations in all conditions, 
which further supports this hypothesis.  
Regarding comparison between normoxic and hypoxic conditions, there are some alterations, 
as the gain of PTCH1, CREM, MLH3 and BRCA1 and losses of MGMT and GATA5 in hypoxic 
conditions. The first two alterations also occurred when cells were submitted to 3 Gy in both 
environmental conditions and to the other low radiation doses. PTCH1 [NCBI-Gene: 5727] codes 
from a member of the patched gene family and functions as a receptor for sonic hedgehog. Hedgehog 
signalling, in a study developed by Gan et al. (2014), was found to be associated to radioresistance, 
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being involved in tumour repopulation after radiation. The gain of this gene at the lowest radiations 
could be associated to an enhancement of tumour repopulation, helping explain the radioresistant 
phenotype of this cell line. At the highest doses, the gain did not happen probably because the 
damages to the cells were too big for the cancer cells to be able to recover. As for CREM [NCBI-
Gene: 1390], it encodes a transcription factor that is able to bind to cyclic adenosine monophosphate 
(cAMP) responsive elements. It already has many alternatively spliced transcripts variants described, 
which encodes different isoforms that may act as activators and repressors of transcription. Due to 
the high frequency of cAMP responsive elements in promoters and the different isoforms coded by 
this gene it is impossible to suggest a relation between radiation response using only this data. Further 
studies requiring proteomic analysis are needed.  
As for BRCA1 gain, this is an alteration that only appears in cells on hypoxic conditions in 
BICR-10 cell line. BRCA1 [NCBI-Gene: 672] codes for a protein that plays a role in maintaining 
genomic stability and it is described as a tumour suppressor. Furthermore, it is known that it has an 
important role in DNA repair of DSBs. As it was already mentioned, one of the most deadly lesions 
produced by irradiation is DSBs. The enhancement of expression of this gene had already been 
associated to a radioresistant phenotype in breast cancer (Abbott et al., 1999) and, since the lack of 
O2 is a known contributor to radioresistance, it is highly possibly that BICR-10 cell line 
(radioresistant) had a decrease in radiation response on hypoxic conditions, since the amplification 
of this gene is able to repair the DSB provoked by radiation to the cells, allowing them to avoid 
apoptosis and progress in the cell cycle.   
PAX5 is a gene that suffers gain at the low doses of radiation, only in normoxic conditions. 
This gene has already been extensively discussed in this study and since there is a lack of concordant 
results in the literature, accessing the possible role of this gain in radiation response is hampered. In 
order to take any conclusions, it is necessary to access the role of this gene in HNSCC development. 
However, the fact that it suffers an amplification at low doses in the radioresistant cell line and it 
suffers loss at low doses in the radiosensitive cell line may suggest that this gene could be involved 
in response to radiation, for example, by preventing cell death or enhancing cell proliferation. 
Nevertheless, these suggestions need to be available after a thorough study of the gene.   
A further study of these genes and their functions is imperative, to validate any of the results 
present in this study. Expression and proteomic analysis are required and, for further validation, the 
comparison with samples from patients. All together , these data suggest that there are differences in 
the cell lines submitted to radiation that can help explain not only the effects that radiation has on 
them, but also why their behaviour differs so much in regarding to radiation treatment. A more 
focused study can help understand if these genes are really involved and elucidate the possible 
mechanisms behind it, having in mind that it is highly possible that, even under the same conditions 
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and after being submitted to different radiation doses, cells could favour CNV of other genes than 
the ones described here in order to try and maintain their malignant phenotype or alterations that 
could lead to cell death.  
Regarding all the other CNV that this study demonstrated, it is possible that, when irradiation 
produced DNA DSBs randomly in the cells, some errors had happened that were amplified during 
the following mitotic divisions of the cells, leading to totally random CNV on both cell lines. 
 
5.2.3 Methylation alterations 
It was already proven that irradiation exposure can affect the DNA methylation pattern, even 
though little is known about how DNA methylation is able to originate alterations in cancer cells 
after irradiation (Ilnytskyy and Kovalchuk, 2011; Kim et al., 2013). So, it was expected that the 
results obtained with MS-MLPA showed alterations on both cell lines after radiation treatment. 
However, there are no great alterations in the methylation pattern of the cell lines after treatment with 
radiotherapy. Besides, epigenetic alterations originated by changes in the oxygen levels of the cells 
were also expected (Smits et al., 2014) and, similar to what happened after irradiation, none alteration 
is noticeable in our study.  One of the possible reasons behind these results relates with the fact that 
MS-MLPA is a target technique, meaning that it is possible that irradiation, and even hypoxia could 
induce methylation changes on the cells. However, the genes affected were not on this MS-MLPA 
panel probe. An epigenomic technique would be more appropriate to access this hypothesis. Another 
possible explanation relates to reports that show that one of the epigenetic events that occurs more 
frequently after irradiation is hypomethylation, rather than hypermethylation, which is not accessed 
by MS-MLPA (Kim et al., 2013). 
Even so, HSC-3 cell line presented alteration in two genes after irradiation treatment. When 
submitted to a dose of 0,5 Gy, the response of this cell line falls in the category of adaptive response 
and a higher proliferation rate is observed. Under these conditions, an unmethylated gene becomes 
methylated, MSH6. It was found to be methylated in cancer (Moelans et al., 2011) and it is possible 
that its methylation after irradiation is related with a high proliferative ratio. Since it acts in G1 and 
early S phase, its lack of activity will not induce cell cycle arrest for DNA reparation, thereby leading 
to a quick advance to the last phases of cell cycle. This gene was also methylated after the HSC-3 
cell line was submitted to 2 Gy. This alteration can also induce mitotic catastrophe, because it is 
possible that the non-repaired damages in the DNA would be too high for the correct finalization of 
cellular division. This last hypothesis is more likely since the radioresistant cell line only showed 
one alteration after radiation treatment in all conditions: methylation of MSH6 in cells submitted to 
10 Gy. Since this is a high dose and the cells end up dying, the proliferation enhancement theory is 
unlikely. On the contrary, inducing cell death by mitotic catastrophe, is a possible explanation for 
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the results obtained. It is then possible that methylation of MSH6 induced different outcomes in the 
cells due to the amount of damages produced by the irradiation dose, also depending on the genetic 
radiosensitive/radioresistance intrinsic characteristics of cells irradiated.  
After a dose of 2 Gy, in HSC-3 cell line, ATM gene was also methylated. As previously 
stated, the encoded protein of ATM gene is essential for the survival of cells after irradiation 
(Sankunny et al., 2014). Due to its methylated state, the cells submitted to 2 Gy would not be able to 
survive, therefore enhancing treatment efficiency. As previously noticed, cells submitted to a dose 
of 2 Gy of radiation are the ones which present more alterations, so, a further comprehensive study 
about the effect of this radiation must be performed. 
Further studies on radiation-induced epigenetic alterations in cancer are required and may 
help develop targeting therapies, improving radiation outcome.  
 
5.2.4 Uncovering possible explanations for the radioresponse differences 
There are several pathways that can be involved in the radiation response of the tumours and 
that could be helpful to further understand the differences of outcome in these cell lines. The 
explanation for these differences can have a genetic association and, cell death and DNA damage 
repair differences can also be involved. Ionizing radiation is able to induce a complex response in 
cells, making it very likely that the answer for this major problem – radioresponse differences in 
cancer patients – can only be assessed after integrating all the pathways that can influence the cells 
outcome. After a genetic and epigenetic approach, we analyse the differences in DNA damages 
between the cell lines in normoxic and hypoxic conditons. Factors that we also intend to take in 
consideration are the differences regarding the type of cell death chosen by the cells after radiation 
treatment and the cell cycle phase of the cells, since studies show that the proliferation rate is 
correlated with radiotherapy response (Joiner and van der Kogel, 2009). 
For the analysis of the results obtained with the comet assay, the parameter choosen was tail 
moment. Tail moment is defined as the product of the tail length and the fraction of total DNA in the 
tail. Since this parameter had many zeros due to the comets that did not present tails, the distribution 
was heavy-tailed and a normal distribution could not be assumed. Taking this into consideration, a 
non-parametric approach, the Kruskal-Wallis test, for testing the different conditions was applied. 
Even though three independent experiments were performed for each condition, the results obtained 
are still preliminary. However, these results suggest that the cell lines exposed to radiation in hypoxic 
conditions are more resistant to irradiation treatment, since the amount of damages present in the 
cells on this conditions are significantly smaller. This is in accordance with the literature, whereas 
lack of oxygen is a known contributor to radioresistance (Kelsey et al., 2013). There is a necessity 
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to performe more independent experiments, enhancing the n of this assay. This will help uncovering 
possible explanations for the preliminary results obtained with comet assay.  
For the analysis of cell death and cell cycle phase, FC was perfomed. However, since only 
two independent experiments were made and due to the difference in the results, no statistical 
analysis was performed. It is imperative to perform at least three more times, since the data obtained 
was too different, to reach any conclusions. 
 
5.3 PREDICTING RADIOTHERAPY RESPONSE 
Due to the differences in radiation response, one of our cell lines is much more radioresistant 
than the other. After obtaining this information, we analyse our data in order to find genetic 
differences that could, somehow, predict tumour radiosensitivity. This particular aspect has been the 
focus of radiobiologists, once every tumour has its own particular characteristics that can lead to a 
more sensitivity or resistance to radiation treatments. The capacity to predict tumour radiossensitivity 
through the development of an assay or through the discovery of biomarkers, is a big step to 
personalized medicine, making it possible to develop personalized treatment options in radiobiology, 
which would lead to fewer side effects, quicken patient recovery and improve cure rates. Since our 
limitations were high, once we only had two cell lines, which had many differences regarding 
molecular characteristics and anatomic region, we try to verify some results that were described in 
literature as possible predictors of radiation response.  
Regarding CNV associated to radioresistance, we have losses of 4p11-pter, 8p23.3 and 11q 
distal and 3q26.1 and 7p11.2-12 gains (Parikh et al., 2007; van den Broek et al., 2007; Gollin, 2014). 
At 8p23.3 two genes are mapped that could explain the higher radioresistance of the tumours: 
MIR596 and Rho Guanine Nucleotide Exchange Factor 10 (ARHGEF10). Regarding MIR596 a study 
developed by Endo et al. (2013) reported that miR-596 was a tumour suppressor miRNA and a 
potential therapeutic target in OSCC (Endo et al., 2013). They notice that the enhancement of miR-
586 and LGALS3P knockdown (a target of miR-586) lead to a lower proliferation rate and induced 
apoptosis (Endo et al., 2013). Then, MIR596 loss would lead to an enhancement of LGALS3P and, 
consequently, to a high proliferation rate and apoptosis inhibition. ARHGEF10 has also been 
postulated to be a strong candidate for a tumour suppressor, since it is responsible for RhoB 
activation, which is needed for DNA damage-apoptosis. The deletion of this gene could, then, 
diminish apoptosis in the cells (Cooke et al., 2008). Both alterations can lead to a reduction in 
apoptosis, which could, then, contribute to the radioresistance observed in BICR-10 cell line. As for 
the other regions, distal 11q loss and 3q26.1 did not show any alterations in genes, whereas 4p11-
pter and 7p11.2-12 are regions too large for this type of analysis.  
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Furthermore, BICR-10 is described to have TP53 mutations and, the deletion of FHIT gene 
alongside with TP53 mutations is associated with a more radioresistant phenotype.(Raju et al., 2015) 
Moreover, a study also concluded that mutations on TP53 and PAX5 methylation were associated to 
a decrease in radiosensitivity (Guerrero-Preston et al., 2014). BICR-10, the radioresistant cell line, 
besides TP53 mutations, also has FHIT deletion and PAX5 methylation. 
 On the contrary, 8p23.3, 10q11-22, 14q13, 14q distal, 15q11.2-q21.3, 17q, 18q21.2 and 22q 
gains and 18q losses were associated to a higher radiation sensitivity (Cowan et al., 1993; Singh et 
al., 2000; van den Broek et al., 2007). At 18q21.2 there are two genes that can help explain the good 
radiation response observable on HSC-3 cell line: Dynactin Associated Protein (DYNAP) and DCC 
netrin 1 receptor (DCC). DYNAP codes for dynAP protein, which is thought to activate Akt, leading 
to high rates of proliferation in cancer cells. As it is known, a high proliferation rate is associated to 
a higher radiosensitivity (Kunoh et al., 2010). Concerning DCC gene, it is TSG that codes for the 
DCC protein [Uniprot: P43146], which is involved in apoptosis induction. This copy gain could, 
therefore, be favourable to the induction of apoptosis after irradiation.  
 In our study, there were four particular regions that showed CNV with some interest and that 
could help unveil biomarkers for radiation response: 4p11-pter, 8p23.3, 14qter and 18q21.2. These 
four regions were particularly interesting because 4p11-pter loss seems to be associated to 
radioresistance and 8p23.3, 14qter and 18q21.2 gains seem to be associated to a more radiosensitive 
phenotype. BICR-10 shows loss of all the regions, whereas in HSC-3 there is gain. As mentioned, 
these four regions have already been associated to radiation treatment. However, due to the extension 
of the alteration, it is not possible to associate to any specific genes, except for the two genes, DCC 
and DYNAP at 18q21.2. 
 Another interesting gene is not located in any of the regions mentioned above, however, its 
expression has already been correlated to a better response to radiation treatment in HNSCC 
(Tehrany et al., 2015). CDKN2A gene is amplified in the radiosensitive cell line and deleted in the 
radioresistant one. In this aspect, both aCGH and MS-MLPA results are concordant and, due to the 
ratios obtained from both techniques, it is highly improbably that this gene has any copy in BICR-
10 cell line. More interestingly, this is an alteration that is maintained in all the conditions that both 
cell lines were submitted, highlighting the hypothesis that this gene could be important to determine 
the radiation response of the tumour. Due to its role in cell cycle, it makes perfect sense that it could 
be responsible for a more radioresistant/radiosensitive phenotype of the tumour. Our study supports 
this theory. However, a gene expression profile must be performed.  
 Nonetheless, both cell lines present CNV associated to worse prognosis in HNSCC 
(Bockmuhl and Petersen, 2002; Martin et al., 2008; Gollin, 2014). So, it is imperative to associate 
these alterations with a more specific cause for the worst prognosis, since HSC-3 is metastatic, but it 
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has a high response to radiation treatment and BICR-10 is not metastatic but does not respond well 
to radiotherapy. Furthermore, response to chemotherapy could also be a reason for the association 
with a worse prognosis. Altogether, our data highlight the need to define the reason behind the 
association of some alterations to a poor prognosis in order to define better treatment approaches and 
give the patients a better quality of life. 
It is interesting, however, to notice, that, by our study, the increasing genetic complexity was 
correlated with a more radiosensitive phenotype, which was also observed in another study (Singh 
et al., 2000). Moreover, a recent paper (Shaukat et al., 2015) concluded that CIN caused sensitivity 
to metabolic stress. As known, CIN is commonly observable in tumours and is defined as the 
continuous propensity of a cell to suffer gains and losses of chromosomes at each cell division. This 
is known to be associated to metastasis and low survival rates. In the paper, they hypothesize that the 
fact that CIN causes stress to the cells in order to give them the ability to tolerate high-stress 
conditions, also pushes them close to their tolerance threshold. They showed that the induction of 
CIN made the cells of the tumour very sensitive to oxidative stress, with high levels of DNA damage 
and apoptosis as a response to metabolic stress, in particular, since these alterations were not enough 
to damage normal cells. Then, they concluded that cells with high CIN were sensitive to alterations 
in cellular metabolism, such as redox status (Shaukat et al., 2015). Since radiation causes damages 
to the cell mainly by the formation of ROS, which induce oxidative stress (Kelsey et al., 2013), one 
can hypothesize that CIN cells will be more sensitive to radiation. This could help explain why the 
tumour with higher radiosensitivity was HSC-3 cell line in our study, since the number of 
chromosomal alterations in that line is much higher than BICR-10 cell line. However, this theory 
needs further developments and studies.  
 
5.4 COMPARISON BETWEEN ACGH, KARYOTYPING AND MS-MLPA 
In general, the results between aCGH and MS-MLPA regarding CNV are concordant. 
Furthermore, the results obtained with the realization of karyotyping are complementary to both 
techniques referred. MS-MLPA has also the advantage to analyse the methylation profile of the 
samples stydied.  
MS-MLPA has been compared to other methods for methylation detection, like methylation-
specific PCR (MSP) and it has a big advantage, since it does not need sodium bisulfite conversion 
of unmethylated cytosine residues, which is hard to optimize. MS-MLPA is able to analyse samples 
with mixed populations of cells. In addition, MS-MLPA is able to analyse up to 50 probes in one 
reaction and can be combined with copy number and point mutation analysis simultaneously (Cabello 
et al., 2011; Homig-Holzel and Savola, 2012). This makes MS-MLPA a valuable technique to use in 
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clinical and daily analysis in order to profile the patients tumours, helping in a more accurate 
diagnostic, prognostic and choice of treatment.  
However, some results between MS-MLPA and aCGH were not concordant. In some cases 
there were losses/gains in MS-MLPA that were considered normal in aCGH and genes normal in 
MS-MLPA that presented CNV in aCGH results. This is explained by different possible reasons: (1) 
there is a possibility of a mutation or polymorphism in or close to the probe-homologous sequence, 
which can lead to decreases in the peak, bringing the necessity of confirmation of MS-MLPA results 
by other techniques; (2) MS-MLPA probes are target to a specific exon, meaning that the totality of 
the gene may not be altered, just that specific exon; (3) aCGH needs at least three probes for the 
region in order to validate a result, and it is possible that aCGH did not have them for some 
genes/regions; (4) Existence of different subclones in the samples, since the different sensitivities of 
the techniques  prevent the identification of some alterations that only happen in some subclones.  
Although aCGH is not able to detect alterations in a single exon, it provides the advantage of 
detecting chromosomal imbalances through all the genome, making it possible to have a full picture 
of all the CNV presented in the tumour cells. It is very useful for the discovery of 
genetic/chromosomic alterations that could be used as biomarkers in cancer. However, it is a very 
expensive technique to perform on daily basis. One possibility is precisely the use of aCGH as a first 
approach in a study, for example to determine biomarkers for radiation response, and then create a 
MS-MLPA probe panel with the biomarkers discovered, since the latter technique is a much cheaper 
and faster technique. 
Even so, both aCGH and MS-MLPA are not able to detect polyploidy, balanced aberrations 
or marker chromosomes. For accessing this problem, karyotyping is a possible solution. Despite the 
lower resolution (5-10 Mb) (Bickmore, 2001), it is a good complementary technique. However, it is 
important to highlight that solid tumour cells normally have low mitotic index and a low quality of 
metaphases, making difficult to analyse them. Furthermore, cancer is characterized for a high 
chromosomal instability and this can hamper the karyotype analysis. The best way to address this 
problem is by Spectral Karyotyping (SKY), since it “paints” each pair of chromosomes with a 
different fluorescent colour, allowing the visualization of all chromosomes at one time. 
Finally, there is another problem with MS-MLPA, particularly, when using it to study cancer 
samples. MS-MLPA is only able to establish CNV/methylation alterations based on the results from 
references probes, which are used to normalize the values obtained from the target genes. However, 
cancer is a very heterogeneous disease with high genomic instability and these characteristics hamper 
the choice of adequate reference probes. In our study, several reference probes presented CNV, 
indicating that those reference probes are not adequate for analysis of tumour samples of HNSCC. 
Overall, the results obtained with the three techniques were rather concordant.
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6 CONCLUSIONS 
 
Taken all the data together, the goals proposed for this study were accomplished. The 
experiments allowed several conclusions and assumptions regarding genetic alterations and its 
association with radiation treatment in HNSCC. Additionally, the results between the karyotyping, 
MS-MLPA and aCGH were rather concordant, being the three techniques helpful for genetic and 
epigenetic characterizations and their results are complementary. The following conclusions were 
drawn from this study: 
 The genetic and genomic characterizations obtain from this study are considered to 
be pivotal for the use of these cell lines in following studies; 
  The results obtained with MS-MLPA, aCGH and karyotyping allowed the 
confirmation of HSC-3 as a metastatic cell line and hypothesized BICR-10 as a cell 
line in a phase of dysplasia; 
 In general, HSC-3 and BICR-10 are two commercial cell lines well suited to studies 
regarding HNSCC, since both presented alterations that were associated to the 
carcinogenesis model suggested to HNSCC; 
 Besides the alterations associated to different stages of development, these two cell 
lines are very dissimilar from one another, as the example of the number of 
chromosomes and the ratio between copy gains and copy losses; 
 Co-methylation of TP73 and ESR1 could be a predictor of the development of 
metastasis, especially when the lymph nodes are involved; 
 It is possible that these six genes, RARβ, PAX5, PAX6, WT1, CADM1, GATA5, could 
be important biomarkers for HNSCC, since two cell lines so different from each 
other showed methylation on the gene’s promoters 
 According to the clonogenic assay, the BICR-10 cell line (LD50 = 3,542) is more 
radioresistant than the HSC-3 cell line (LD50 = 0,821); 
 Chromosomal aberrations after radiotherapy do not appear to be random and 
conventional cytogenetics demonstrates that there is a higher frequency of  deletions 
in some chromosomes after irradiation treatment, has del(2)(q10) and 5q-; 
 aCGH allowed the identification of several genes that could be involved in tumours 
response to radiation, highlighting WRAP73, SLC22A18 and COL1A1, that showed 
alterations on both cell lines; 
 MS-MLPA also suggested possible alterations on CNV and methylation of TSG in 
response to radiotherapy, as MSH6 and CHFR; 
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 This study suggested, however, that the alterations on the tumour cells were 
dependent of the dose of irradiation to which they were subjected; 
 This study emphasized the possible role of four regions in predicting radiotherapy 
response: 4p11-pter, 8p23.2, 14qter and 18q21.2. In the latter, possible important 
genes are DCC and DYNAP. In 8p23.2, MIR596 and ARHGEF10 also seem good 
biomarkers for radiotherapy response; 
 Other important gene that could be helpful in predicting radiotherapy outcome is 
CDKN2A; 
 This study showed that, even though both cell lines presented very different 
responses to radiotherapy, both had CNV associated to worse prognosis, being 
important to understand why some regions are associated to worse prognosis. 
Overall our data suggests genetic, epigenetic and chromosomic alterations associated to 
radiation response and radioresistance, which could allow, in the future, the prediction of patients’ 
outcome, better choice of treatment approaches and a better quality of life for HNSCC patients. This 
study demonstrates to be pivotal for a comprehensive knowledge of radiation effects in HNSCC 
patients and a pilot for further analysis in the radiation biology area applied to HNSCC, in particular. 
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7 FUTURE PERSPECTIVES  
 
In spite all technological advances, cancer remains one of the major causes of dead 
worldwide, and the incidence of HNSCC is alarming. Since this number is still enhancing, an 
extended knowledge about HNSCC carcinogenesis and the need to find better biomarkers, either for 
prognostic, early diagnostic and treatment outcome, are imperative. Taking this into consideration, 
researchers worldwide develop their studies with commercial cell lines and, in order to fully 
understand the results obtained, a comprehensive study of the cell line must be performed. In here, 
we elucidate some genetic and epigenetic characteristics of HSC-3 and BICR-10 cell line, however, 
their study is not concluded, especially regarding karyotyping. Only 10 metaphases were analysed 
per condition, and so, in order to achieve a more robust conclusion, more cells have to be analyzed. 
Furthermore, SKY analysis is one of the next tasks in order to perform a more accurate evaluation 
of the karyotype. The continuing characterization of these cell lines should provide and increasingly 
useful resource to further studies, especially if they are used for translational research.  
Moreover, the five-year survival rate remains low in this type of cancer, being one of the 
major problems the late diagnostic of the disease. These patients are treated with a multidisciplinary 
approach with high toxicity rates. One of the options is radiotherapy, which is associated to several 
problems in patients quality of life and it is now well accepted that it also causes late toxicities in 
tissues distant from the irradiated region. Besides, patients often respond different to this approach, 
some of them developing radioresistance. With this study we proposed some genetic alterations that 
could be important to understand and predict patients’ different responses to treatment, however, 
gene expression and protein analysis are required for the validation of these results. In the future, a 
study comparing the results obtain with the two commercial cell lines and HNSCC patients may also 
contribute for this validation and even introduce other possible biomarkers not mentioned here.   
Finally, the enhancing of independent events regarding flow cytometry and comet assay need 
to be looked into eith more detail in order to draw some conclusions regarding the different responses 
induced by radiation in cell lines, particularly the differences in a radioresistant and a radiosensitive 
cell line. This may elucidate the mechanisms behind the worse response of the first one, contributing 
to the development of target therapies for improving treatment outcome in patients that do not 
respond well to radiotherapy. 
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Appendix I - Abstract of an oral presentation in the VIII Conferences of Genetic and 
Biotechnology, 26-28th March 2015. Vila Real, Portugal 
Comparison between a radiosensitive and a radioresistant cell line – 
could the difference be in copy number variations?  A preliminary study. 
Rodrigues, J1*; Ribeiro, IP1,2, Abrantes A2,3, Simões P4, Borrego M4, Lavoura, N1; Dourado, M2,5; 
Melo, JB1,2; Botelho MF2,3, Carreira, IM1,2 
1Cytogenetics and Genomics Laboratory, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 2CIMAGO - 
Center of Investigation on Environment, Genetics and Oncobiology - Faculty of Medicine, University of Coimbra, 
Coimbra, Portugal; 3Biophysics Unit, IBILI, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 
4Radiotherapy Department, CHUC, Coimbra, Portugal; 5Faculty of Medicine, University of Coimbra, Portugal. 
*joanadmrodrigues@gmail.com 
Keywords: HNSCC; aCGH; Radioresistance; Radiotherapy;  
Introduction:  
Head and Neck Cancers (HNC) are a group of tumours located in the upper aero-digestive 
tract. Head and Neck Squamous Cell Carcinoma (HNSCC) represent about 90% of all HNC cases. 
It has been considered the sixth most malignant tumour worldwide and, despite clinical and 
technological advances, the overall 50% five-year survival rate has not improved much in the last 
years.  
Nowadays, HNSCC is well established as a heterogeneous disease and its development is 
due to accumulation of genetic events, which play major roles in key functional pathways.  
Apart from the majority of the patients being diagnosed in an advanced stage, HNSCC is 
also a disease with poor therapeutic outcome. One of the therapeutic approaches is radiotherapy. 
However, this approach has different drawbacks like the radioresistance acquired by some tumour 
cells, leading to a worse prognosis.  
Identification of genetic markers associated to radiotherapy response in patients is an 
essential step towards an improved diagnosis, higher survival rate and a better life quality for the 
patients.  
Methods:  
HSC-3 and BICR-10 cell lines were cultured in DMEM supplemented with 10% fetal bovine 
serum and 1% of penicillin and streptomycin. In the case of BICR-10 cell line, 1% of hydrocortisone 
was also added. Both lines were exposed through different doses of RX, ranging from 0,5 to 15 Gy. 
Cell viability was accessed using the clonogenic assay. The genetic characterization of the two cell 
lines was performed by Array Comparative Genomic Hybridization.  
Results:  
Comparing the preliminary results from the clonogenic assay for the two cell lines, HSC-3 
cell line appears to be more radiosensitive than BICR-10 cell line since, for the same irradiation, 
HSC-3 has a higher decrease in colonies formation.  
The genetic characterization showed huge differences between the two cell lines, regarding 
the number of alterations and copy number variations, namely at 1p, 1q, 3q, 4p, 5q, 9p, 9q, 10p, 10q, 
11p, 12p, 12q, 14q, 17p, 17q, 20p and 20q. 
Conclusion:  
Taken together our preliminary data suggests chromosomal alterations that could be related 
to the radioresistance acquired by tumour cells after radiation treatment, allowing, in the future, the 
prediction of patients’ outcome and a better choice of treatment approaches.   
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Appendix II - Abstract of a poster presentation in XXXIX Portuguese Genetics Conference, 
25-27th May. Braga, Portugal 
Genetic Characterization of Two Head and Neck Squamous Cell 
Carcinoma Cell Lines by Karyotyping and Array CGH 
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Mascarenhas1; Nuno Lavoura1; Joana B Melo1,2; Isabel M Carreira1,2 
1Cytogenetics and Genomics Laboratory, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 
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Head and Neck Cancers represent tumours located in the upper aero-digestive tract, being 
about 90% Head and Neck Squamous Cell Carcinoma (HNSCC). It was considered the sixth most 
malignant tumour worldwide and it is estimated the occurrence of 600 000 new cases per year. 
Despite clinical and technological advances, the five-year survival rate has not improved much in 
the last years. The characterization of commercial cell lines has obvious benefits, since they are one 
of the most used model in biomedical studies. As such, genetic characterization is a necessity to have 
as much information as possible about the cell lines, especially if they are used for translational 
research.  
HSC-3 (metastatic) and BICR-10 (non-metastatic) cell lines were cultured in DMEM 
supplemented with 10% fetal bovine serum and 1% of penicillin and streptomycin. For BICR-10, 
1% of hydrocortisone was also added. The genetic characterization was performed by karyotyping 
and array Comparative Genomic Hybridization (aCGH). 
Our results showed the presence of copy number variations (CNV) on BICR-10 that were 
associated with early events and progression from a dysplasia to a carcinoma in situ stage, as the case 
of 11q distal loss. The HSC-3 cell line presented regions associated with a metastatic stage, such as 
1q and 3q gains. Both exhibited regions associated to a worse prognosis. The non-metastatic line 
showed less CNV than the metastatic one and the latter presented alterations at nearly every 
chromosome. The BICR-10 cell line showed on average 40 chromosomes and HSC-3 56. Our results 
between aCGH and karyotyping were concordant.  
We conclude that both aCGH and karyotyping are helpful for genetic characterizations and 
their results are complementary. Furthermore, both lines presented CNV that were associated to the 
carcinogenesis model suggested to HNSCC. All sum up, these two cell lines represent an important 
resource for further investigation into HNSCC’s development. 
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Predicting Radiotherapy Response: Could the answer be in Copy 
Number Variations? 
Joana Rodrigues1; Ilda P Ribeiro1,2, Ana Margarida Abrantes2,3, Salomé Pires Lourenço2,3, 
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University of Coimbra, Coimbra, Portugal; 3Biophysics Unit, IBILI, Faculty of Medicine, University of 
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Head and Neck Cancers (HNC) are a group of tumours located in the upper aero-digestive 
tract. Head and Neck Squamous Cell Carcinoma (HNSCC) represent about 90% of all HNC cases. 
It has been considered the sixth most malignant tumour worldwide and, despite clinical and 
technological advances, the five-year survival rate has not improved much in the last years 
Nowadays, HNSCC is well established as a heterogeneous disease and its development is due to 
accumulation of genetic events.  
Apart from the majority of the patients being diagnosed in an advanced stage, HNSCC is 
also a disease with poor therapeutic outcome. One of the therapeutic approaches is radiotherapy. 
However, this approach has different drawbacks like the radioresistance acquired by some tumour 
cells, leading to a worse prognosis.  
Identification of genetic markers associated to radiotherapy response in patients is an 
essential step towards an improved diagnosis, higher survival rate and a better life quality.  
HSC-3 and BICR-10 cell lines were cultured in DMEM supplemented with 10% fetal bovine 
serum and 1% of penicillin and streptomycin. For BICR-10 cell line, 1% of hydrocortisone was also 
added. Both lines were exposed through different doses of RX, ranging from 0,5 to 15 Gy. Cell 
viability was accessed using the clonogenic assay. The genetic characterization was performed by 
Array Comparative Genomic Hybridization.  
Comparing the results from the clonogenic assay, HSC-3 cell line appears to be more 
radiosensitive than BICR-10 cell line since, for the same irradiation, HSC-3 has a higher decrease in 
colonies formation.  
The genetic analysis showed four regions that could be associated to radiotherapy response: 
4p11-pter, 8p23.3, 14q distal and 18q21.2. 
Taken together all of our data suggests that its chromosomal alterations could be related to 
the radioresistance, allowing, in the future, the prediction of patients’ outcome and a better choice of 
treatment approaches. 
